Synthesis of novel anticancer agents by McKeown, Paul
Synthesis of Novel 
Anticancer Agents 
A Thesis submitted in part fulfilment 
of the requirements of the degree 
of Doctor of Philosophy 
Paul McKeown 
Department of Chemistry 
University of Glasgow 
Glasgow G12 8QQ 
June 1996 
(C) Paul McKeown 1996 
" My head is tired, my hand sore. My eyes be'dimmed 
with overmuch looking at the white paper ... .... " 
William Caxton (1422-1491) 
If you can meet with triumph and disaster 
and treat those two imposters just the same ..... 
"If", Rudyard Kipling 
"The man who thinks he knows something does not 
yet know as he ought to know" 
1 Corinthians 8:2 

Acknowledgements 
I would like to thank Professor David Robins for his supervision throughout 
my time in the Henderson Laboratory and for his patient reading and correcting of 
this thesis. 
I would like to express my gratitude to the staff of the Chemistry department 
who helped with the analysis and characterisation of the compounds described in 
this thesis: Mr James Gall, Mr James Mciver and Dr David Rycroft for NMR 
spectra, Mr George McCuliouch and Mr James Tweedie for IR spectra, Mr Tony 
Ritchie for mass spectra, Mrs Kim Wilson for elemental analysis, Ms Isabel Freer 
for UV spectra and Dr K.W. Muir for X-ray crystallography. Mr Philip O'Connor's 
expertise in electrospray mass spectrometry is also gratefully acknowledged. 
Additional thanks to Drs John Carnduff and Bob Hill for useful guidance and 
advice throughout my studies and to Drs Stephen Lacy and Andrew Tebbutt for 
proof-reading this thesis. 
The biological evaluation of the tyrphostins was supervised by Dr Valerie 
Brunton of the Department of Medical Oncology, University of Glasgow, and Dr 
Alan McGown of the CRC Paterson Institute, Manchester. Professor Rona Mackie 
of the Department of Dermatology, University of Glasgow and Dr Lloyd Kelland of 
the CRC Institute of Cancer Research, Royal Marsden NHS trust supervised the 
testing of the antimelanoma compounds. The efforts of these people and their 
colleagues are acknowledged with thanks 
Funding from Engineering and Sciences Research Council is gratefully 
acknowledged 
The Henderson lab has been a fun place to work - thanks to everyone for 
the laughs and the support especially L.A, Greig, Martin and Jolly. I will never 
forget the gonk incident! 
To the folk who've exercised patience with me this year, thanks for hanging 
in there. And finally, Rhona, thanks for being such a source of strength through the 
ups and downs of this research. Your patience, support and love have kept me 
going. 
Summary 
Although traditional anticancer agents have been designed to disrupt the 
replicative process in the nucleus of a cell, much recent work has focused on 
events occurring earlier in the growth cycle. Among the gene products implicated 
in the onset of proliferative diseases are protein tyrosine kinases (PTKs), a family 
of enzymes which catalyse the phosphorylation of tyrosine residues by ATP. 
Several receptor molecules are known to contain internal PTK domains, including 
the epidermal growth factor receptor (EGFR), insulin receptor (InsR) and platelet 
derived growth factor receptor (PDGFR). Chemical agents which can inhibit the 
function of PTKs (known generically as 'tyrosine kinase inhibitors') have potential 
as anticancer agents. A large number of tyrosine kinase inhibitors has been 
obtained from both natural sources and chemical synthesis. Foremost among 
these is the natural product erbstatin (i) which has become the template for a 
series of synthetic analogues known as 'tyrphostins'. The common structural 
feature of most tyrphostins is the benzylidene malononitrile nucleus (ii, R=CN). 
OH 
~R 1,9 CN 
OH 
(i) (ii) 
Some compounds of this type inhibit the EGFR tyrosine kinase with IC50 
values in the low J.lM concentration range; several show the ability to discriminate 
between different members of the PTK family. In vivo antitumour activity has also 
been reported. 
At our point of entry into this field, little work had been performed on 
heterocyclic tyrphostins and we were keen to become involved with this interesting 
area of research. To this end, a set of 24 tyrphostins based on quinoline were 
prepared, of which 18 were novel compounds. The general structure is depicted 
below (iii), with R being an electron-withdrawing group. Derivatives were prepared 
with R as nitrile, substituted diene, ester, amide, thioamide and carboxylic acid 
functions. The tyrphostins were tested against a range of cancer cell lines under 
the supervision of Dr Valerie Brunton at the Department of Medical Oncology, 
University of Glasgow. The most active compounds were quinoline derivatives 
substituted at either the 2- or 4- position with a diene side-arm bearing three nitrile 
groups and an amine function (iv). These compounds had IC50 values against the 
EGFR kinase as low as 1.7 J.lM. 
CN CN 
~~CN ~N~ NH2 
(iii) (iv) 
We considered the key structural features of (iv) to be the conjugated 
aliphatic side arm and the amine group, which could impart a partial negative 
charge onto the terminal nitrile groups by delocalisation. The importance of 
conjugation was tested by preparing 12 novel compounds containing aromatic or 
conjugated aliphatic side-arms, using both Knoevenagel and Wittig chemistry. Our 
work showed that tyrphostins incorporating straight-chain diene or triene side arms 
were particularly active. A further discovery was that the cis- nitrile moiety in 
structure (iii) could be replaced by another electron-withdrawing group or even 
hydrogen without loss of activity. Four tyrphostins with dimethylaminobenzene as 
the aromatic moiety were prepared to determine whether electron push into the 
side-arm was beneficial for activity. Three of these proved to be inactive. 
To address the solubility problems encountered with tyrphostins, we 
developed three water-soluble tyrphostins which incorporated triethylene glycol 
and polyethyleneglycol moieties. The hydrochloride salt and N-oxide of (iv) were 
prepared, as well as two hydroxylated tyrphostins. The compounds prepared in 
this series were tested by Dr Alan McGown at the CRC Paterson Institute for 
Cancer Research, Manchester. Although no clear structure-activity relationship 
was observed, we succeeded in generating a further six compounds with IC50 
values of <5 JlM and one (v) with an IC50 value of 500 nm against the MCF-7 
breast cancer cell line. 
(v) 
Another area of research which we have explored has been the 
development of chemotherapeutic agents for the treatment of malignant 
melanoma. This disease originates within melanocytes, the cells responsible for 
the synthesis of melanin pigments. Melanin synthesis is dependent upon 
tyrosinase, an enzyme which is unique to melanocytes and catalyses the oxidation 
of tyrosine (vi) to dopa (vii) and then dopa quinone (viii). The quinone then 
undergoes further transformations to produce melanin polymers. 
, TYROSINASE 
, , 
, , 
, , 
, , 
, , 
COO- jJ' HO~COO- '\ 0 COO-~ , "= ~ , .. .. HO h +NH3 [0] HO h +NH3 [0] 0 h +NH3 
(vi) (vii) (viii) 
Quinones are electrophilic and readily react with any available nucleophiles, 
including those in DNA bases. By administering drugs which are substrates for 
tyrosinase, it may be possible to generate an excessive amount of quinone 
species which could poison the cell by alkylating DNA or inhibiting key enzymes 
such as DNA polymerase. This process may account for the well-established 
cytotoxic and depigmenting effects of phenols and catechols. 
Amide (ix) was prepared previously both as an antihypertensive and 
antimelanoma agent. In preparing amide (ix) for biological evaluation, it became 
apparent that little had been done to optimise the activity of this compound. 
OH 
o yo 
S~N~ 
H 
(ix) 
We prepared a series of 17 structurally related compounds, represented by the 
general structures (x) and (xi), which were tested by Professor Rona Mackie of 
the Department of Dermatology, Glasgow University, and Dr Lloyd Kelland at the 
CRC Institute of Cancer Research, Royal Marsden NHS Trust. Of particular 
significance was the discovery that increasing the bulk of the side-arm, either a-
to nitrogen (R1 and R2) or at the acyl position (R3) increased drug potency. 
R1 R2 0 
ArS0N~R3 
H 
(x) (xi) 
Ar = phenol, fluorobenzene 
heterocyclic 
n = 1 or 2 
R = nitrile, acid, amide 
R1 , R2 = H, alkyl 
R3 = alkyl, aryl 
OH 
o yo S~N)lR 
H 
(xii) 
Three drugs in this class (xii, R = methyl, ethyl or tbutyl) showed a marked 
improvement in activity over the parent compound (ix) in vitro and in vivo. 
Optically active derivatives and analogues with improved water solubility have also 
been prepared. 
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1 
Cancer - An Overview 
1.1 The History of Cancer 
A constant presence with us throughout the course of human 
evolution, cancer has a history as old as that of man himself. Egyptian 
medical records some 3,500 years old describe the incidence and 
symptoms of diseases which are now recognised as cancer. Archaeologists 
have unearthed human remains from this era which show the distinctive 
scarring common to victims of malignant melanoma. Through the ages, 
cancer has always been feared; its rise to global significance, however, has 
been a remarkably recent phenomenon. Mortality statistics taken from the 
American census of 1850 show that only one of every 190 deaths was 
attributable to cancer. The corresponding figure in 1986 was one in five. 1 
This dramatic increase was due in no small part to a decrease in mortality 
from infectious diseases over the same period. Advances in nutritional 
expertise and public hygiene, coupled with the discovery of antibiotics, 
helped reduce the incidence of diseases like pneumonia and tuberculosis 
which had been the scourge of previous generations. Improved health 
meant increased longevity and by the end of the 20th century the average 
life-span in the developed nations had grown by almost 20 years. With the 
demise of infectious diseases and the demographic shift towards an older 
population it's not surprising that cancer, primarily a disease of the old and 
middle aged, should have assumed greater importance in our time. 
1.2 Causes of Cancer 
Cancers originate when a cell replicates itself using a faulty genetic 
programme; but how does the cell's remarkably ordered schedule become 
corrupted in the first place? The error must either arise from inside the 
confines of the body by some kind of intrinsic mechanism, or it must be the 
result of external factors acting upon the cell. The clear weight of evidence 
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indicates that external agents such as radiation, chemicals and viruses 
account for the incidence of most human cancers. This, in one sense, is 
fortuitous. Were cancer to arise spontaneously from intrinsic causes we 
would have little or no preventative measures with which to fight it. It might 
be argued that one's genetic make-up could constitute an intrinsic cause. 
The fact is that heredity only indicates a genetic predisposition to cancer. It is 
not, of itself, the cause of the disease. 
As it is, science has been able to establish clear correlations between 
certain environmental factors and the incidence of cancer, which allow us to 
take sensible precautions against the disease. One estimate suggests that 
some 90% of all human cancers could be prevented with a fuller knowledge 
of these external factors.2 The principle environmental causes of cancer are 
outlined below. 
1.2.1 X-Rays 
A few years after the discovery of X-rays in 1895, technicians working 
in the field started to develop cancer. Little was known about the medical 
effects of this new form of radiation; indeed, one technician who died from 
metastatic cancer was known to have tested the X-ray tubes he was 
manufacturing by projecting the beam onto the back of his hand. By 1908, 
animal experiments had proved that X-rays could cause cancer and that the 
associated risk was proportional to the degree of exposure.3 Despite this 
discovery, doctors in many countries continued to use X-rays to treat a 
variety of non-malignant diseases. In Israel, a common treatment for 
ringworm of the scalp was to administer a dose of X-rays to the head and 
upper body. Israel now has the third highest incidence of thyroid cancer in 
the world.4 Denmark, by contrast, where X-rays have never been used to 
treat non-malignant diseases, has one of the lowest rates of thyroid cancer 
in the world.5 
Attempts to use high doses of X-rays in therapy for other diseases, 
such as tuberculosis, have also proved ill-fated. One group of women in this 
category proved to be ten times as likely to develop breast cancer after their 
radiation treatment. There is also clear evidence that embryos exposed to X-
rays in utero have a greater likelihood of developing leukaemia in early 
childhood.6 
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Improved shielding and focusing, coupled with sparing use of this 
powerful technique, have made the risks from diagnostic X-rays extremely 
small. If used carefully, there is no reason why X-rays should not continue to 
find applications in medicine and the sciences. 
1.2.2 Radioactive Elements 
As with X-rays, the crippling effects of radioactive elements have been 
well documented over the years. Marie Curie, who co-discovered the 
elements polonium and radium, died from an anaemia induced by her 
repeated exposure to radioactive ores. Another famous example of radium 
poisoning early this century involved a group of 1000 American women who 
were employed to paint the luminous figures onto watch dials.7 In licking the 
points of their brushes to maintain a fine point, these workers unwittingly 
ingested dangerous amounts of radium, the chemical which gave the paint 
its luminous glow. The incidence of bone cancer among these women was 
subsequently found to be abnormally high. 
The long-term consequence for the survivors of the atomic bombs 
dropped on Hiroshima and Nagasaki has been a legacy of leukaemia and 
cancers of the breast, lung, stomach, thyroid, lymphatic system and uterus. 
More recently, the American government has disclosed alarming statistics 
regarding its own post-World War II nuclear testing. 26 explosions were 
carried out from 1951-1958 in the Nevada desert. The occurrence of infant 
leukaemia in neighbouring southern Utah increased during this period and 
fell back to the national average after testing stopped. A similar trend was 
witnessed among the soldiers who were involved in military exercises near 
the test area.8 
The Chernobyl nuclear disaster in 1986 has been profoundly 
damaging, not only in the former Soviet Union, but much further afield. 
Livestock in England and Wales showed contamination levels well in excess 
of safe limits in the months following the accident. 9 
1.2.3 Ultraviolet Radiation 
Exposure to ultraviolet (UV) radiation is the principal causal factor in 
malignant melanoma. Statistics from several countries show that the 
incidence of this disease has been doubling every decade: only lung cancer 
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in women has been growing at a faster rate.10 UV radiation, in large doses, 
is a mutagen which can induce cancer of the skin. The body's natural 
protection against UV radiation is the pigment melanin, synthesised in 
dedicated cells close to the surface of the skin. A clear correlation exists 
between skin type and the incidence of malignant melanoma. These factors 
will be discussed further in chapter 5. 
1.2.4 Chemicals 
Relatively few people handle carcinogenic chemicals on a daily 
basis, except for a limited number in science, medicine and industry. 
Stringent new legislation in this country (Control Of Substances Hazardous 
to Health act) has helped reduce the risks to employees working in these 
areas. The main threat to public health from chemicals comes as a direct 
result of our lifestyle in the late 20th century. Overcrowded cities, dominated 
by the motor car, belch carcinogenic fumes into the atmosphere, making city-
dwellers more likely to contract cancers of the respiratory tract. Dietary 
changes, particularly an increased intake of fat and processed foods, have 
also been detrimental to our health. Ultimately, though, the biggest risk 
comes from tobacco. Lung cancer is the leading cause of cancer deaths 
among men, accounting for 30.2% of the total number in England and Wales 
in 1990.11 The West of Scotland has the fourth highest male mortality rate 
due to lung cancer in the world. 12 Although breast cancer still predominates 
in females, the increased social acceptability of women smoking has seen 
lung cancer grow at an alarming rate in the past 25 years. 
Cigarette smoke is a lethal cocktail of some 6000 chemicals, 50 of 
which are known carcinogens including arsenic, benzanthracene, benzene, 
naphthylamine, nitrosamines and polonium-210. The effect of smoking on 
life expectancy is well researched. A 30 year-old man smoking 40 cigarettes 
a day can expect to lose, on average, eight years from his life-span, as well 
as increasing his risk of cardiovascular and respiratory disease.13 Of the 
110692 deaths due to smoking in the UK in 1988, as many were from 
coronary heart disease as were from cancer (29% each).14 The number of 
smoking related deaths in Scotland that year was 10617 (17% of all deaths) 
and the estimated cost to the NHS was £ 68,786,000.15 
·4· 
1.2.5 Oncogenic Viruses 
Viruses are microscopic parasites which invade cells and use the 
metabolic 'factory' there to reproduce their own kind. Many thousands of 
viral particles may be produced in a matter of hours, draining the host cell of 
its resources and possibly causing it to rupture. The newly-liberated virus 
particles then infect further cells, propagating the disease throughout the 
body. Herpes, the common cold, influenza, polio and measles are all viral in 
origin. 
Oncogenic viruses, however, are more subtle in their action. After 
entering a cell, the viral DNA becomes incorporated into the host cell's 
chromosomes, thereby altering its genetic programme. The net result is that 
the transformed cell continues to reproduce without restraint, passing its 
mutated 'immortal' genes on to its progeny. The proportion of cancer deaths 
due to oncogenic viral infection is relatively small. The chief protagonists are 
Herpes Simplex II, implicated in cervical and penile cancer, and Epstein-
Barr virus which is associated with certain lymphomas and nasal cancers. 
1.3 Cell Growth and Cancer 
The preceding section has given an outline sketch of the various 
causes of human cancer. The common thread which links them all is the 
ability to modify the genetic programme of a cell adversely. But what 
constitutes 'normal' growth, and how does a cancerous cell differ from a 
healthy one? This section explores those questions as a prelude to section 
1.4, where the current forms of cancer chemotherapy are discussed. 
1.3.1 The Growing Cell 
Since the elucidation of the structure of DNA by Crick and Watson in 
1953, the science of cell biology has come to rapid maturation. Many secrets 
of the nucleus have been uncovered, particularly with respect to the 
processes surrounding DNA synthesis. Recent science has been geared 
towards understanding the peripheral processes which govern cell function, 
now that the central events in the nucleus are relatively well understood. 
For many years it was thought that cells were constantly synthesising 
DNA between mitoses. It is now known that the cell cycle consists of at least 
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four distinct phases, classified as growth (G), synthesis (S) and mitosis (M) 
(Figure 1). 
2 daughter cells 
Figure 116 
G 1 is the period during which the nuclear material necessary for the 
synthesis of DNA is constructed, in preparation for the S phase . The 
replication of DNA takes place during this phase, followed by a period 
during which the nucleus prepares itself for mitosis (G2). Separation into two 
daughter cells (M) completes the cell cycle. The time taken to complete one 
growth cycle depends entirely on the type of cell: liver cells take 400 days to 
replicate, whereas cells in the lining of the gut require only 13 hours.17 The 
lengths of the S, G2 and M phases are remarkably consistent across all cell 
types: typical values are 8, 3 and 0.7 hours respectively. Consequently, it is 
the length of time spent in the G1 phase which determines the overall rate at 
which a cell replicates. This period is known as G1 arrest. 
One of the key properties of a healthy cell is the ability to 'decide' how 
long to remain in G1 arrest. If, for example, part of the liver was surgically 
removed, the G1 period of the liver cells would decrease from hundreds of 
days to a matter of hours. After the tissue had been repaired, the cells would 
revert to their normal G1 period. 
A further characteristic of normal cells is differentiation - the process 
by which they assume a particu lar role and function. In embryonic 
development, for instance, certain cells develop into organ tissue, while 
others form bone and cartilage. As cells start to adopt a more specialised 
- 6 -
role, so their rate of reproduction slows down. In addition, cell-death is 
programmed into them during this process. Once adulthood has been 
reached, those tissues which regenerate exist in a steady state as old cells 
die and are replaced by new ones. The precision with which this process 
continues is one of the marvels of nature. 
1.3.2 Cancerous Cell Growth 
Surprisingly, there is little to distinguish a cancer cell from many other 
cells in the body; but one crucial difference exists. A cancer cell has lost the 
ability to stay in G1 for the appropriate length of time and tends to enter the S 
phase prematurely. This shortening of G1 is rarely pronounced and certainly 
does not lead to the frenetic reproduction wrongly associated with cancer. It 
does, however, mean that the cells do not become fully differentiated and 
consequently do not slow down or stop reproducing. The net result is the 
generation of poorly differentiated, malfunctioning cells which, essentially, 
fail to die. As the cancer grows it monopolises nutrients, oxygen and space 
at the expense of healthy tissue. Growing tumours can rupture veins or 
blood vessels and so impair the function of vital organs: many cancer victims 
die as a result of organ failure. If cancer cells enter the circulatory or 
lymphatic system, secondary colonies can develop in other sites around the 
body by a process known as metastasis. By this stage of the disease 
prognosis is very poor. Early diagnosis and treatment are therefore essential 
for the long-term prospects of the sufferer. 
1.4 Current Cancer Therapies 
A common misconception among the general public is that there is 'a 
cure for cancer'. In reality it seems unlikely that a single 'blanket' cure will 
ever be found, given that more than 100 different types of cancer are 
known.18 Current therapies have been successful in extending the life-spans 
of cancer patients, sometimes dramatically, but there is room for a great deal 
of improvement. Broadly speaking, three types of treatment are used in 
practice today: surgery, radiotherapy and chemotherapy. 
Surgery has proven particularly useful in cases of malignant 
melanoma. This disease, which produces warty, dark-coloured lesions on 
the skin, can be detected early and treated before the cancer has a chance 
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to metastasise. Prognosis is good for patients who discover the disease in its 
early stages and have the tumour excised immediately (Chapter 5, Section 
5.1.2). Since most cancers originate inside the body, however, it is often too 
late for surgery by the time the disease has been diagnosed. At this stage 
radiotherapy or chemotherapy is required. 
It has already been mentioned that radiation in high doses can cause 
cancer (Section 1.2.1). Nevertheless, radiotherapy plays a key role in 
treating internal cancers, provided they are still well defined and non-
metastatic. Both X-Rays and radioactive elements such as cobalt-60 can be 
used for this purpose. Although radiation harms healthy and diseased 
tissue, cells with a shorter cell cycle are particularly sensitive to its effects. 
Consequently, a cancer will be more susceptible to damage than the tissue 
from which it derives. It also means that rapidly dividing cells, such as those 
found in the lining of the stomach and in bone marrow, will be the hardest 
hit. The side effects of radiotherapy, vomiting, nausea, diarrhoea and hair 
loss, are a direct consequence of this. 
Cells which are in G1 arrest, particularly those with long G1 phases, 
are less likely to be damaged by radiation than those in the S phase. Since 
at anyone time a considerable fraction of cancer cells in a tumour will be in 
G 1, radiotherapy takes place in several sessions over a period of months. 
This allows resting cancer cells time to move into the S phase, as well as 
giving the patient a chance to recover from the side effects of the treatment. 
Radiotherapy is frequently used after surgery to destroy the small proportion 
of cancer cells still present. This can never be done with complete certainty 
though, and even one surviving cancer cell allows the possibility of 
recurrence in later years. 
The final treatment in common use is chemotherapy, the 
administration of drugs which interfere with the processes of cell division. 
The drugs in question are largely non-selective and only have a therapeutic 
value for the same reasons as radiation, namely the increased turnover of 
cancer cells. As with radiotherapy, treatment is spread over several sessions 
and causes harmful side effects. Some cancers are known to be sensitive to 
particular chemical agents; methotrexate, for example, achieves cures in 
more than 60% of cases of choriocarcinoma. 19 Unfortunately, cancers also 
have the ability to develop resistance to drugs. Combination chemotherapy, 
where a cocktail of two or three different agents is administered, is one way 
of surmounting this problem. Chemotherapy may be used in combination 
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with surgery and radiotherapy and is the only real hope for patients with 
metastatic cancer. 
Since the subject of this thesis is the development of novel anticancer 
drugs, it seems worthwhile to give a brief overview of the main classes of 
drugs currently in use. Section 1.5 reviews the mode of action of these drugs 
and Section 1.6 points the way forward to a more sophisticated 
chemotherapy. 
1.5 Classes of Chemotherapeutic Agents2o,21 
It is perhaps ironic that the discoveries which fuelled the search for 
chemotherapeutic agents over the past 50 years should have had their 
origin in the science of warfare. Mustard gas, the dreaded poison of the First 
World War, became the model upon which many of today's most successful 
anticancer agents have been based. Although thousands of chemicals have 
been synthesised and investigated for chemotherapeutic value over the past 
50 years, only 40 or so are currently in clinical use. For our purposes these 
can be divided into four broad classifications: alkylating agents, 
antimetabolites, natural products and miscellaneous compounds. 
1.5.1 Alkylating Agents 
This chemically diverse range of compounds, of which nitrogen 
mustard (1, Scheme 1) is the parent, share the ability to form covalent 
bonds with nucleophilic centres in biological molecules. Alkylating agents 
can react with amine, phosphate, sulfhydryl and hydroxyl groups on crucial 
cellular molecules like nucleic acids, nucleotides and enzymes and so 
impair their normal function. The effects of alkylation are most lethal when 
the agent is bi-functional, that is, it has two active alkylating groups. Agents 
such as these can crosslink DNA and make it impossible for the individual 
strands of the double helix to 'unzip' during replication. The cell becomes 
locked in the S phase, cannot progress through the cell cycle and therefore 
dies. Monofunctional alkylating agents cannot form cross links, but they can 
damage the cell by confusing cytosine-guanine base-pairing during DNA 
synthesis. 
Nitrogen mustard exerts its toxicity by undergoing an intramolecular 
SUbstitution reaction, expelling chloride ion to form an aziridine (Scheme 1). 
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This highly electrophilic group is an ideal alkylating agent, reacting readily 
with any good nucleophile. It is, however, too reactive to be of much clinical 
use. 
(1 ) 
~CI 
H C-N 3 _~ 
Nu 
Scheme 1 
Cyclophosphamide (2) is a closely related alkylating agent which is 
widely used in cancer therapy. It has been particularly useful in treating 
carcinoma of the breast and of the bronchus. The delocalisation of the 
nitrogen lone pair, coupled with the increased bulk due to the ring make this 
a more stable drug. 
CNH O;p-c§J II 
N 
c,
f0l
c, 
(2) 
Although inactive itself, cyclophosphamide releases a number of 
cytotoxic compounds upon metabolism. Scheme 2 illustrates the reaction 
between a principal metabolite of cyclophosphamide, nor-nitrogen mustard 
(3), and a key nucleophilic site on DNA, N-7 of guanine. 
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~ 
CI 
(3) DNA 
N 0 CI~I~@:C H N ~ I NH 
L ~NH2 
DNA 
Scheme 2 
This single alkylation may lead to mispairing of bases or strand 
breakage. The second chloroethyl group could, of course, react with a 
further molecule of guanine on the opposite DNA strand to form a cross-link 
shown schematically in Figure 2. 
DNA crosslinking 
Figure 222 
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The success of cyclophosphamide has seen the development of other 
structurally related drugs, such as ifosfamide, melphalan and chlorambucil, 
each of which has found specific clinical applications. Alkylating agents 
which are administered directly in the form of an aziridine include thiotepa, 
particularly useful in cases of bladder cancer, and the related 
hexamethylmelamine. 
A further useful series of drugs are the nitrosoureas, lipid soluble 
alkylating agents typified by bischloroethylnitrosourea (BCNU, 4). 
o 
CI~N)lN~CI 
NO H 
(4) 
In addition to the alkylating properties associated with the chloroethyl 
moiety, metabolites of BCNU are also able to inhibit the enzyme DNA 
polymerase. Since these agents can pass the blood-brain barrier they have 
found some use in treating cerebral tumours, but their only real clinical 
application is in the management of lymphomas. A severe drawback to their 
usefulness is delayed-action toxicity to bone marrow. 
1.5.2 Antimetabolites 
Before a cell can enter the S phase of its cycle it must build up a large 
reserve of the proteins required for the synthesis of nucleic acids. These 
proteins are themselves assembled from essential metabolites, such as 
amino acids, present in the cell. It is vital for cell function that these proteins 
are correctly synthesised: a single alteration in the primary structure of an 
enzyme, for instance, can render it totally ineffective. 
Antimetabolites are chemicals which mimic natural metabolites and 
compete with them as enzyme substrates in protein synthesis. If 
incorporated into nuclear material, anti metabolites throw the normal 
recognition processes of the cell into confusion. Enzymes become 
dysfunctional or irreversibly inhibited, RNA cannot function properly and 
consequently the cell comes to a standstill. In one sense, these compounds 
are acting as metaphorical 'Trojan horses' - the consequence of 
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incorporating them in nuclear reactions doesn't become apparent until it's 
too late. 
5-Fluorouracil (5-FU, 5), a mimic for the pyrimidine bases uracil (6) 
and thymine (7), is one of the most important compounds of this genre. 5-FU 
is known to inhibit cell division in two ways. It blocks the enzyme thymidilate 
synthetase which is essential in the biosynthesis of pyrimidines. It can also 
become fraudulently incorporated into RNA in the form of 5-FU nucleotides 
and so cause confusion in base pairing during the process of transcription. 
The relative importance of the two mechanisms is the subject of much 
debate. 
5-FU is used principally in the management of solid tumours and 
cancers of the breast and gastrointestinal tract. Its main side effects are bone 
marrow suppression and sickness which may be severe in the case of high 
doses. 
Methotrexate (8) is an analogue of the vitamin folic acid (9), the 
reduced form of which plays a role in the synthesis of purines. The enzyme 
which effects this reduction, dihydrofolate reductase, is inhibited by 
methotrexate. Since the affinity of methotrexate for the enzyme is five orders 
of magnitude greater than that of dihydrofolic acid, the enzyme will 
preferentially reduce the antimetabolite. The resultant lack of tetrahydrofolic 
acid means that the cell cannot produce purines or pyrimidines, nor, 
therefore, DNA. Methotrexate is used in cases of acute leukaemia and is 
particularly efficacious in treating choriocarcinoma. The principal toxic 
effects are bone marrow suppression and gastrointestinal upset. 
Other compounds in this class are cytosine arabinose, a nucleoside 
mimic used in the treatment of myeloid leukaemia in adults, 6-
mercaptopurine, a purine antagonist, and 6-thioguanine which also inhibits 
purine synthesis. 
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(8) 0 eOOH 
1.5.3 Natural Products 
Unlike the preceding two classes of anticancer compounds, natural 
products have no common mode of action: they are best dealt with on an 
individual basis. 
1.5.3.1 Vinca Alkaloids 
The Vinca alkaloids, derived from the periwinkle plant Vinca rosea, 
inhibit cell growth by binding to the protein tubulin. During the period of 
mitosis called the metaphase, the doubled set of chromosomes orient 
themselves across the cell's equator in preparation for separation. An array 
of microtubules called the 'spindle' acts as a frame upon which the 
chromosomes position themselves. By binding to tubulin, Vinca alkaloids 
prevent the construction of microtubules and so halt the cell in this phase of 
mitosis. 
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(untangling) 
Anaphase 
(separating) 
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(dividing) 
Figure 3 23 
The three alkaloids in this class, vincristine, vinblastine and 
vindesine, are all in clinical use. Vincristine (10) is of particular utility against 
leukaemias and lymphomas and is notably less damaging to the bone 
marrow than many other anticancer agents. Vinblastine (11) is used in the 
treatment of Hodgkin's disease and vindesine, the most recently introduced 
of these alkaloids, has performed well against malignant melanomas. 
(10) R1= COOCH3, R2= CHO 
(11) R1= COOCH3, R2= CH3 
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1.5.3.2 Anthracycline Antibiotics 
These drugs, produced by different strains of Streptomyces, emerged 
from the search for new antibiotics in the 1960s. Daunorubicin (12) and 
doxorubicin (13) show good activity against a broad range of solid tumours, 
but suffer from marked side effects, particularly bone marrow suppression. 
o OH 
(12) R= CH3 
(13) R= CH20 H 
The mode of action of these drugs is complex and at least five 
potential mechanisms for cytotoxicity have been proposed. 
1) Intercalation (insertion with some form of binding) between the two 
strands of the DNA helix. It is believed that these compounds intercalate 
perpendicular to the long axis of the double helix, leading to partial 
unwinding of the DNA and loss of function. 
2) Membrane binding. This alters the permeability of the cell and may 
change the pattern of ion transport. 
3) Radical formation under enzymatic transformations, leading to 
indiscriminate alkylation. 
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4) Chelation of metal ions, so impairing cell function and possibly 
forming toxic organometallic compounds. 
5) Direct alkylation. 
Despite the excellent broad-spectrum toxicity of these agents, they 
find little use because of their dose-limiting side effects. The search for less 
debilitating isomers has yielded compounds like the anthracenediones 
mitoxantrone and bisantrene which are less toxic but have similar 
antitumour activity. 
1.5.3.3 Non-Anthracycline Antibiotics 
Although not as prolific as the anthracycline antibiotics, this group of 
compounds are also of value in cancer treatment. Actinomycin-D was 
identified in the 1940's as a product of the soil fungus Actinomyces. Its 
anticancer activity is thought to be due to its binding to guanine and 
subsequent intercalation between the DNA helix. Actinomycin-D is primarily 
used to treat paediatric tumours. 
Bleomycin is a family of glycopeptides derived from Streptomyces 
verticil/is, believed to exert toxicity by intercalating between the strands of 
DNA and forming free radicals which can alkylate or cause DNA strand 
breaks. The major use of bleomycin is in combination with other drugs in the 
treatment of testicular cancer and lymphomas. As with Vincristine, bleomycin 
causes notably less damage to the bone marrow than most other anticancer 
agents. 
Mitomycin-C, again isolated from Streptomyces species, is believed 
to act as both an alkylating agent and a radical generator. Its principal use is 
in the treatment of gastrointestinal cancers. 
1.5.4 Miscellaneous Anticancer Agents 
Several anticancer drugs do not fit into any of the above 
classifications. Hydroxyurea, first synthesised over a century ago, inhibits 
ribonucleotide reductase, the enzyme which generates the deoxyribose 
nucleotides necessary for DNA synthesis. L-Asparaginase, itself an enzyme, 
- 17 -
destroys leukaemic cells by depriving them of the L-asparagine they require 
for survival. Although interesting from a scientific perspective, neither of 
these drugs are widely used in practice. 
Cisplatin (14), by contrast, is an important drug in the clinician's 
armoury. One of the few inorganic chemotherapeutic agents, cisplatin acts in 
a manner directly analogous to that of alkylating agents. The chloride ions 
can be displaced by nucleophiles on nucleic acids or proteins. N-7 of 
guanine is again the preferred site, although relatively few cisplatin 
molecules achieve DNA cross-linking. Interestingly, the trans-isomer 
appears to be completely unable to induce cross-strand linkages of the 
double helix. 
(14 ) 
Cisplatin finds applications in testicular cancer and in combination 
with other drugs in treatments for a variety of solid tumours. Its main 
drawbacks are severe nausea and vomiting, coupled with potential damage 
to the kidneys. 
1.6 The Way Forward? 
The preceding sections have given a thumbnail sketch of cancer: its 
causes, character and cures. The past fifty years have seen undoubted 
progress in our understanding of the disease and the cancer patient may 
now be allowed a measure of hope; tempered, it must be said, with realism. 
What progress has been made is best described in terms of containment 
rather than cure, although mortality from Hodgkin's disease, leukaemia and 
testicular cancer has fallen markedly over this period.24 The anticancer 
drugs in clinical use are, at best, 'healing poisons'. Acting indiscriminately 
against both cancerous and healthy tissue, their toxicity renders 
chemotherapy traumatic for the victim. This may seem a small price to pay 
for the chance of prolonging life, but it illustrates vividly the need for new, 
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less toxic, chemotherapeutic anticancer agents. The questions facing 
medicinal chemists in this area are essentially the same as they were 50 
years ago. What distinguishes cancer cells from normal cells? How can this 
be exploited? Can cancer cells be targeted specifically? 
Recent advances in the biological sciences give reasons for optimism 
as more and more mysteries of the cell are unravelled. Through an 
understanding of normal cell function we can come to a greater 
understanding of aberrant function, as in the case of cancer. This new 
knowledge enables us not only to apply principles of rational design to our 
existing anticancer agents, but also to identify completely new targets for 
drug development. The nucleus is no longer the sole focus for our efforts: the 
horizon has expanded to encompass the whole cell. It may well be that this 
shift of emphasis opens the doorway to a new generation of sophisticated, 
less harmful, anticancer drugs. 
Chapters 2-4 of this thesis detail one approach to the rational design 
of a new breed of anticancer agent known as 'tyrphostins'.25 These 
compounds are believed to inhibit cell growth by interrupting biochemical 
processes at the surface, rather than the nucleus, of the cell. 
Chapter 5 and 6 describe how the unique properties of melanocytes, 
the melanin producing cells in the body, can be exploited to combat 
malignant melanoma. 
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2 
Cell Signalling and Cancer 
It has been clear for some time that structural refinement of existing 
anticancer drugs is unlikely to bring much improvement in their therapeutic 
indices. Drugs which indiscriminately inhibit important reactions in the cell 
nucleus will always be handicapped by their extreme dose-limiting toxicity. 
Without denigrating the clinical uses of existing anticancer agents, it is 
evident that progress along the same lines will lead down a cul-de-sac. 
There is an urgent need for new strategies as we work towards a more 
refined cancer chemotherapy. 
Fresh impetus has come as a direct result of the extraordinary 
progress being made in the fields of molecular biology and genetics. In 
particular, the burgeoning array of information related to cell growth has 
furnished the medicinal chemist with a host of new biochemical targets. This 
chapter highlights one of these new targets, a family of enzymes called 
protein tyrosine kinases (PTKs) and explains how PTK inhibition can arrest 
the growth of transformed cells. 
2.1 Growth Factors and Cell Signalling 
The science of growth factors and their involvement in cell signalling 
is still in its infancy, but rapid progress has been made since the discovery in 
195426 of nerve growth factor, the protein from which this class of 
compounds derives its name. Initial studies in this area were stimulated by 
the observation that mammalian cells growing in culture required serum for 
good proliferation. The clear inference was that serum contained agents with 
the ability to promote cell growth. In subsequent years, these growth factors 
were isolated, characterised and synthesised and they are now well 
established as key-players in the regulation of cellular proliferation, 
differentiation and death. Growth factors are small proteins, typically 50 - 100 
amino acid residues long. Figure 4 illustrates their mode of action 
schematically. Upon binding to specific cell surface receptors (1) the growth 
factor activates the internal catalytic domain of the receptor (2). This causes 
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a cascade of biochemical reactions (3) which culminates in cell growth and 
division (4). 
1 
l> 
Figure 4 
The functions of many growth factors and their receptors have been 
established and are well documented.27 The exact sequence of events in 
the signalling cascade is the subject of much ongoing research.28, 29 
There is enormous potential for exploiting these discoveries in 
fighting cancer. Given that the ultimate aim of any cancer therapy is to arrest 
the growth of transformed cells, there would seem to be a vast number of 
points along the signalling pathway at which the signal could be intercepted. 
Figure 5 illustrates the complexity of the network of cellular reactions 
involved in PTK mediated growth. Any of the signalling proteins represented 
could be viable targets for drug design. Indeed, choOSing which target to 
focus on has become a major preoccupation for the pharmaceuticals 
industry. 
2.2 Signalling Proteins and Cancer 
The crucial observation which implicated growth factors in cancer was 
the discovery that cancer cells growing in tissue culture require less serum 
to support their growth than normal cells. The concept emerged that 
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Abbreviations: GF, growth factor; TK, tyrosine kinase; GAP, GTPase activating protein; SH2. 
src homology domain 2; PLCy• phospolipase Cy; Pl3-kinase, phosphatidylinositol-3'-kinase; 
PI(4,5)P2, phosphatidyl inositol-4,5-biphosphate; InsP3. inositol (1,4.5) triphosphate; PI(3)P, 
phosphatidylinositol-3-phosphate; DAG, diacylglycerol; PKC, protein kinase C. 
transformed cells were overproducing growth factors, leading to 
uncontrolled growth either in themselves ('autocrine' growth) or 
neighbouring cells ('paracrine' growth). Figure 6 illustrates both types of 
growth.31 The oncogene sis is one example of a gene which can induce 
autocrine growth. Sis encodes the B chain of platelet derived growth factor 
(PDGF) which modulates the growth of connective tissue cells. Simian 
sarcoma virus, derived from a monkey osteosarcoma, is known to 
overexpress this oncogene.32 The excess PDGF generated interacts with 
both intracellular and surface receptors to stimulate proliferative growth.33 
Other oncogenes believed to act in this manner are fgf-5, hst and int-2 which 
encode for fibroblast growth factor-like molecules. Interestingly the fidelity of 
the coding regions of these genes is preserved, indicating that 
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overexpression, rather than mutation, is the cause of their transforming 
nature.31 
AUTOCRINE 
GROWTH 
Cell produces excess 
growth factors which 
stimulate its own growth. 
PARACRINE 
GROWTH 
Neighbouring cells produce 
excess growth factors, 
stlinu/ating growth in 
adjacent cells. 
Figure 631 
Growth factor receptors are also known to be involved in the onset of 
cancer. Although overexpression of receptor-encoding genes is an 
established phenomenon, mutation of these genes to produce aberrant 
receptors is much more common. A frequent hallmark of mutated receptors 
is ligand independent signalling where the need for a growth factor is 
completely circumvented. In effect, these receptors can send constant 
growth signals to the nucleus of their own volition. The erb-B oncogene, 
which encodes a truncated form of the epidermal growth factor (EGF) 
receptor, forms part of the genome of the avian erythroblastosis virus. The 
EGF receptors encoded by erb-B have no external ligand binding domain 
and a shortened cytosolic C-terminus;34 they are thought to induce cancer 
by ligand independent signalling. 
The erb-B2 oncogene (also known as HER-2) encodes for a 185 kD 
protein which is 44% homologous to the EGF receptor.35 Unlike erb-B, this 
gene encodes for a fully developed receptor with external ligand binding 
and internal tyrosine kinase domains.36 Erb-B2 is structurally related to the 
rat oncogene neu which becomes transformed by point mutation of a single 
nucleotide. This mutation causes substitution of glutamic acid for valine-664 
in the transmembrane segment of the neu-encoded receptor,37 a change 
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which switches the receptor 'on' permanently. It is unclear whether or not 
erb-B2's oncogenic nature is due to mutation or overexpression, but point 
mutation of the equivalent valine in the normal c-erb-B2 gene certainly 
induces transforming character.38 The oncogenes fms, trk and kit are also 
known to encode for membrane receptors. 
These examples are merely scratching the surface of what is now a 
vast area of research. When genes encoding for intracellular transducers 
and nuclear transcription factors are taken into account, it is apparent that at 
least half of all known oncogenes encode for signalling proteins.39 Figure 7 
highlights the diversity of oncogene products which present themselves as 
possible targets for drug development. 
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The potential for developing new cancer chemotherapies is obvious, 
even from this brief overview. Many questions about signalling pathway 
blockers remain, however. Will they simply be cytotoxic agents, no better 
than existing anticancer drugs? This is a valid question, given that normal 
and transformed cells share the same signalling pathways and it's unlikely 
that any selectivity could be built in to guide the drugs to the cancer cells. 
Despite this, the way the signalling network has evolved may work in our 
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favour. There is considerable redundancy within the cellular network: in 
other words, there are several ways for a biochemical signal to get from 'A' 
to '8'. The cell has a natural ability to cope with changes in its environment 
and if a particular signalling pathway is blocked, others may be used in its 
place. This gives healthy cells a form of resilience. Cancerous cells share 
this resilience, but they frequently exhibit overexpression of a specific 
signalling pathway. Administration of a drug which inhibits that pathway 
should arrest the growth of transformed cells without significantly debilitating 
the healthy cells around it. Once the runaway growth of the transformed cells 
has been suppressed, it would be possible to eradicate them by 
administration of small doses of conventional anticancer drugs. 
Combinations of cytostatic and cytotoxic drugs such as that described above 
are widely used in clinical medicine. 
A further question which needs to be addressed is where to arrest the 
growth signal. There are almost as many opinions on this issue as there are 
researchers in the field, but broadly speaking the answer lies in striking a 
balance between drug specificity and toxicity. Targets close to the cell 
membrane, including growth factors and receptors, aI/ow a high degree of 
specificity because of their unique function. As described above, however, 
there is also the risk that redundancy in the system could aI/ow the signal to 
be re-routed through alternative pathways. Inhibition further down the chain 
is likely to cause unacceptable toxicity as too many signal transduction 
pathways would be knocked out for the cell to function properly. Research is 
ongoing at almost every available junction in the signalling network, but for 
the purposes of this discussion it is necessary to focus on the area relevant 
to this research; protein tyrosine kinases. 
2.3 Protein Tyrosine Kinases. 
The term 'protein tyrosine kinase' encompasses a family of some 100 
or so related enzymes with a pivotal role in normal cell division and 
abnormal cell proliferation.41 PTKs are an integral part of many membrane 
bound receptors but can also be found as nonreceptor kinases in the 
cytoplasm. The function of PTKs is to catalyse the transfer of the 'Y-phosphate 
of ATP to the hydroxyl group of tyrosine on certain key proteins. This reaction 
is illustrated in Scheme 3. 
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Overexpression of PTK activity is a common feature of many 
proliferative diseases including cancers, psoriasis, atherosclerosis and 
restenosis.42 
2.3.1 Structure and Function of Receptor PTKs 
Despite evolutionary differences, all members of the receptor PTK 
family share three conserved features: an extracellular ligand binding 
domain, a transmembrane helix which acts as an anchor and an internal 
PTK domain. A schematic diagram of a receptor PTK is given in Figure 8. 
DOMAINS N 
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Figure 843 
Many of the common growth factor receptors such as epidermal 
growth factor receptor (EGFR), insulin receptor (InsR) and platelet derived 
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growth factor receptor (PDGFR) share these common features. The primary 
difference which distinguishes them from one another is the nature of their 
ligand binding domains (Figure 9). This enables receptors to be selective in 
accepting or rejecting proteins which attempt to bind to them. 
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Figure 944 
Binding of a growth factor causes a conformational change in the 
receptor leading to dimerisation or oligomerisation. Subsequently, specific 
tyrosine residues in the receptor are phosphorylated by ATP, the reaction 
being catalysed by the receptor PTK. 45 It is uncertain whether this process 
involves self-phosphorylation or trans-phosphorylation but what is evident is 
that only a very few specific tyrosine residues participate. In the case of 
EGFR there are 4 known sites, all located at the carboxy terminal end of the 
receptor. 46 In effect this phosphorylation 'switches on' the receptor's latent 
tyrosine kinase activity. The phosphorylated tyrosine residues in the receptor 
have a high binding affinity for cytoplasmic proteins which contain non-
catalytic domains of about 100 residues known as src homology regions 
(SH2). As a result, once the receptor has been activated, the phosphorylated 
receptor tyrosines can bind signalling proteins such as GAP, Pl3-kinase, 
PLC and the serine/threonine kinase raf-1, drawing them from the cytoplasm 
towards the PTK domain of the receptor. The substrate proteins become 
activated in their signalling function by conformational change or a further 
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PTK catalysed phosphorylation, thus starting the 'knock on effect' which 
leads to mitosis.30, 47, 48 
In summary, the binding of a growth factor activates a receptor's latent 
tyrosine kinase activity and causes a mitogenic signal through activation of 
cytoplasmic signalling proteins. 
2.3.2 Inhibition of Receptor PTKs 
As discussed above, the signalling reaction to be blocked is the 
phosphorylation of intracellular tyrosine residues by ATP, catalysed by 
receptor PTKs. The function of the enzyme is to hold the substrates in 
position while transferral of the y-phosphate takes place. It is reasonable to 
expect the catalytic domain to consist of at least two specific binding sites, 
one for A TP and the other for the tyrosine residue. Peterli et al.49 have 
postulated a transition state in the EGFR catalysed phosphorylation (Figure 
10) where the y phosphorus atom in ATP is pentacoordinated and oxygen 
atoms on the ~ and y phosphates are complexed to bivalent metal ions, 
usually Mn2+ or Mg2+. Lysine 721 of the EGFR has been shown to participate 
in ATP binding. Point mutation of this residue arrests all EGF dependent cell 
functions. 50 This bi-substrate model was confirmed recently when the crystal 
structure of the insulin receptor's TK domain was elucidated.51 In its 
unphosphorylated, inactive form, the catalytic site consists of an amino-
terminal lobe, believed to bind ATP, and a nearby larger lobe containing the 
peptide binding site. Interestingly these 'pockets' are oriented away from 
one another in the inactive molecule, confirming that the TK activity of the 
receptor is latent until it is autophosphorylated. An extended sequence in the 
large lobe called the 'activation loop' contains the three tyrosines which 
become autophosphorylated during receptor activation. Crucially, one of 
these (Tyr 1162) sits directly in the active site, hydrogen bonded to Asp 
1132. This precludes any substrate phosphorylation until Tyr 1162 is itself 
phosphorylated, bringing about the conformational change which frees the 
enzyme to express its PTK activity. 
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2.4 Natural Inhibitors of PTKs 
By designing molecules which compete for one or other of the 
substrate sites it is possible to inhibit the catalytic effects of PTKs. Natural 
products have provided several lead compounds in this area. Quercetin 
(15), a flavone derived from plants, inhibits the growth of a number of tumour 
cell lines. 52 In vitro and in vivo studies show that the tyrosine 
phosphorylation activity of the pp60v-src protein product is abrogated in the 
presence of quercetin.53 The same workers have established that quercetin 
competes with respect to the ATP subsite, a fact which accounts for its 
inhibition of other enzymes like cAMP-dependent kinase and PKC. 
Structural modifications to the basic structure have afforded analogues with 
improved selectivity. 54 Quercetin is also known to inhibit topoisomerase /I 
and the transport of lactate, D-glucose and calcium ions in cells. 
Genistein (16), a closely related isoflavone, is a potent inhibitor of 
tyrosine kinases with improved selectivity over quercetin. Although ATP 
competitive, genistein inhibits the pp60v-src and EGFR tyrosine kinases with 
IG50 values of 6-7JlM compared to values of >1 OOJlM for the cAMP and PKC 
kinases. 55 A significant complication with genistein is the fact that it inhibits 
topoisomerases I and II which stimulates double strand breaks in DNA. 56 As 
with quercetin, systemic toxicity is likely to be high and mitigates against the 
use of genistein in vivo. 
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Herbimycin A (17) is a broad spectrum TK inhibitor with established 
in vivo activity, although there is some debate about its mode of action. This 
compound irreversibly blocks the TK activity of EGFR and the protein 
products of src, bcr-abl and erb-B2.30 Inhibition can be prevented by the 
administration of sulfhydryl reagents such as mercaptoethanol, suggesting 
that the quinone moiety (which is easily attacked by nucleophiles) may be its 
key chemical feature.57 
o 
o 
( 17) 
Lavendustin A (18), isolated from Streptomyces griseolavendus is a 
potent TK inhibitor with IG50 values in the nanomolar region. It exhibits mixed 
inhibition characteristics, competing with both ATP and the peptide for 
occupation of a catalytic site.58 Poor transport through the cell membrane 
has been overcome by minor structural modifications, including formation of 
the methyl ester.59 Other analogues, incorporating only two of the three rings 
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in the parent compound, have also proved interesting. Compound (19) 
inhibits p56 'ck with an IC50 value of 60 nM.60 
COOH 
'.-9 ~ 
OH HoD 
(18) 
OH 
OH 
(19) 
COOH 
OH 
Erbstatin (20), also isolated from Streptomyces, has become the 
template for many synthetic TK inhibitors. This compound is the first of the 
natural products to inhibit by competing for the substrate site, and as such 
would seem to offer more potential for rational drug design. Initial studies 
suggested that erbstatin could selectively inhibit tyrosine kinases over 
serine/threonine kinases61 but more recent work indicates that the 
compound inhibits both sets of enzymes in the same concentration range.62 
Erbstatin has been shown to inhibit a substantial range of tumour cell lines 
and phosphorylation events in vitro.3o A mechanism has been proposed for 
the breakdown of erbstatin in serum, a process which occurs readily and 
requires the presence of oxygen and ferric ions. Analogues with improved 
stability have been synthesised: methyl 2,5-dihydroxycinnamate (21) is 
equipotent to erbstatin but is four times as stable in aqueous solution.63 
OH OH 
~ COOMe 
OH OH 
(20) (21) 
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2.5 Synthetic Inhibitors of PTKs 
2.5.1 Tyrphostins 
Tyrphostins are low molecular weight compounds designed to be 
substrate competitive inhibitors of tyrosine kinases. The earliest tyrphostins25 
mimicked erbstatin and consisted of variously substituted benzene rings 
bearing conjugated sidearms. (For the remainder of this thesis a 'tyrphostin' 
is defined as an aromatic or heteroaromatic group in conjugation with an 
exocyclic double bond , usually bearing a cis- nitrile moiety). A study of 
some 70 tyrphostins indicated that the substructure responsible for activity 
was the benzylidenemalononitrile group (22). Compound (23) proved to be 
three orders of magnitude more active against the EGFR than the InsR.25 
~R V eN 
(22) 
HO~CN 
HO~ CN 
(23) 
The second wave of tyrphostins included heteroaromatic derivatives, 
which proved largely inactive, and conformationally constrained compounds 
which confirmed the importance of the cis- nitrile moiety.64 Several of these 
constrained drugs were active at concentrations of less than 10 flM. A further 
set of amide tyrphostins showed some discrimination between the EGFR 
and erb-B2 kinases. Compound (24), typical of the series, inhibited EGFR 
fifty times more effectively than erb-B2.64 Introducing an S-aryl substituent on 
to the 5'-position of the benzene ring reversed this trend in selectivity. 
Compound (25) inhibited the erb-B2 kinase preferentially, again by a factor 
of about 50.65,66 The ability of tyrphostins to discriminate between normal 
and transforming abl proteins has also been demonstrated.67 
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Recent work has uncovered compounds with even higher selectivity 
such as (26) which expresses a five hundred fold preference for inhibition of 
the erb-B2 tyrosine kinase over the EGFR kinase.68 
t BU0~ CSNH2 
I # CN 
HO 
t Bu 
(26) 
Although these results show promise, there are still many grey areas 
surrounding tyrphostins which require clarification. Originally purported to be 
non-competitive with respect to ATP, recent evidence suggests that most 
tyrphostins are mixed inhibitors of tyrosine kinases.69 Indeed, there is some 
doubt as to whether their anti proliferative activity is due to inhibition of PTKs 
or other signalling proteins further downstream. The stability of tyrphostins 
has also been brought into question. In one study a tyrphostin degraded in 
serum to give a new product which was 10-fold more inhibitory to the PTK in 
question than the original compound,70 Few in vivo results have been 
published for tyrphostins and these have not been overly convincing,71 
There is clearly some way to go before these compounds are sufficiently 
developed to be of any clinical use. 
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2.5.2 Other Synthetic PTK Inhibitors 
The interest in TK inhibitors has grown so rapidly in the past decade 
that a comprehensive review is well beyond the scope of this thesis. Several 
excellent reviews have already been published.28, 30, 39, 72 A brief outline of 
the main structures currently being developed in industry follows. 
ST-638 (27), developed by the Kaneka corporation, is undergoing 
preclinical trials in Japan. The structure resembles early tyrphostins with the 
addition of the methylenethiophenyl moiety on the ring. The reported ICso 
value for this compound against the EGFR tyrosine kinase was 0.4 /lM,73 As 
yet no in vivo data have been forthcoming. The Warner-Lambert company 
has developed a series of 2-thioindole dimers, the best of which is PO 
151514 (28). The series showed a clear structure-activity relationship 
depending on the substitution pattern of the indole ring and discrimination 
between different TKs was possible. Typical ICso values for the series were 
in the order of 1-5 /lM,74, 7S In vivo studies are currently in progress. 
Eta 
q 
HN 
CN 
HO 
s--\ ) 
(27) (28) 
Other compounds in development are Ciba Geigy's bis(arylamino) 
phthalimides (29),76 Farmitalia's methylene-oxindoles (30)77 and 
Biosignal's coumarin analogues (31 ),78 By far the most potent TK inhibitors 
however, are Zeneca's substituted anilinoquinazolines,79 typified by 
compound 32, which exhibit ICso values as low as 5 nM. 
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Anilinoquinazolines have also been shown to inhibit growth of a human 
naso-pharyngeal cancer cell line at nM concentrations. 
(29) 
H°1(Y°YO 
~CN 
(31) 
HO 
~ HNV 
Mead,,=: I N 
Mea ~ N) 
(32) 
2.6 Rationale for postgraduate Research Project 
The Cancer Research group at Glasgow University entered the field 
of tyrosine kinase inhibitors in 1991 with the award of a PhD studentship to 
work in the area. This was quickly followed by two more in 1992. Our initial 
aim was to determine whether or not tyrphostins incorporating heterocyclic 
moieties could be as active as the polyhydroxylated benzene derviatives 
which led the field at that time. A limited study of heterocyclic tyrphostins had 
cast doubt on their potential64 and we were keen to pursue this line of 
investigation. It quickly became apparent from our research that 
heteroaromatic tyrphostins could indeed show excellent activity. Imidazole 
and thiophene derivatives inhibited the EGFR with ICso values in the low /lM 
concentration range. Incorporation of a nitro function onto the thiophene 
increased the activity even further. With these exciting results in hand, work 
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progressed to incorporate quinoline tyrphostins which formed the basis of 
most of this PhD work. The next two chapters detail the synthesis and 
biological evaluation of these compounds, charting the progress from initial 
structure-activity relationships to a more rational form of drug design. 
- 36-
3 
Synthesis and Biological Evaluation 
of Quinoline Tyrphostins: I 
3.1 Introduction 
The initial aim of this project was to synthesise a range of quinoline 
tyrphostins as quickly and simply as possible. Few heterocyclic tyrphostins 
had been reported64•8o and it seemed expedient to build up a broad base of 
compounds from which to derive structure-activity relationships. The basic 
structure of quinoline tyrphostins could readily be disconnected to yield 
qUinolinealdehydes and malononitrile derivatives as starting materials 
(Figure 11). The forward reaction corresponding to this disconnection is the 
Knoevenagel condensation. 
+ 
Figure 11 
3.1.1 The Knoevenagel Condensation8l 
The Knoevenagel condensation, first reported in 1894, is the 
condensation of aldehydes and ketones with compounds containing 
activated (acidic) methylene groups with catalytic amounts of a weak base, 
often an amine. In 1896 Knoevenagel studied the reaction of benzaldehyde 
with ethyl acetoacetate in the presence of piperidine as catalyst (Scheme 4). 
At room temperature the bis adduct (33) was obtained, but at lower 
temperatures the elimination product (34) predominated. 
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Scheme 4 
The Knoevenagel reaction is now well established in the synthetic 
chemist's repertoire due to its wide applicability. The reagents for the 
reaction are generally inexpensive, a variety of solvents can be employed 
and reactions can often be performed at room temperature. Knoevenagel 
products are themselves useful synthetic intermediates and find many 
applications in the synthesis of dyes, natural products and drugs. 
The mechanism of the Knoevenagel reaction depends strongly upon 
the nature of the catalyst. With primary and secondary amines the reaction 
proceeds via an iminium intermediate, a mechanism referred to as the 
Knoevenagel mechanism. Tertiary amines and stronger bases cause the 
reaction to proceed via the Hann-Lapworth mechanism, involving an 
hydroxy intermediate (Scheme 5). The end product is the same in both 
cases. 
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It is clear from this scheme that geometrical isomers can be obtained 
in the Knoevenagel reaction, provided that X and V are different. The 
stereochemistry of the products (£ or Z) is governed by the thermodynamic 
stability of the respective transition states. The lowest energy conformation 
has the bulkiest groups as far removed from each other as possible prior to 
elimination, leading to trans stereochemistry in the product. A wide variety of 
aldehydes and ketones undergo Knoevenagel condensation, although the 
use of ketones can be limited by their lower reactivity. Reactions with 
aromatic or a,/3- unsaturated aldehydes or ketones are particularly 
favourable due to the extension of conjugation in the product. The key 
chemical feature of the other reagent is an activated methylene group, that 
is, one which is bonded to two electron withdrawing groups, in which the 
hydrogen atoms are relatively acidic (pKa - 13). The reagents used most 
often are acyclic 1,3-dicarbonyls, malonates, acetoacetates, acetonitriles, 
acetylacetone and malonodinitrile. Cyclic compounds such as 1,3-
cyclohexanediones have also been used. Although amines are the most 
common catalysts, phase transfer reagents, Lewis acids and potassium 
fluoride have also been employed. 
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The Knoevenagel condensation is strongly solvent dependent. 
Formation of the initial anion and its subsequent addition to the carbonyl (or 
iminium) function is favoured in highly polar solvents. The second step, a 
1,2-elimination, is disfavoured by protic solvents, hence polar aprotic 
solvents such as DMF are preferred. Ambient conditions are often sufficient 
to allow the reaction to proceed, although removal of the water generated in 
the reaction, either azeotropically or over molecular sieves, can improve 
yields. 
3.1.2 Application of the Knoevenagel Reaction in the 
Synthesis of Quinoline Tyrphostins. 
The aldehydes required for our purposes, 2-, 3- and 4-quinoline 
carbaldehyde, and a range of compounds containing an activated 
methylene group were readily available from chemical suppliers. We chose 
to work with malononitrile (35), malononitrile dimer (36), methyl, ethyl, nbutyl 
and tbutyl cyanoacetates (37-40), cyanoacetamide (41) and 
thiocyanoacetamide (42). This gave a total of 24 compounds as shown in 
Figure 12. 
Compounds with Activated Methylene Groups 
RCH 2CN 
R compound R compound 
CN 35 COonBu 39 
C(NHz)-C(CN)2 36 COOtBu 40 
COOMe 37 CONH2 41 
COOEt 38 CSNH2 42 
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Figure 12 
3.2 Synthesis and Characterisation of Quinoline 
Tyrphostins. 
Literature precedent25 and our own experience suggested that the 
reactions should proceed well at room temperature in ethanol with 
piperidine as catalyst. These conditions proved successful in all but two 
cases, 61 and 64, which will be discussed later. Although most of the 
reagents were readily soluble in ethanol, the products tended to be 
insoluble, hence precipitation was a useful guide to the progress of the 
reaction. The precipitates could generally be recovered, washed and 
recrystallised with ease. 
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The structural similarity between these tyrphostins means that they 
have spectroscopic characteristics in common. These are summarised in 
Section 3.2.1. The only spectral data which are discussed in subsequent 
sections are those which are specific to the class of compound under 
scrutiny. 
The issue of product stereochemistry has already been raised in 
Section 3.1.1. For each compound synthesised in this series, only one 
isomer was present by TLC and NMR. On the basis of thermodynamic 
arguments one would expect this to be the isomer with the nitrile group cis to 
the ring, which allows the bulkier groups to adopt the less sterically hindered 
trans arrangement. Although the configuration of these tyrphostins has not 
been determined experimentally, similar studies have been performed 
within our group. X-ray studies on 2,4-dicyano-3-amino-5-[2-(5-nitrothienyl)]-
penta-2,4-dienonitrile (67) confirmed the cis relationship between the 
thiophene ring and the nitrile function.82 Nuclear Overhauser experiments 
and 13C_1 H coupling constants established that tyrphostin RG-13022 (68) 
preferentially formed the cis configuration.83 
CN 
(67) (68) 
3.2.1 General Spectroscopic Properties of Quinolines 
~I 
~ N 
The 13C, 1H, 14N and 15N NMR spectra of quinoline have all been 
determined and fully analysed.84 The 1 Hand 13C NMR chemical shifts for 
quinoline in CCI4 are shown in Figure 13. 
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Figure 13 
1H and 13C NMR 0 values of quinoline 
The effect of the electronegative nitrogen is readily seen by 
comparing the spectra of naphthalene with those for quinoline. The nitrogen 
atom pulls electron density away from its nearest neighbours via the a 
system, so deshielding C-2 and C-8a. A similar effect is seen in the 1C 
system. Resonance structures with a negative charge on nitrogen and a 
positive charge on the ring contribute to the overall electronic character of 
the compound. The ring is therefore electron deficient relative to benzene 
and several of its protons, particularly those at the 2- and 4- positions, are 
deshielded as a result. 
The similarity in chemical shift for H-5 and H-8, and H-6 and H-7 
makes it difficult to distinguish between them in some of the quinoline 
derivatives. Coupling constants prove particularly helpful in correctly 
assigning these protons. The J values for quinoline protons are illustrated in 
Figure 14.84 Of particular note in Figure 14 is that the three-bond coupling 
between H-5 and H-6 is 8.2 Hz whereas that between H-7 and H-8 is 8.6 Hz. 
Assuming that these couplings stay fairly constant when quinoline is 
substituted in the pyridine ring, one can differentiate between protons 5 and 
8 on the basis of the measured J values. Similarly, the four-bond coupling 
between H-5 and H-7 (1.4 Hz) is different to that between H-6 and H-8 (1.0 
Hz) and helps distinguish between protons 6 and 7. 
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Figure 14 
1H NMR Jvalues of quinoline (Hz) 
The IR spectrum of quinoline is reproduced in Figure 15.85 The 
spectrum shows two C-H stretching absorptions above 3000 cm- 1, three 
bands near 1600 cm-1 and five in the region of 1300-1500 cm-1 for the ring 
stretching modes (C=C and C=N). The 700-900 cm-1 region shows bands for 
C-H wagging similar to those of naphthalene. 
I I 
3200 2000 1500 1000 500 200 
Figure 15 
IR spectrum of quinoline 
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3.2.2 Derivatives with Malononitrile (43-45) 
These compounds have previously been synthesised to study the 
effects of the conjugated side-arm on the UV spectrum of quinoline.86 They 
have also been patented for use in the field of electrophotographic 
photoconductors.87 Syntheses proceeded smoothly and rapidly to form the 
compounds 43, 44 and 45 in moderate to good yields. 43 recrystallised 
well from ethyl acetate, whereas isopropanol proved better for 44 and 45. 
The 1 H NMR spectrum for each compound showed a singlet integrating for 
one proton in the region of 08.6-9.4, corresponding to the product's olefinic 
proton. The carbon bearing this proton gave a characteristic resonance at 
ca. 0 158 in each of the 13C NMR spectra. Two nitrile carbon resonances 
were seen in the region 0 112-114. The nitrile functions were also evident in 
the IR spectra, giving strong, well-defined absorptions at approximately 2220 
cm-1, the region associated with a,fi-unsaturated nitriles. 
3.2.3 Derivatives with Malononitrile Dimer (46-48) 
These compounds have also been prepared for UV studies.86 
Syntheses proceeded rapidly to produce 46, 47 and 48 as yellow 
compounds in moderate to good yields. All products were pure by TLC. 
Recrystallisation was attempted from ethanol, ethyl acetate, acetone, 
isopropanol and acetonitrile without success. Mixed solvent 
recrystallisations also failed. The compounds were, however, pure enough 
to proceed with characterisation. 
The 1 H NMR spectra showed two broad singlets in the range 09.2-
9.5, commensurate with the amine function. The olefinic proton was clearly 
visible in each spectrum as a sharp singlet between 0 8.2 and 8.9. The 
conjugated sidearm produced some interesting features in the 13C NMR 
spectra. The carbon bonded to the nitrogen of the amine was consistently 
the farthest downfield, due to the two 1l'-acceptor groups fi to it and the 
inductive effect of the nitrogen atom. These carbons came into resonance at 
ca. 0 165. The carbon bearing two nitrile groups was always the furthest 
upfield, occurring at around 0 50. Increased electron density due to 
delocalisation of the amine lone pair, coupled with the effects of two a nitrile 
groups accounts for its unusual upfield position. The IR spectra confirmed 
the presence of the primary amine function with two sharp, medium strength 
absorptions between 3190 and 3400 cm-1. Sharp, well-defined absorptions 
in the region of 2200-2220 cm-1 corresponded to the nitrile groups and 
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those in the region of 1643-1660 cm-1 were due to carbon-carbon stretching 
of the alkene. 
3.2.4 Derivatives with Cyanoacetates (49-60) 
Compounds 49-60 have similar spectral properties which enables 
them to be dealt with together. The syntheses of these compounds generally 
proceeded smoothly to yield white or cream coloured products in moderate 
to good yields. Solubility of the products was good in alcohol, ethyl acetate 
and chlorofom. Ethyl acetate was the optimum solvent for recrystallisation 
and compounds 58-60 provided particularly good crystals. 
A notable exception to the above was compound 57 which formed 
less readily and had to be purified by column chromatography. 
The characteristic singlet for the olefinic proton was present in all of 
the 1 H NMR spectra (ca. 88.5-9.1). Each set of compounds showed the 
expected signals in the alkyl region for the particular ester function they 
contained. Compounds 49-51 gave a singlet integrating for three protons 
due to the methyl group of the ester, the resonance coming in the range 0 
3.9-4.0. 52-54 showed the classic pattern for ethyl groups attached to 
oxygen, a downfield quartet integrating for two protons at ca. 04.4 and a 
triplet integrating for 3 protons at ca. 8 1.4. The 3J value was 7.1 Hz as 
expected. The 1 H NMR spectra for 55-57 showed four distinct groupings for 
the four types of protons in the nbutyl group. These ranged from the most 
deshielded methylene, a triplet at ca. 84.4, to the terminal methyl group, a 
triplet centred on ca. 8 1.0. Each of the four groupings integrated for the 
correct number of protons. Compounds 58-60 showed a large singlet at ca. 
8 1.6 due to the nine methyl protons of the tbutyl ester. 
The carbonyl carbon of the ester function was a preserved feature of 
the 13C NMR spectra of compounds 49-60. The position of this, the most 
deshielded carbon, was consistently in the range 8 160-162. The alkyl 
groups of the ester were once again a distinctive structural motif in 
confirming the structure of the products. The deshielded methyl carbon in 
compounds 49-51 came relatively far downfield at ca. 8 54. With the ethyl 
esters 52-54, the methyl carbon came at ca. 8 14 whereas the methylene 
resonated at ca. 8 63. The nbutyl compounds 55-57 showed four distinct 
peaks at ca. 8 67, 31, 19 and 13 for the three methylene and one methyl 
groups respectively. This pattern showed a direct correlation with distance 
from the oxygen atom. The quaternary carbon of the tbutyl groups in 58-60, 
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deshielded by the oxygen atom, occurred relatively far downfield at ca. 084. 
The carbons of the three methyl groups came consistently at ca. 028. 
The ester carbonyl carbons were clearly seen in all the I R spectra, 
absorbing strongly in the range 1720-1730 cm-1. The C-O stretching mode 
was also present as a strong absorption between 1250 and 1270 cm-1. 
3.2.5 Derivatives with Cyanoacetamide (62 & 63) 
Compounds 62 and 63 were prepared in moderate yields in the 
usual fashion, but compound 61 could not be prepared by this method. 
Neither extending the duration of the experiment to 24 h nor elevating the 
temperature to 40°C assisted the reaction. At this stage in the project is was 
not considered worthwhile expending more effort on compound 61. 
62 and 63 showed two broad singlets for the amide protons in the 1 H 
NMR spectra, coming in the region 07.9-8.3. The olefinic proton was evident 
in both spectra (08.5-8.9). The carbonyl carbon of the amide was evident at 
ca. 0 162 in the 13C NMR spectra. The N-H stretching modes in the IR 
spectra were poorly defined but both compounds showed a strong 
absorption at ca. 1700 cm-1 for the amide's carbonyl group. 
3.2.6 Derivatives with Thiocyanoacetamide (65 & 66) 
Compounds 65 and 66 formed readily in moderate yields under the 
conditions already described. Attempts to form compound 64 by the same 
method inevitably resulted in an inseparable brown reaction mixture. An 
alternative preparation using alumina as catalyst also proved 
unsuccessful. 88 
The thioamide protons appeared as broad singlets well downfield in 
the 1H NMR spectra (0 10.0-10.5). The thiocarbonyl carbon at ca. 0193 was 
the distinguishing feature of the 13C NMR spectra. The IR spectra showed 
sharp absorptions above 3300 cm-1, indicative of thioamide N-H stretching 
modes, and thiocarbonyl absorptions in the regions of 1616-1650 cm-1 
(amide II) and 1260-1270 cm-1 (amide I). 
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3.2.7 Synthesis of Quinolinyl Propenoic Acid Derivatives 
From compounds 59 and 60 it was a short step to hydrolyse the ester 
and generate acidic derivatives for testing. This transformation was effected 
by stirring the parent ester in formic acid for four hours (Scheme 6).89 
HCOOH 
RT,4 h 
75-83 % 
Scheme 6 
3' = (69) 
4' = (70) 
The clearest indication of product formation in the 1 H NMR spectra 
was the absence of the tbutyl methyl protons. The carboxylic acid proton was 
too broad to be seen. The 13C NMR spectra were notable for the carbonyl 
resonance at ca. 0 163 and the disappearance of the tbutyl carbon signals. 
The IR spectra showed a broad absorption well over 3000 cm-1 and a slight 
lowering of the carbonyl frequency relative to that in the ester. Physical 
characteristics which confirmed the transformation were the lower Rf values 
and higher melting points (due to H-bonding) of the products. 
3.3 COSY NMR Studies on Compounds 50 and 55 
In attempting to characterise the tyrphostins the main difficulty came in 
assigning the protons and carbons of the NMR spectra of the benzene ring 
in quinoline. Although splitting patterns helped with the 1 H NMR spectra, the 
13C NMR carbon signals were often too close together to assign with any 
confidence. To resolve this problem, 20 COSY NMR spectra were prepared, 
correlating the 13C and 1 H NMR spectra for tyrphostins 50 and 55. The 
COSY spectrum for 55 is reproduced in Figure 16. The y-axis shows the 
portion of th'e 1 H NMR spectrum containing the aromatic protons. 
Assignments were made on the basis of chemical shift and coupling 
constants. For an explanation of the numbering system used, please see 
Section 7.2.2. The x-axis represents the section of the 13C NMR spectrum 
concerned, from 0 155-120 . 
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The peaks at B 153.6 and 137.0 correspond to C-3 and -6 as 
expected. The peaks at B 130.5, 130.2, 128.8 and 127.5 are due to C-10, 
-11, -9 and -8 respectively. This order could not have been ascertained 
without this NMR technique since C-10 and -11 differ by only 0.3 ppm. It is 
interesting that the order observed for the 13C NMR spectra bears no 
resemblance to that seen in the 1 H NMR spectrum (H-11 , -8, -10 and -9). The 
remaining peak due to C-5 is easily identified since it is always the most 
upfield quinoline C-H carbon. 
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A comparison of the chemical shift of carbons 8-11 for the 2-quinoline 
ester derivatives (49, 52, 55 & 58) shows enough consistency to suggest 
that the order C-1 0, -11, -9 and -8, is valid for this series. This only holds true 
because of the electronic similarity of the ester compounds and no 
inferences can be drawn about the correct order for the other tyrphostins 
without further 20 COSY NMR experiments. 
A similar treatment for compound 50 gave the order C-1 0, -11, -8 and 
-9 which holds valid for the series of 3-quinoline esters (50, 53, 56 & 59). 
3.4 Biological Testing of Quinoline Tyrphostins 
The initial biological testing of compounds 43 to 70 was carried out in 
collaboration with Professor Paul Workman and Dr Valerie Brunton at the 
Department of Medical Oncology at the CRC Beatson Laboratories in 
Glasgow. Our aim was to study the ability of the compounds to act both as 
antiproliferative and cytotoxic agents. To this end, the tyrphostins were 
subjected to two biological assays which are summarised below. 
3.4.1 Biological Assays 
EGFR receptor tyrosine kinase activity was measured in membrane 
fractions prepared from the HN5 cell line. The EGFR kinase activity was 
determined by measuring the EGF-dependent phosphorylation of a synthetic 
substrate, poly (Glus, Ala3, Tyr1) by [y_32P] ATP. The inhibitors were prepared 
as stock solutions and diluted in distilled water before administration to the 
cells in concentrations of 0.01 IlM - 50 IlM 
Human squamous cell carcinoma or MCF-7 breast adenocarcinoma 
cells were used to assess the cytotoxicity of the tyrphostins. The cells were 
distributed into 96-well plates and incubated for five days. A range of 
inhibitor concentrations (0.01 IlM - 50 IlM) was then administered and after 
24 h the growth medium and inhibitors were removed by suction and 
replaced by fresh medium. The remaining cells were allowed to grow over a 
period of three days after which time a small concentration of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT, 71) was added to each 
well. MTT90 is a water soluble salt which gives a yellow colouration in 
aqueous media. Under the action of dehydrogenase enzymes, the 
compound is converted into insoluble purple formazan by cleavage of the 
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tetrazolium ring. The change in colour (Le. the absorbance) of the solution 
can therefore be taken as a measure of the concentration of living cells. 
(71) 
After addition of MTT the plates were incubated for a further four 
hours. Medium and residual MTT were removed by suction and the 
formazan crystals were dissolved in DMSO and buffer. The absorbance of 
the solution for each well was recorded and log concentration response 
curves were generated. IG50 values were determined as the dose to inhibit 
MTT absorbance by 50% relative to a control. 
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3.4.2 Results of Biological Assays. 
Table 1 records the ICso values for quinoline tyrphostins 43-70 in the 
assays previously described. 
Table 1 
Ar 2-QUINOLINES 3-QUINOLINES 4-QUINOLINES R 
~ CCJr.R c$CN I h N~ CN N R I -...::: -...::: R h ~ 
N 
No. ICso (I-lM) No. ICso (I-lM) No. ICso (I-lM) 
MCF-7 EGFRK MCF-7 EGFRK MCF-7 
CN 43 58 >100 44 400 76 45 170 78 
)=<CN 46 1.7 77 47 27 52 48 4.7 55 
H2N CN 
C02Me 49 200 59 50 450 >100 51 250 16 
C02Et 52 240 17 53 >500 >100 54 330 
C02nBu 55 50 57 56 >500 >100 57 275 22 
C02tBu 58 145 14 59 >500 61 60 325 1.6 
CONH2 62 >500 63 140 49 
CSNH2 65 300 >100 66 38 41 
COOH 69 350 >100 70 380 >100 
Comparison of ICso values for the EGFR kinase antiproliferative assay 
show that for each R group, the order of potency was 2-quinoline > 4-
quinoline > 3-quinoline. Compounds 46 , 47 & 48 incorporating the 2-
aminoethene-1,1-dinitrile moiety (hereafter referred to as 'dimer', from 
malononitrile dimer) were the most potent tyrphostins having ICso values of 
1.7, 27.0 and 4.7 I-lM respectively. Placing the structures in decending order 
of potency for this assay gives: 
- 52 -
2-Quinolines 
"dimer" 
nbutyl ester 
CN 
CONH2 
tbutyl ester 
Me ester 
Et Ester 
3-Quinolines 
"dimer" 
CSNH2 
COOH 
CN 
Me ester 
CONH2 
nbutyl ester 
tbutyl ester 
Broadly speaking this follows the trend 
4-Quinolines 
"dimer" 
CSNH2 
CONH2 
CN 
Me ester 
nbutyl ester 
tbutyl ester 
Et ester 
COOH 
"dimers" »> thioamides > nitriles & amides > esters & acids 
which correlates well with previous observations in the Iiterature.2S.80 
A wide range of ICso values was obtained for the cytotoxicity assay 
but there was no clear structure-activity relationship. Nor was there a direct 
correlation between cytotoxicity and the ability to inhibit EGFR in the 
antiproliferative assay. However these compounds are killing cells, it 
appears not to be solely via EGFR mediated pathways. 
3.5 Further Studies on Compounds 46-48. 
The success of the quinoline "dimer" compounds in the 
antiproliferative assays suggested that they should be the focus of our 
attention. As a result the compounds were dispatched to various other 
cancer groups for further study (see Section 3.6) and we set about 
investigating their properties further. 
3.5.1 Stability Studies 
It was somewhat ironic that compounds 46-48, which were the most 
active tyrphostins, should have had the least desirable physical properties 
including poor solubility and difficulties with crystallisation. Another concern 
was the stability of the compounds in solution. When NMR samples of 
quinoline "dimers" were prepared in DMSO it was noted that they changed 
colour from yellow to green over the course of a few days. A simple NMR 
experiment confirmed that there was indeed a chemical change occurring in 
solution. A fresh solution of 48 (50 mg) in DMSO (1 ml) was prepared and its 
1H and 13C NMR spectra recorded immediately. The sample was left sitting 
in daylight and its NMR spectra were recorded again after two hours and 
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then 24 hours. Over the two hour period no change was seen in the 1 H or 
13C NMR spectrum. After one day, however, identifiable peaks had 
appeared in the 1 H NMR spectrum and there was a distinct 'doubling up' of 
the peaks in the 13C NMR spectrum. The lH NMR spectra for 0 hours and 24 
hours into the experiment are shown in Figure 17. 
4-H 3-H 5-H 
........ ", 
'I ) l 
xw",rr~ 9.5 9.0 8:5 8.0 7.5 
o hours 
CN 
(48) 
4'-H 
Hi.o 
Figure 17 
CN 
24 hours 
5'-H 
/ 
7.5 7.0 
The peaks corresponding to protons 3, 4 and 5 are marked on the 
spectrum taken at 0 h. By 24 h a new product had formed with distinct 
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doublets at () 9.02 and 7.42. It is clear from the coupling constants (4.4 Hz) 
that these are the equivalents of protons 4 and 5 in the new product (4' and 
5'). In addition there is a small singlet at () 8.94 for the new olefinic proton (3'-
H). It is possible that a double bond isomerisation is taking place in solution 
whereby the E-and Z- forms of 48 are in equilibrium with one another 
(Figure 18). 
This theory may rationalise the observed upfield shift for proton 5. In 
the E- form of 48, rotation about the bond joining C-2' to the carbon bearing 
the amine group can bring the amine nitrogen's lone pair close to proton 5'. 
A similar rotation in the Z- form cannot achieve the same effect. Hence 
proton 5' may experience slightly more shielding on average than proton 5, 
pushing the signal upfield. 
Assuming that the initial sample of 48 was pure Z- isomer (see 
Section 3.2 for rationale), comparison of the integrals for protons 4 (43.54) 
and 5' (9.70) gives the ratio of Z." E after 24 h as 78 : 22 at this stage of the 
equilibration. These observations concur with previous studies on the 
tyrphostin RG-13022 (68) which is known to undergo a light-induced 
cis/trans isomerism (Figure 19).71 
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I 
N hv 
"" 
Z-isomer (68) 
Figure 19 
E-isomer 
Unpublished observations within our own group have shown that this 
phenomenon is both light and solvent dependent. Solutions of either 
geometric isomer of 68 kept at room temperature in the dark do not 
equilibrate, nor do solid samples when exposed to light. When a pure 
sample of either isomer is dissolved in d6-DMSO and studied by NMR over a 
period of days the solution forms an equilibrium mixture of 78% E- and 22% 
Z- isomers, regardless of which isomer was initially chosen. In THF the ratio 
changes to 53% E and 47% Z at equilibrium. 
These observations on compound 48, although not comprehensive, 
are sufficient to suggest that it is equilibrating in solution. Thus compounds 
46-48, which have been prepared as the Z-isomers, should never be stored 
as stock solutions. For NMR experiments and biological assays the samples 
should be prepared and used immediately. 
3.5.2 Oecoupling Experiments on Compound 48 
As previously mentioned (Section 3.2.1), elucidation of the proton 
NMR spectra for quinolines is straightforward apart for the benzene ring. 
Decoupling experiments were performed on 48 to enable the proton 
spectrum to be correctly assigned (Figure 20). These experiments were 
performed on a Bruker 360 MHz NMR machine. 
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CN 
CN 
(48) 
A 
c 
B E 
D 
'i"" I' 'I;' " r ' , i' i"" i"" i'" i I'" ii' i" i' i" i i Ii i i" i' i i' iii' 
8.,. 6.15 8.\8 8.15 S... 7.~S 1.91 m1.BS 7.88 7.75 7.7' 7.65 7.61 1.55 
Figure 20(a) 
Figure 20a showS detail of the region B 7.55-8.15 before irradiation. 
The sample of 48 contained a small amount of 4-quinolinecarbaldehyde 
which accounts for the small peaks on the baseline. The region of the 
spectrum shown contains five protons, labelled A to E. A and B are either 
protons 8 or 11, split only once by a three-bond coupling to its neighbour. 
The complex pattern of C and D is due to proton 5, a doublet, superimposed 
upon either proton 9 or 10, which appears as a ddd system with two three-
bond couplings and one four bond coupling. The remaining ddd multiplet is 
either proton 9 or 10. 
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A (irradiated) c E 
\ 
D 
B 
Figure 20(b) 
c 
E 
D 
A 
B (irradiated) 
~.....,..,,........ ........... .,.L,t.-..,..,..,..,..,..,.'T'T" , , , iii iii ii' iii iii iii' , i ' , iii' , • , i ' , 
1.9S 7,9, 1.85 l,U· 7.75 1.7. 7,65 1,61· 1.SS 
m 
Figure 20(c) 
Figure 20b showS the result of irradiating at B 8,08, the chemical shift 
associated with proton A, Proton D collapses into a doublet with some long-
range coupling and proton E loses its four-bond coupling, 
Figure 20c shows the effects of irradiating at B 8,01, the chemical shift 
of proton B. Proton E collapses to a doublet showing a little four-bond 
coupling, 
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It follows that protons A and D and Band E are adjacent neighbours. 
An examination of the coupling constants for these protons gives 4JO= 1.3 
Hz, 4JE= 1.2 Hz, 3JA= 8.1 Hz and 3JB= 7.6 Hz. Assuming that the coupling 
constants will be similar to those of quinoline (Section 3.2.1), this leads to 
the conclusion that A is proton 11, B is proton 8, D is proton 10 and E is 
proton 9. This pattern is in agreement with the observed chemical shifts for 
quinoline itself. 
3.6 Further Biological Evaluation of Tyrphostins 46-48 
The promising results of 46-48 in the EGFR kinase assay (Section 
3.4.2) suggested that it would be worth investigating these compounds 
further. Samples were dispatched to several cancer research groups, 
including the National Cancer Institute in the United States, to help get a 
fuller picture of their potential. 
3.6.1 CRC Department of Medical Oncology. Further Testing 
The ability of these tyrphostins to inhibit EGFR dependent growth 
suggested that they may be acting as EGFR inhibitors. We were keen to 
establish whether or not this was the case with intact cells, rather than 
speCialised membrane preparations such as those prepared from HN5. Dr 
Brunton chose to examine the cytotoxic effects of 46 and 48 on a panel of 
squamous cell carcinomas with a wide range of EGFR expression. The IC
so 
values for both compounds correlated well with the level of EGFR 
expression in the cell lines (Table 2). 
·59 -
Cell Line EGFR Number 1C50 (/.lM) 
(x 106/cell) 
Compound 46 Compound 48 
HN5 5.195 38.3 ± 7.5 8.9 ± 2.4 
{Tonguel 
A431 1.554 45.7 ± 7.5 6.3 ± 1.0 
(Vulva) 
CaSki 0.785 69.0 ± 17.1 36.3 ± 3.8 
(Cervix) 
SiHa 0.114 >100 >100 
(Uterus) 
Table 2 
The HN5 line, which has the highest number of receptors, was 
generally the most sensitive to the tyrphostins whereas the SiHa cell line, 
with a lower number of EGF receptors, was resistant to both inhibitors. This 
information suggests that these tyrphostins are inhibiting at some stage of 
the EGFR kinase signalling pathway. However, more detailed studies of the 
effects of tyrphostins 46-48 on HER 14 cells revealed that treatment with 
compounds 46 and 47 did not reduce the levels of EGF receptor 
autophosphorylation, even at concentrations as high as 100 J.lM. Treatment 
with 100 J.lM of compound 48 arrested all EGF-induced tyrosine 
phosphorylation, presumably as a consequence of its toxicity at such high 
concentrations. All three compounds, however, specifically inhibited the EGF 
dependent phosphorylation of a 50 kDa protein. The function of this protein 
is not yet known but it may be involved in the mitogenic response to EGF. 
In summary, it seems that although the compounds do not inhibit 
receptor autophosphorylation, they can inhibit subsequent phosphorylations 
of cytosolic proteins. This can be understood in the light of recent studies on 
the insulin receptor (Section 2.3.2). This work showed that the process of 
auto phosphorylation caused a conformational change in the receptor's 
tyrosine kinase domain. It may be that these tyrphostins are unable to bind to 
the active site of the enzyme until this re-adjustment has occurred. 
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3.6.2 Testing at the Institute of Cancer Research. Surrey and 
the National Cancer Institute. USA. 
Given the uncertainty about the mode of action of compounds 46-48, 
it seemed expedient to check whether or not these agents were damaging 
DNA directly. Dr Lloyd Kelland at the CRC Institute of Cancer Research, 
Royal Marsden NHS trust, agreed to test compound 48 for us. In this assay 
the human ovarian cell line SKOV-3 was exposed to tyrphostin 48 for 2 h at 
50 and 100 JlM concentrations and then assessed for induction of DNA 
strand breaks. Dr Kelland found no evidence of DNA damage with this 
compound. 
Compound 46 was submitted to the National Cancer Institute in the 
United States for in vitro testing against a panel of 60 human tumour cell 
lines. The mean Glso graph (corresponding to 50% growth inhibition, Figure 
21) shows that the majority of non-small cell lung cancers were resistant to 
the drug, whereas most of the colon, central nervous system, melanoma and 
renal cell lines were relatively sensitive. The NCI did not consider these 
results sufficient to warrant progress to in-vivo testing. 
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Figure 21 
Test Data for compound 46 from the NCI screening programme. The 
vertical line represents the log of the mean GI50 value based on all 60 
cell lines. Bars to the right represent activity greater than the mean, 
(lower log (GI50) while bars to the left represent activity lower than the 
mean (higher log (GI50)' 
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3.7 Structural Analysis of Lead Compounds 46-48. 
By this stage of our work we had achieved our initial goal, in that we 
had shown that heterocyclic tyrphostins could match the activity of 
polyhydroxylated tyrphostins. This work is currently in press.91 Our studies 
indicated that compounds 46-48 should be the model for the next 
generation of quinoline tyrphostins, despite questions over the exact nature 
of their biological action. But why were these compounds more active than 
the others? The important structural unit seemed to be the 2-aminoethene-
1,1-dinitrile moiety which differed from the other substituents in two main 
ways: its extended conjugation and its electronic character. 
None of the other tyrphostins contained two alkene double bonds in 
the side-chain. Did this simply make the molecules a better 'fit' in an enzyme 
substrate pocket, or did it significantly alter their chemical properties? Was 
the increased partial negative charge on the terminal nitrile groups due to 
delocalisation from the amine lone pair an important feature? In designing 
the next set of tyrphostins these were some of the questions we sought to 
answer. We also wanted to improve upon the poor physical properties of 
46-48, particularly with regards to solubility. These aims led to new, more 
varied chemistry and provided the basis for further work in this field. 
eN 
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4 
Synthesis and Biological Evaluation 
of Quinoline Tyrphostins: II 
Our work to this point had established that the quinoline udimer" 
compounds 46-48 are the most potent anticancer agents in the series. One 
of the distinguishing features of these compounds was the extended 
conjugation in the side-arm. We decided to synthesise a range of 
conjugated quinoline tyrphostins to determine whether or not extended 
conjugation accounted for the superior activity of 46-48. The simplest way to 
achieve this aim was to condense quinolinecarbaldehydes with activated 
methylene compounds containing aromatic groups and it was to this pursuit 
that we now turned. 
4.1 Tyrphostins Incorporating Aromatic Substituents 
Several aromatic tyrphostins were readily prepared by condensation 
of 2-quinolinecarbaldehyde with 4-aminobenzylcyanide, 72, and derivatives 
(Schemes 7 & 8). 
(72) 
i. HCI (aq), stir 
i, ii CN 
95% 
NHCOCH3 
NHCOCH3 
(73) (74) 
ii. (CH3CObO, NaOAc iii. 2-quinolinecarbaldehyde, piperidine 
EtOH, 30 min 
Scheme 7 
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Amine 72 was acetylated with acetic anhydride92 to give amide 73 in 
excellent yield. The 1 H NMR spectrum for 73 showed a signal at 02.08 tor 
the methyl protons and the 13C NMR spectrum showed the amide carbonyl 
carbon at 0 168.5. The melting point of 73 agreed with that previously 
reported. 93 Amide 73 condensed readily with 2-quinolinecarbaldehyde to 
form tyrphostin 74 under the standard Knoevenagel reaction conditions 
described in Section 7.2.1. The 1H NMR spectrum of compound 74 showed 
a new olefinic proton at 0 8.08 and a shift in the nitrile absorption in the IR 
spectrum (from 2247 to 2217 cm-1) confirmed that it had moved into 
conjugation. 
When 72 was treated with dPbutyldicarbonate (BOC-O-BOC), it gave 
the carbamate 75 in almost quantitative yield (Scheme 8).94 The tbutyl 
protons of 75 were present as a large singlet at 0 1.51 in the 1H NMR 
spectrum. The carbamate carbonyl carbon showed clearly in the 13C NMR 
spectrum (0 152.7) and the C=O stretching mode was present at 1700 cm-1 
in the IR spectrum. Condensation of 75 with 2-quinolinecarbaldehyde 
proceeded rapidly to give compound 76 which was identified by the olefinic 
singlet at 0 8.12 in the 1H NMR spectrum and a conjugated nitrile absorption 
at 2214 cm-1 in the IR spectrum. Carbamate 76 could be deprotected in 
good yield by bubbling HCI gas through a solution of the compound in ethyl 
acetate. 
ii 
99% 71% 
NHBOC 
(72) (75) 
i. (BOC)20 , dioxane/water, 14 h 
ii. 2-quinolinecarbaldehyde 
EtOH, tBuOK, 5 min 
iii. Hel (g), EtOAc 
iv. NaOH 
Scheme 8 
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(76) 
- 90%1 iii, iv 
~ CN 
(77) 
CN 
NHBOC 
The 1 H NMR spectrum of crude 77 showed that the tBDC group had 
been cleaved, although a trace of 76 was still present. The amine protons 
were present in the 1 H NMR spectrum as a new broad singlet at 0 5.16. 
Crude 77 was used in a subsequent reaction without further 
characterisation. Compound 77 could not be formed directly by condensing 
2-quinolinecarbaldehyde with 72 because the competing reaction, imine 
formation, predominated (Scheme 9). 
i. EtOH, RT, 5 min 
ii. 2-quinolinecarbaldehyde 
EtOH, tSuOK, 30 min 
(79) 
iii. NaSH4, MeOH, 16 h 
iv. 2_quinolinecarbaldehyde 
EtOH, tSuOK, 30 min 
(81) 
Scheme 9 
(80) CN 
The imine product, 78, showed a singlet at 0 8.75 in the 1 H NMR 
spectrum tor the proton attached to the imine carbon. The IR spectrum 
contained a new absorption at 1624 cm-1 corresponding to C=N stretching 
modes. Condensation of 78 with 2-quinolinecarbaldehyde failed with 
piperidine as catalyst, but an equivalent of potassium tbutoxide in ethanol 
(generating ethoxide ion) proved to be a good alternative giving 79 in good 
yield. Assignment of the 1 H NMR spectrum of 79 was problematic because 
of the duplication of quinoline signals, but the two crucial singlets due to the 
imine C-H proton and the new olefinic proton were present at 0 8.70 and 
8.01 respectively. The absorption at 2214 cm-1 in the IR spectrum was 
commensurate with an a,p-unsaturated nitrile function. Interestingly the UV 
spectrum of 79 showed an absorption maximum at 370 nm, indicating the 
presence of a highly conjugated chromophore. 
Several attempts were made to reduce the imine function of 79 with 
sodium borohydride.95 MS of the crude products showed a significant 
fragment with an m/z ratio of 412 corresponding to the molecular weight of 
81, but this product could not be isolated by chromatography. An alternative 
route involved the reduction of imine 78 to give amine 80, which was 
subsequently condensed with 2-quinolinecarbaldehyde affording amine 81 
(Scheme 9). The 1 H NMR spectrum of 80 showed a doublet integrating for 
two protons at 0 4.57, corresponding to the newly formed methylene group. 
The methylene carbon appeared at 049.1 in the 13C NMR spectrum and an 
N-H stretching absorption was apparent in the IR spectrum at 3348 cm-1. 
Initial attempts to react compound 80 with 2-quinolinecarbaldehyde 
gave a product with the correct molecular ion but a surprisingly low Rt value. 
We believed that this was an iminium species formed by reaction of the 
aldehyde with the secondary amine function in 80. To avoid this side 
reaction we preformed the anion of 80 by stirring a solution of 80 in ethanol 
with tBuOK before addition of the aldehyde. This approach gave the desired 
product after chromatography. The IR spectrum of 81 showed the presence 
of amine N-H stretch (3387 cm-1) and a,p-unsaturated nitrile absorptions 
(2213 cm-1). 
4.2 Tyrphostins with Heteroaromatic Side-arms 
A survey of the literature, particularly a review by Fatiadi on 
malononitrile derivatives,96 suggested some interesting heterocyclic 
compounds as potential adducts with quinolinecarbaldehyde. The synthesis 
of a cyclic malononitrile trimer, 82, had been reported96 and it was reasoned 
that, given the right conditions, it should be possible to condense this with 
quinolinecarbaldehydes to give compounds structurally related to 
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tyrphostins 46-48 (Scheme 10). Trimer 82 was prepared as described in 
the literature and its 1 Hand 13C NMR spectra correlated well with previous 
work.97,98 
38% 
i. ZnCI2, DMF, reflux, 15 min 
ii. 2_Quinolinecarbaldehyde, DMF 
cat. piperidine, tSuOK 
• 
NH2 
NCD=: 
H2N I N'" CN 
(82) 
48% ~ ii 
CN 
NH2 
(83) 
Scheme 10 
NH2 
CN 
Condensation of 82 with 2-quinolinecarbaldehyde proved 
problematic, primarily due to solubility problems. Reactions in ethanol and 
isopropanol failed, but DMF gave satisfactory results. The product 83 
showed a singlet at b 8.23 for the new olefinic proton in the 1 H NMR 
spectrum and the presence of alkene C=C stretch (1662 cm-1) and a,f3-
unsaturated nitrile stretch (2208 cm-1) in the IR spectrum. 
The preparation of a similar substituted pyridine has been reported 
(Scheme 11 }.96 
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i-iii 
53% 
NC>=r CN 
NC' e)-CN 
ii. HCI (conc.), extract EtOAc 
iii. NaHC03, stir, 2 h 
iv. Acetone, HCI (conc.) 
CN Na<B 
(84) 
Scheme 11 
CN 
iv .. NC_, i ",:-', CN 
14% ,X .. X 
CI N NH2 
(85) 
Pentanitrile 84 was prepared using the methodology of Kelly et al.99 
An interesting feature of the 13C NMR spectrum was its simplicity. Only six 
different carbons were present. This was, of course, due to de localisation of 
the lone pair which conferred symmetry on the molecule. 
The IR spectrum of 84 showed a strong absorption at 2200 cm-1 
corresponding to a,jJ-unsaturated nitrifes. A smaller absorption at 2270 cm-1 
confirmed the presence of an unconjugated nitrile group. 
Treatment of 84 with concentrated HC! in acetone afforded crude 85 
after chromatography. The 1H NMR spectrum of 85 showed two broad 
downfield singlets for the NH2 protons and a singlet at B 4.27 for the 
methylene group. Three distinct nitrile carbons were evident in the 13C NMR 
spectrum and the correct molecular ion (m/z= 217) was present in the mass 
spectrum. Trinitrile 85 was used without further characterisation in an 
unsuccessful condensation reaction with 2-quinolinecarbaldehyde. 
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4.3 Tyrphostins with Conjugated Aliphatic Side-arms 
Although there was merit in preparing aromatic derivatives, the fact 
remained that tyrphostins 46-48 contained an aliphatic and not an aromatic 
side-arm. The most straightforward way of testing the significance of the 
diene moiety to the activity of 46-48 was to prepare other tyrphostins 
containing this unit (Figure 22). 
co~ CO~ I .# N~ \., :> I .# N~CHO+ 
.f{)-R 
CN 
Figure 22 
Disconnection of the second extraannular double bond led to those 
compounds containing activated methylene groups used previously, and 
quinolinyl propenal derivatives. A literature search for these substituted 
propenals provided surprisingly little information, apart from a useful 
synthesis of 3-(4-quinolinyl)-2-propenal using Wittig chemistry (Scheme 
12).100 
CHO 
i • iii Ph 
I 
+ Ph -P =CHCHO 
I 
Ph 54% 
(86) (87) 
i. PhN02, N2 , 24 h, RT ii. Hel, organic wash 
Scheme 12 
Triphenylphosphoranylidene acetaldehyde (86) is commercially 
available and as a stabilised Wittig reagent would be expected to give E-
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stereochemistry in the product. Reaction according to the literature 
procedure gave 3_(4-quinolinyl}-2-propenal (87) in moderate yield. The 
isomeric ratio was established by examination of the 1 H NMR spectrum of 
87 (Figure 23). The coupling constant between protons He and Hb, 15.9 Hz, 
indicates that they are in a trans- configuration across the double bond. 
Consequently the E- form of 87 is the major isomer. The percentage of each 
isomer was determined by comparing the integrals of the aldehyde protons 
Ha and Ha' which gave a ratio of 92% E to 8% Z. 
Ha 
JH.O H, H. ~ N 
Ha' 
:y -7.8Hz 
HaHb 
YHbHc'" 15.9 Hz 
He 
I 
I 
Figure 23 
I I 
Hb 
/ 
The Rt values of the E- and Z- forms of 87 were so close as to make 
them virtually inseparable by column chromatography. Rather than 
separating the isomers by HPLC at this stage, we decided to progress with 
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aldehyde 87 as an EIZ mixture to determine whether or not derivatives with 
87 were worth pursuing. Mixture 87 was condensed with malononitrile (35), 
malononitrile dimer (36) and 'butyl cyanoacetate (40) (Scheme 13). 
CN 
(88) 
CHO 
Scheme 13 
COO'Su 
~ CN 
Although compound 88 could be made readily in good yield it was 
unstable and decomposed in a matter of hours upon standing. A further 
sample of 88 was prepared and kept in the dark but this also decomposed. It 
seems likely that 88 is moisture sensitive and if prepared again it should be 
rigorously dried and stored under anhydrous conditions. Compound 88 was 
not fully characterised but the spectra obtained were sufficient to establish its 
identity beyond doubt. The 1H NMR spectrum confirmed that the E- isomer of 
88 predominated. The coupling constant for the protons of the first 
extraannular double bond (He and Hb) was 15.0 Hz and the new olefinic 
proton (Ha) appeared as a doublet at B 8.46 with a coupling constant of 11.4 
Hz. The I R spectrum showed a sharp absorption at 3029 cm-1 for alkene =C-
H stretching and a strong band at 1603 cm-1 for alkene C=C stretch. A large 
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peak for the molecular ion (m/z= 231) was seen in the low resolution mass 
spectrum. 
Compound 89 was the first tyrphostin containing a triene side-arm to 
be prepared. Given that the starting material was stereochemically impure 
and that the stereochemistry of the Knoevenagel reaction could in theory 
lead to E- or Z- geometrical isomers, four geometrical isomers of 89 were 
possible from the reaction (Figure 24). 
CN CN CN 
CN 
E,E 
E,Z CN 
CN CN 
Z,Z ZoE 
Figure 24 
Possible Geometric Isomers of Compound 89 
The Z, E- and Z, Z- isomers could only account for 8% of the total 
reaction product because of the stereochemistry of the starting aldehyde. 
The unfavourable interaction of the 1, 1-dinitrile-2-aminoethene moiety with 
Hb in the E, E- isomer may mitigate against its formation. This isomer has 
considerably less rotational freedom that the E, Z- isomer which would 
appear to be the least sterically hindered and therefore the most 
energetically favourable isomer. The 1H NMR spectrum of 89 confirmed the 
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presence of both the E, Z- and E, E- isomers. Evidence for the Z, E- and Z, z-
isomers could not be seen, presumably because the signals from these 
products were masked. Proton Hb appears as a quartet, split by Ha (11.2 Hz) 
and He (15.0 Hz) and centred on 3 7.58. A much smaller quartet with exactly 
the same coupling constants can be seen, shifted about 0.1 ppm upfield. If 
the assumption about the relative stabilities of the E isomers is correct then 
the former quartet is due to the E, Z- isomer and the latter the E, E- isomer. 
This could be verified by carrying out nOe NMR studies on Hb which should 
have a significant through-space interaction with the amine protons if 89 
exists predominantly in the E,E-form. Alternatively, the isomers could be 
separated by HPLC and studied by X-ray diffraction provided that suitable 
crystals could be grown. Other spectral data which confirmed the structure of 
89 were a strong absorption at 2215 cm-1 for the nitrile groups and strong 
bands at 1647 and 1607 cm-1 for C=C stretching modes in the JR spectrum. 
The 1 H NMR spectrum for compound 90 showed predominantly one 
geometrical isomer which gave the same splitting pattern as 87 for the 
alkene protons. The 13C NMR showed signals for the carbonyl carbon at 0 
160.0 and the methyl carbons of the tbutyl group at 0 27.7. A strong 
absorption at 1724 cm-1 in the IR spectrum confirmed the presence of the 
ester function. 
Thiophene and nitrothiophene tyrphostins have formed some of the 
most potent anticancer agents under development within our group.82, 101 
We were keen to discover whether extended conjugation of the aliphatic 
side-arm would enhance the activity of thiophene-containing tyrphostins. 3-
(2-Thienyl)propenal (91) was prepared 102 and condensed with 
malononitrile dimer as shown in Scheme (14). 
iii 
~ n ~CLrCHO 
S CHO 34% S 68% 
(91) 
CN CN 
# # CN 
NH2 
(92) 
i. CH3CHO (40%), 0 °c, 3.5 h ii. CH3COOH iii. EtOH, malononitrile dimer, RT, 1 h 
Scheme 14 
·74· 
The coupling constant for the alkene protons of 91 was 15.6 Hz, 
confirming that the distilled product consisted entirely of the E- isomer. An 
absorption at 1672 cm-1 in the IA spectrum confirmed the presence of an 
u,,B-unsaturated aldehyde. Condensation of 91 with malononitrile dimer 
proceeded smoothly to give 92 which showed amine (3334 and 3217 cm-1), 
nitrile (2212 cm-1) and alkene (1658 cm-1) absorptions in the IA spectrum. A 
new doublet with a coupling of 11.2 Hz was evident at 07.82 in the 1H NMR 
spectrum which corresponded to the new olefinic proton. 
4.4 Novel 'Dimer' Structures 
A scan of the literature showed that many compounds similar in 
structure to malononitrile dimer had been synthesised. Several of these 
seemed worth preparing for our purposes. The reaction of malononitrile with 
methyl cyanoacetate to form a "crossed" dimer has been reported (Scheme 
15).103 
i. NaOCH31 Toluene 
ii. HCI/H20 
Scheme 15 
(93) 
Despite many attempts at this reaction the major product was always 
malononitrile dimer rather than the "crossed" dimer which was prepared in 
61 % yield according to the literature. In attempting to circumvent this 
problem we tried pre-forming the methylcyanoacetate anion before adding 
the malononitrile solution. This did not improve the yield of 93, nor did 
adding the solution of malononitrile in methyl cyanoacetate dropwise over a 
period of ten minutes. By following the literature preparation on a large scale 
and after purification by chromatography a small amount of pure 93 was 
obtained. The 1 H NMA spectrum of 93 showed a broad singlet integrating 
for two protons at 0 9.10, corresponding to the amine protons. The only other 
resonances present were the methylene protons at 0 3.87 and the methyl 
protons at 0 3.72. The low resolution mass spectrum gave the correct 
molecular ion (m/z=165). Compound 93 was used without further 
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characterisation in an unsuccessful condensation reaction with 2-
quinolinecarbaldehyde. 
Attempts to form 94, the dimer of methylcyanoacetate, proved more 
successful (Scheme 16).104 
_~ ... H3COOC~CN 
61% H2N COOCH3 
i. Na, MeOH, reflux, 1 h (94) 
Scheme 16 
The 1 H NMA spectrum of 94 confirmed the presence of a primary 
amine, showing two broad singlets at 8 9.13 and 8.94. N-H stretching modes 
were present in the IA spectrum at 3402 and 3290 cm-1 as well as a strong 
absorption at 2206 cm-1 for the conjugated nitrile. The configuration of 94 
was of interest to us since in their paper, Junek and Wolny represented the 
dimer with the ester groups cis to one another (94a, Scheme 17). This 
seemed counter-intuitive on the basis of thermodynamic arguments, which 
would suggest that the bulkier groups should be as far removed from one 
another as possible leading to the trans isomer (94b). 
G) 
E(JH\ 
~ N=C COOCH3 
-J 
NCB'COOCH3 
94a - methoxyl groups cis 
(E - isomer) 
.. 
Scheme 11 
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HNrcoOCH3 
NC COOCH3 
base \ 
94b - methoxyl groups trans 
(Z - isomer) 
One could also argue that the Z- isomer would have the added benefit 
of a stabilising hydrogen bonding interaction (Figure 25). 
H 
: I 3 O+H~N COOCH 
O-O~ CN 
OCH3 
Figure 25 
Stabilisation of Z- form of 94 
by hydrogen bonding. 
Given these observations, we believed that the structure in reference 
104 had been wrongly assigned. To test this theory we performed nOe' NMR 
studies on compound 94 to examine the interaction of the amine protons 
with those of the methoxyl groups. Molecular modelling of 94a showed that 
the methoxyl group trans to the amine could not approach close enough to 
exhibit a nuclear Overhauser enhancement. The closest approach was of 
the order of 4-5 A. In 94b, however, several conformations of the COOCH3 
unit allowed the methoxyl group to come into proximity to the amine protons. 
This was also the case for the geminal methoxyl group in both 94a and b. 
One would therefore expect to see only one nOe enhancement if 94a 
predominated, and two if 94b predominated. Our studies showed small but 
measurable enhancements for both methoxyl groups and the methylene 
group when the amine protons were irradiated. The nOe difference spectrum 
when the amine function is irradiated is reproduced in Figure 26. This 
indicated that the ester groups adopt a trans arrangement as represented in 
structure 94b. 
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1\ methylene protons 
methoxyl protons I /' 
--~IJ~ 
___ -~-JI _~_A ___ . __ _ 
.,~,-:ffi..---.." '~I ~i ~I 
3.90 3.80 3.70 3.60 3.50 3.40 3.30 3 20 p~ . 
Figure 26 
NOE difference spectrum for compound 94 
after irradiation of amine protons 
Diester 94 was condensed with 2- and 4-quinolinecarbaldehyde 
under more forcing conditions than normal to give tyrphostins 95 and 96 in 
low to moderate yields (Scheme 18). These compounds were similar to 
tyrphostins 46 and 48 in that they possessed an electron-withdrawing 
group cis to the ring and an amine function which could confer a partial 
negative charge on the terminal groups of the side-arm by electronic 
delocalisation. 
(94) + 
i. DMF, tsuOK, 90°C, 16-18 h 
Scheme 18 
2' - (95) 
4' - (96) 
46% 
16% 
Both compounds showed the new olefinic proton as a singlet in the 
1 H NMR spectra (0 8.32 and 8.46 respectively). The IR spectra showed 
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carbonyl absorption bands at 1720-1726 cm- 1 and strong alkene 
absorptions between 1620 and 1664 cm-1. 
4.5 Solubilisation of Tyrphostins 
The hydrophobic nature of tyrphostins 46-48 was problematic, 
especially in terms of their potential as ingested or injected drugs. Empirical 
solubility tests on compound 46 showed that the maximum concentration 
achievable in 1 % DMSO-water solution was only -100 JlM. To achieve 
concentrations greater than this required a larger proportion of DMSO which 
is undesirable for in vivo testing. In attempting to solve this problem the 
approaches available to us were to 'solubilise' existing tyrphostins or to 
design entirely new, more hydrophilic tyrphostins. Both methods were 
employed. 
Many commercially available drugs are sold in the form of their 
hydrochloride salts to confer increased solubility in aqueous media. The 
quinoline moiety in compounds 46-48 provided a basic site for protonation 
by strong acid. By dissolving the compounds in ethanol and bubbling Hel 
gas through the solution, the hydrochloride salt (97) of compound 48 was 
obtained in almost quantitative yield. This preparation proved superior to 
methods using aqueous acids. The proton attached to the quinoline nitrogen 
gave a broad singlet at () 10.49 in the 1H NMA spectrum and the IA spectrum 
showed a broad absorption at 2430 cm- 1, indicating the presence of 
quaternary N-H stretching modes. As expected, the At of 97 was very low 
when subjected to TLC with non-polar organic solvents as eluents. 
eN 
~ 
0.& e N CI 
H 
(97) 
Solubility tests were carried out on compound 97 to determine 
whether or not it showed improved solubility over compound 48. 18.3 mg of 
97 was dissolved in 337 JlI of DMSO to give a 0.2 M solution. 10 JlI of this 
was added to 990 JlI of water, giving a 200 JlM solution in 1 % DMSO-water. 
Although initially transparent, the solution became cloudy within minutes, 
presumably because of precipitation of the free base (Scheme 19). 
CN 
CN 
~ 
0'& e 
N CI 
H 
(97) 
-
CN 
-. 
+ 
o e H 0 CI -3 + 
Scheme 19 
The pKa of 97 has not been measured, but that of protonated 
quinoline is 4.94. Assuming that the pKa values for the two species are fairly 
similar, the extent of dissociation of 97 in dilute aqueous solution (pH 7) is 
given by the Henderson equation. 
pH = pKa + log [A-]l[HA] 
[A-]/[HA] = antilog [pH-pKa] 
= antilog [7-4.94] 
= 114.8 
This shows that at physiological pH, 97 exists primarily (-99%) as the 
free base. This degree of precipitation is clearly unacceptable. 
An alternative strategy involves the solubilisation of drugs by the 
attachment of water-soluble groups. The most commonly used agents are 
polyethylene glycols (PEGs) which have been functionalised to react with 
nucleophilic or electrophilic centres. PEG-COOH, PEG-NH2 and PEG-NCO 
and many similar derivatives are commercially available. The advantages of 
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using PEGs as solubilising agents are many; they are non-toxic 
, 
biocompatible and soluble, both in organic solvents and water. They are not 
biodegradeable and can therefore pass through the body without harm. 
Several well-known drugs such as penicillin V, aspirin, amphetamine, 
quinidine and atropine have been solubilised with PEGS.l0S 
Applying this methodology to our work, we chose to work with the 
short-chain compound triethyleneglycol methyl ether (MTEG, 98) and a 
polyethyleneglycol methyl ether with an average molecular weight of 2000 
(MPEG, 100). By esterifying these reagents with cyanoacetic acid, we were 
able to prepare water soluble compounds containing an activated 
methylene function (99, 101). These compounds would be exactly 
analogous to the cyanoacetates used previously to prepare tyrphostins 
(Scheme 20). 
NC) + HO~o1CH3 
HOOC \- n 
n = 3 (98) 
n = -45 (100) 
Dean-Stark, toluene 
• NC-"COO'/.../'o1CH3 PTSA, reflux 14h \ -
n 
(99) 66% 
(101) 71% 
Scheme 20 
Esterification of ethers 98 and 100 with cyanoacetic acid, with 
azeotropic removal of the water formed during the reaction, gave the 
products 99 and 101 in moderate yields. The lH NMR spectrum of 
compound 99 showed the correct number of protons for the product, most of 
which came into resonance in the region 8 3.34-3.56. The Singlet due to the 
methoxyl protons was distinct at 8 3.20. The IR spectrum of 99 showed 
unconjugated nitrile (2261 cm- l ) and ester (1749 cm- l ) absorbances. 
Spectral analysis for compound 101 was more difficult because the large 
number of ethylene glycol units (- 45) dwarfed the signals from the other 
functional groups. The l3C NMR spectrum proved to be the most instructive, 
showing resonances for the carbonyl carbon, the nitrile carbon and the 
interposing methylene group at 8 165.3, 115.3 and 24.9, respectively. 
Compound 99 was reacted with 4-quinolinecarbaldehyde and 4-
dimethylaminobenzaldehyde to produce the novel solubilised tyrphostins 
102 and 103 (Scheme 21). The rationale behind choosing 4-
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dimethylaminobenzaldehyde is explained in Section 4.7. Both compounds 
were readily soluble in water with gentle heating. 
i. 4-quinolinecarbaldehyde 
Et20, cat. piperidine, stir 14 h 
ii. 4_dimethylaminobenzaldehyde 
EtOAc, cat. piperidine, stir 1 h 
29% 
ii 
72% 
Scheme 21 
(102) 
(103) 
Compounds 102 and 103 showed the characteristic singlet for the 
new olefinic proton at 8 8.86 and 7.87 in the 1H NMR spectra. The IR spectra 
showed absorptions corresponding to the conjugated nitrile (2212-2230 cm-
1), ester (1714-1734 cm-1) and ether (1103-1188 cm-1) functions. 
The PEG solubilised tyrphostin 104 was prepared by reaction with 4-
quinolinecarbaldehyde (Scheme 22). 
- 82· 
i. 4-quinolinecarbaldehyde 
EtOH, stir, 18 h 
.. 
56% 
Scheme 22 
(104) 
As with compound 101, spectral analysis was somewhat difficult 
because of the intense signals from the ethylene glycol units. Despite this, 
the quinoline signals were clearly seen in both the 1H and 13C NMR spectra. 
Comparison of the integrals for the quinoline protons with that for the 
methylene group attached to the ester (the only MPEG signal easily 
distinguished) confirmed that a small amount of starting material (- 6%) was 
still present. IR spectroscopy confirmed the presence of an a,p-unsaturated 
nitrile but also a trace of unconjugated nitrile from the starting material. The 
physical and chemical properties of 101 and 104 are dictated by the 
polymer chain, making separation difficult by any other method than HPLC. 
We felt that, at this stage of development, we should proceed with testing 
with a view to remaking and purifying compound 104 if the results proved 
interesting. 
Electrospray mass spectrometry (ESMS) proved to be a useful tool in 
analysing compound 104 and other PEG solubilised anticancer agents 
(Section 6.7). This relatively mild technique is particularly useful for analysis 
of high molecular weight species such as proteins and polymers since it 
produces little fragmentation. Similar in principle to conventional mass 
spectrometry, the main difference is the method of introducing the compound 
into the analyser. A solution of the sample containing a small percentage of 
an electrolyte is injected into the spectrometer and carried towards the probe 
by a heated carrier gas, usually nitrogen. The liquid passes over a sharp-
edged capillary which is at high voltage, causing formation of microdroplets. 
Spontaneous evaporation of solvent frees the charged ions, which 
accelerate towards the detector under the influence of the applied potential 
difference. The detector then measures and records the mass to charge ratio 
for each species present. The ESMS spectrum of compound 104 is 
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reproduced below (Figure 27). The breadth of the mass distribution reflects 
the variation in polymer length inevitable with compounds such as MPEG. 
PM208 J (090.~) 
100 
214.1 
% 
400 
708.2732.3 796.1 
'~ 
600 800 1000 1200 14()0 )6()U )!lUU 
Figure 27 
ESMS Spectrum of Compound 104 
When pure MPEG is subjected to ESMS, the distribution is centred on 
a mass/charge ratio of - 660 (Section 6.7, Figure 38) which indicates that 
most of the detected ions are triply charged. This is also true of the ESMS 
spectrum of 104, although the skew in the graph indicates that doubly 
charged ions are also present. The centre of the distribution is at 
approximately 732 which corresponds to an overall molecular weight of 3 x 
732 = 2196. The empirical formula of 104 is C104H190N20 47 which gives a 
molecular mass of 2218. This discrepancy equates to an error of 1 %. Given 
the imprecision in estimating the centre of the distribution, it seems 
reasonable to conclude that the product 104 has indeed been formed. 
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4.6 Hydroxylated Quinoline Tyrphostins 
Previous work has shown that the activity of benzylidene-based 
tyrphostins increased as more hydroxyl substituents were introduced into the 
ring. 25,Bo We were interested in preparing hydroxylated quinolines, not only 
to improve activity and solubility, but as a 'handle' for further 
functionalisation of the compounds. A literature search led to several 
hydroxylated quinoline aldehydes but most were substituted in the benzene 
ring which was not of direct interest to us at that time. Of more use to us was 
a preparation of 4-hydroxyquinoline-3-carbaldehyde (105) from 4-
hydroxyquinoline (Scheme 23)106 
OH 
~ 
UN) 58% 
i. NaOH, CHCI3"H20, reflux, 5 h 
Scheme 23 
OH 
~CHO 
U~I) N 
(105) 
The formation of aldehyde 105 was confirmed by the presence of a 
singlet at 0 10.22 in the 1 H NMR spectrum due to the aldehydic proton and a 
resonance at 0 188.8 in the 13C NMR spectrum from the carbonyl carbon. 
Compound 105 can tautomerise in solution, giving rise to 'keto' and 'enol' 
forms (Figure 27). 
OH 
c&~ CHO 1#.& --N 
'enol' form 
o 
roCHO I # I N 
H 
'keto' form 
Figure 28- Tautomers of Compound 105 
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In DMSO, only one set of signals for the compound was seen in the 
13C NMR spectrum, implying a preference for one tautomer in solution. The 
carbon at the 4' position of the quinoline ring came into resonance at 0 176.3 
which is far enough downfield to indicate a carbonyl rather than an hydroxyl-
bearing carbon. Further evidence comes from the work of Coppola et al. who 
prepared a series of non-tautomerising 2- and 4-quinolones. 107 When the 
quinolone nitrogen is substituted with a methyl group rather than a proton as 
in structure 106 , carbon 4' comes into resonance at 0 178.4, which is 
similar to the value observed for the analogous carbon in 105. 
° ro' CHO I 4 I ~ N 
I 
CH3 
(106) 
The inference is that in DMSO solution, 105 prefers to exist in the 
'keto' form, which is really a vinylogous amide. This observation concurs 
with studies on the tautomerism of 4-quinolone-3-carboxylic acid derivatives 
carried out by De la Cruz et al. 1 08 who concluded that these compounds 
preferentially exist in the 'keto' form in DMSO solution. The IR spectrum of 
105 confirms the presence of vinylogous amide absorptions at 1616 and 
1554 cm-1, but also shows a broad absorption at 3444 cm-1, indicating 
hydrogen-bonded OH. This observation, coupled with the presence of two 
distinct carbonyl absorptions at 1704 and 1682 cm-1 would suggest that both 
tautomers are present in the solid state. Compound 105 was condensed 
with tbutyl cyanoacetate to give the novel tyrphostin 107 (Scheme 24). 
o o 
cCrCHO I I + ~ N 14% 
H 
i) DMF, 16 h, RT (107) 
Scheme 24 
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The 1 H NMR spectrum showed the expected olefinic proton at 0 9.02 
commensurate with the Knoevenagel product. The ester carbonyl carbon 
came at 0 161.9 in the 13C NMR spectrum and gave a strong C=O absorption 
at 1719 cm-1 in the IR spectrum. Strong absorptions at 1621 and 1553 cm-1 
were due to the vinylogous amide in 107. 
Compound 108, an hydroxylated tyrphostin, has been prepared 
previously as a potential tyrosine kinase inhibitor. We were interested in 
preparing 108 not just as a tyrphostin but also as a potential antimelanoma 
agent. Phenols and catechols are known to possess significant activity 
against melanomas (Chapter 5). Knoevenagel condensation between 4-
hydroxybenzaldehyde and malononitrile afforded 108 is good yield. The 
key spectral features of 108 were the broad O-H absorption at ca. 3350 cm-1 
in the IR spectrum and the presence of the characteristic olefinic singlet at 0 
8.30 in the 1H NMR spectrum. 
NC HO-o-FCN 
(108) 
4.7 Electron-Rich Tyrphostins 
The electronic distribution in the side-arm of compounds 46-48 
distinguished them from the other tyrphostins in the initial series. 
Delocalisation of the amine lone pair conferred a partial negative charge 
onto the terminal nitrile groups which may assist in binding to an enzyme. 
We reasoned that compounds containing the 4-dimethylaminobenzene 
mOiety as the free base would be able to mimic this effect and so increase 
electron density on the terminal groups of the side-arms. Four new 
tyrphostins were prepared from dimethylaminobenzaldehyde as shown in 
Figure 29. 
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R 
CN 
C(NH2)=C(CN)2 
CSNH2 
3-pyridyl 
Figure 29 
COMPOUND 
109 
110 
111 
112 
All of these compounds showed the characteristic singlet 
corresponding to the newly formed olefinic proton and the correct 
functionality as evidenced by the IR spectra. 
4.8 A Bioreducible Tyrphostin 
Bioreductive anticancer agents are a class of drugs which exploit a 
particular feature of solid tumours - oxygen deficiency. The demand for 
oxygen in proliferating tissue is such that the normal supply cannot keep 
pace with tumour growth. Cells which are poorly served by capillaries die' , 
others, known as 'hypoxic' cells manage to survive on a sub-optimal oxygen 
supply. Under these conditions, reductase enzymes are often 
overexpressed and drugs which contain a reducible functional group such 
as a nitro, quinone or N-oxide moiety can be metabolised to their reduced 
forms. These reductions generate radical species which can alkyl ate DNA in 
a manner analogous to that described in Section 2.4. The ideal bioreductive 
agent would be a non-toxic prodrug which only becomes active upon 
reduction within the tumour. 
We were interested in forming the N-oxide of our most potent 
tyrphostin 46 as a potential bioreductive agent. Attempts to form the N-oxide 
by direct oxidation seemed fruitless since epoxide formation would almost 
certainly be a competing reaction. An alternative scheme starting from 
quinaldine was proposed (Scheme 25). 
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I 
o 
e 
(113) 
i. H20 2 (27.5%), CH3COOH, 70°C, 30 min 
ii. Se02, dioxane, 70 - 80°C, 1 h 
iii. EtOH, malononitrile dimer, 2 h 
Scheme 25 
~ ~~ACHO 
I g 
(114) 
39% ~ iii 
~ CN CN 
I CN 
Q NH2 
(:) (115) 
Oxidation of quinaldine with peracetic acid (generated in situ)109 gave 
the N-oxide monohydrate 113. The melting point of the product and the 
spectral data concurred with those in the literature. Further oxidation with 
selenium dioxide11o afforded the aldehyde 114 in moderate yield. The 
carbonyl carbon of the aldehyde was evident at () 186.5 in the 13C NMR 
spectrum, as were C=O stretching modes (1694 cm-1) in the IR spectrum. 
Condensation with malononitrile dimer gave 115, the N-oxide of tyrphostin 
46. 80th amine and olefinic protons were present in the 1 H NMA spectrum at 
() 9.35, 9.30 and 8.43 respectively. The IA was notable for the strong nitrile 
absorption at 2216 cm-1 and the broad absorption due to N-O stretching at 
1262 cm-1. 
4.9 Biological Evaluation 
The biological evaluation of the tyrphostins described in this chapter 
was carried out by Dr Alan McGown and colleagues at the CAC Paterson 
Institute for Cancer Research in Manchester. Cytotoxicity testing was 
performed on two breast cancer cell lines, MCF-7 and MCF-7/ADR which 
expresses a higher level of EGFR activity. The results are summarised in 
Table 3. 
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COMPOUND 
74 
79 
81 
83 
89 
92 
Table 3 
STRUCTURE 
NHCOCH3 
er:h I Q N~ ~N 
~ H ~N~N 
N I 
H2N 
NH2 
CN 
NH2 
CN 
~ CN 
~ CN 
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CYTOTOXICITY 
ICSO (11 M) 
MCF-7 MCF-
71ADR 
25.9 11.2 
31.2 44.4 
31.5 3.0 
13.4 14.0 
4.0 5.7 
12.3 9.1 
Table 3 (contd.) 
CYTOTOXICITY 
COMPOUND STRUCTURE ICSO (11 M ) 
MCF-7 MCF-
7/ADR 
CH3 
I 
95 CO):!: I ,# No&: ,# ,# COOCH 3 25.2 48.1 
NH2 
COOCH3 
H2N 9' CN 
96 9' COOCH3 1.0 0.9 
~ ~ 
I ~ ~ N 
eN 
H2N 
-::? eN 
97 -::? eN 1.0 1.4 
~ ~ 
I 
,# ®A f> N C 
H 
102 
ct~ror3CH3 0.9 1.1 
~ ~ 
I~ ...!: 
N 
104 
c$~or4~H3 4.9 6.7 
~ ~ 
In ...!: 
N 
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Table 3 (contd.) 
CYTOTOXICITY 
COMPOUND STRUCTURE ICso (IJM) 
MCF-7 MCF-
7/ADR 
0 
107 
dnCOO'BU 83.4 nd. 
19 I CN 
N 
H 
108 
NC 147.1 14.1 ijCN 
HO 
NC 
109 
'ijCN 101.5 97.5 
/ -
NC 
NC 0 CN 
110 - 0 
108.8 38.0 
'N ~ 0 NH2 / 
NC 
, vICSNH' 194.8 112.6 111 /N ~ 0 
NC 
- 0.5 0.5 
112 , - 0 ~ " N ~ 0 N / 
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4.9.1 Comment on Biological Evaluation 
Compounds 74 and 79 showed only moderate activity against these 
MCF-7 cell lines. Interestingly, the reduced form of 79, compound 81, 
performed significantly better against the MCF-7/ADR line, suggesting that it 
may be inhibiting EGFR mediated growth. Compound 83 was more active 
than the other aromatic compounds but showed no selectivity between the 
cell lines. Better still was compound 89, a triene, which inhibited with ICso 
values of 4.0 and 5.7 JlM, figures comparable to those of the corresponding 
diene 48. Significantly, 89 does not incorporate a cis-nitrile function which 
was previously believed to be important for activity.2S Compound 92, a 
thiophene with a triene side-arm, also performs well. It appears that for these 
compounds the important structural motif is the 1, 1-dinitrile-aminoethene 
mOiety in conjugation with the heterocycle, regardless of the presence or 
absence of the cis-nitrile functionality. 
The novel dimers 95 and 96 show a surprising disparity in activity, 
the 4'-isomer out-performing the 2'-isomer by more than an order of 
magnitude. This trend is not evident for compounds 46 and 48, suggesting 
that the extra steric bulk of the methyl ester functions may be detrimental to 
the binding properties of 95. Tyrphostin 96 performs as well as compound 
46 and 48 and shares with them the ability to feed electrons from the 
primary amine onto the terminal functional groups. 
As expected, tyrphostin 97 exhibits good activity, showing a small 
improvement in ICso value compared to its free base 48. This may simply be 
attributable to improved solubility. Compounds 102 and 104, MTEG and 
MPEG solubilised esters showed a marked improvement over the ester 
derivatives previously synthesised. It seems likely that this may also be due 
to better uptake and transport through the cell membrane. 
The hydroxylated tyrphostins 107 and 108 performed poorly, 
although 108 showed a tenfold increase in activity against the cell line 
expressing higher EGFR kinase activity. The dimethylaminobenzene 
derivatives were inactive in these assays with the exception of 112, which 
proved to be the most potent tyrphostin in this series. Such was the interest 
in this compound that it was submitted to the University of Bradford's Clinical 
Oncology Unit for further evaluation by Professor J.A. Double. Compound 
112 was tested against a panel of 5 cell lines for 96 hours in vitro. The ICso 
values are reported in Table 4. 
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Table 4 
ICso values for Compound 112 (IlM) 
Breast Leukaemia Leukaemia Colon Colon 
MT-1 K562 WEHI-3B HT-29 DLD-1 
> 4 0.5 0.64 1.1 2.4 
These data show that tyrphostin 112 exhibits slight selectivity for the 
leukaemic cell lines but possesses a fairly broad spectrum of activity. Given 
these facts and the lack of discrimination between MCF-7 and MCF-7/ADR it 
seems likely that 112 is not inhibiting solely by TK mediated routes. 
Dr Ian Stratford at the MRC Radiobiology Unit, Didcot, agreed to test 
our N-oxide compound 115 and the parent structure 46 to determine 
Whether there was sufficient difference in activity to warrant further 
investigation. Studies against three cell lines differing in their expression of 
EGFR kinase activity showed that the two compounds performed very 
similarly (Table5). 
Table 5 
Cell Line EGFRK activity ICso Values (Il M ) 
(relative) 46 115 
MCF-7 1 60 70 
MDA-231 15 60 80 
MDA-468 640 60 90 
Given that we had ~een hoping for 115 to be inactive until reduced, it 
was evident that the compound would not be suitable for development as a 
bioreductive agent. 
4.10 Discussion and Suggestions for Future Work 
Our initial objective for this project was to establish whether or not 
heterocyclic tyrphostins, particularly quinolines, could match the activity of 
the polyhydroxylated benzene tyrphostins developed by Levitzki et al. This 
objective has been achieved. Of the eight most active tyrphostins, two exhibit 
ICso values of <5 /lM against the EGFR tyrosine kinase (46 & 48) and six 
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inhibit MCF-7 growth with ICso values of ~1 JIM (96, 97, 102 & 112) or ~5 
JIM (89, 104). 
Although the overall structure/activity pattern is still unclear, this work 
has established some important guidelines for further development. Much 
has been made of the 'dimer' structures 46 and 48, in particular the diene 
side-arm which we felt was crucial to their activity. Our own work and that of 
others has shown that tyrphostins which incorporate 1,1-dinitrile-2-
aminoethene moiety frequently, if not always, show good activity. Why is 
this? We believed that extended conjugation and the ability to delocalise 
charge onto the terminal nitrile groups were the crucial features which made 
this moiety biologically active. By preparing tyrphostins incorporating 
aromatic and heterocyclic groups in the side-arm, it became apparent that 
extension of conjugation, certainly through cyclic systems, was no guarantee 
of activity. Even compound 83, which bears a close resemblance to 46 in 
terms of functionality, could not improve upon its activity. The pyridine-
containing tyrphostin 112, however, showed excellent activity against a 
variety of cell lines as described in the previous section. It seems likely, 
given that the steric bulk of the aromatic ring appears not to be beneficial , 
that the basic nitrogen of this heterocycle is of importance. The condensation 
products of 2-quinolinecarbaldehyde with 2- and 3-pyridylacetonitrile (116, 
117) have also been prepared.91 
(116) (117) 
Both compounds show good activity against the MCF-7 cell line (ICso 
values of 5 and 8 JIM respectively), although they inhibit the EGFR kinase 
only poorly (ICso values of >500 JIM). These data add weight to the 
suggestion that tyrphostin 112 is not inhibiting by TK mediated pathways. 
Tyrphostins incorporating an aliphatic triene side-arm (89 and 92) 
showed good activity, although this may be attributable to the fact that they 
both contain the 1,1-dinitrile-2-aminoethene moiety. Interestingly, compound 
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92 shows a marked improvement in activity over its diene counterpart (118, 
ICso >50 against MCF-7).80 A preparation of the highly conjugated thiophene 
aldehyde (119) has been reported 111 (Scheme 26) which may be worth 
condensing with malononitrile dimer to see whether further conjugation 
improves activity. 
n ~S))-CHO 
n JIN JIN "S/~y"""CN 
NH2 
(118 ) 
Scheme 26 
(119) 
The role of the extra double bond in modifying the activity of 102 is 
unclear. It may simply act as a 'spacer', causing the molecule to fit better into 
an enzyme pocket. It could, however, be altering the chemical properties of 
the compound. A highly conjugated group such as the side-arm of 102 
could bond with nucleophilic centres on proteins or enzymes in a Michael 
reaction, and so inhibit cellular function. Conjugate addition of this type is 
known to account for the inhibitory properties of other anticancer agents 
such as Herbimycin A (Section 2.4). As an initial step towards establishing 
whether or not Michael-type conjugation is important to the efficacy of these 
compounds, their ability to react with sulfhydryl reagents such as ethanethiol 
or cysteine could be determined. Simple NMR experiments could provide 
this information. One would expect to see a direct relationship between the 
ability to conjugate and activity if this is an important mode of action of these 
drugs. 
It would seem worthwhile preparing further tyrphostins with 
quinolinylpropenals to investigate the properties of these promising 
compounds more thoroughly. Would, for instance, incorporation of another 
double bond improve the activity of the less reactive tyrphostins previously 
synthesised? Of particular interest would be compound 88 which was 
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synthesised but decomposed rapidly and was not tested. This structure 
closely resembles that of 46, apart from the cis-nitrile (which seems 
unimportant) and the amine moiety. 
(88) 
CN 
# CN 
CN CN 
CN 
(46) 
Comparing the activity of compound 88 with that of 46 would disclose 
information about the importance of the delocalised charge in the side-arm. 
An alternative method of achieving the same effect would be to attenuate the 
delocalisation by acetylating the amine (Scheme 27). It may prove difficult to 
effect this transformation given that the amine lone pair is not localised on 
nitrogen. It would be worthwhile developing this chemistry since the amine 
provides the only real structural handle for further modification of 
compounds 46 and 48. 
CN CN Strong Base 
--------- ... 
CN 
CN CN 
(C~~~~:~/. 
" 
NHCOCH3 
Scheme 27 
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The question of the electronic distribution in tyrphostins is an 
interesting one and evidence that it may have a bearing on their activity is 
found in several other publications. Levitzki et al. report that tyrphostin 120, 
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an hydroxylated benzene, inhibits the EGFR kinase with an ICso value of 
0.125 11M. 2S When a nitro function is introduced ortho to the hydroxyl 
function, as in compound 121, the activity decreases to 60 11M. 
HO 
R 
COMPOUND R 
120 H 
121 N02 
ICSO (11 M ) 
0.125 
60 
The introduction of the N02 group changes the electronic distribution 
of the tyrphostin since the lone pair of the hydroxyl oxygen can delocalise 
into it. This has the effect of reducing the overall partial negative charge in 
the dimer side-arm and may account for the loss of activity. 
Levitzki and others 112, 113 have developed potent TK inhibitors (68, 
122) incorporating methoxyl substituents which can delocalise into the 
sidearm in an exactly analogous manner. 
OCH3 
(68) (122) 
Maguire et al., who prepared a series of 63 3-substituted quinoline 
compounds as tyrosine kinase inhibitors, concluded that the presence of 
6,7-dimethoxy groups on the quinoline ring was advantageous, if not 
essential, for good activity.113 
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Applying this thinking to our work, we prepared several tyrphostins 
incorporating the dimethylaminobenzene moiety which, in theory, could feed 
electrons into the side-arm. The pKa of protonated dimethylaminobenzene is 
of the order of 4, so at physiological pH one would expect it to exist largely 
as the free base. We were surprised to find that, with the notable exception 
of the pyridine derivative 112, these compounds were inactive, which 
suggests that increasing the negative charge in the side arm actually 
diminishes activity. Indeed, compound 110, which should have an 
abundance of negative charge at the nitrile terminal end, was among the 
least active tyrphostins in the series. Although electronic distribution does 
seem to play a part in determining activity, no clear structure-activity 
relationship has emerged. This warrants further investigation. 
Suggestions for Further Work 
• The mode of action of tyrphostins 46 and 48 should be established, with 
a particular emphasis on discovering the nature of the 50 kDa protein 
they bind to (Section 3.6.1). We have had conflicting reports about the 
sensitivity of these compound to cell lines with different levels of EGFR 
kinase expression. This needs further clarification. The most active 
tyrphostins should be evaluated for inhibition of the EGFR kinase. 
• More tyrphostins containing diene or triene side-arms should be 
prepared and evaluated as potential Michael acceptors as described 
previously. 
• The importance of the amine function in 46-48 should be established by 
either removing it or disabling it. The chemistry of this amine should be 
investigated. 
• The most active tyrphostins should be solubilised with MTEG, which is 
considerably easier to work with than MPEG. If the amine moiety in 46, 
48 and 96 can be employed, it may be possible to form amides (e.g. 
123) with suitably functionalised MTEG derivatives such as MTEG 
succinate (Chapter 6). The amide linkage may be metabolised to release 
the free amine in vitro. 
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(123) 
An alternative approach would be to prepare quinolines with 
substituents in the benzene ring which would lend themselves to further 
functionalisation (such as hydroxyl, amine or carboxyl or ester groups, 
Figure 30). This would avoid compromising the integrity of the 
substituents in the pyridine ring. 
Figure 30 
• The effects of electron-releasing and donating substituents on the activity 
of tyrphostins should be investigated. A simple benzene tyrphostin such 
as 124 could be substituted by a variety of functional groups with 
differing electronic properties. These could then be tested for cytotoxicity. 
The process should be repeated with other tyrphostin side-arms to 
determine whether a consistent pattern of activity is seen. The 
substituents which prove most beneficial to activity should be 
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incorporated into existing tyrphostins at the appropriate position to exert 
the correct 'pull' or 'push' of electrons. 
(124) 
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Malignant Melanoma: Causes 
and Cures. 
5.1 Introduction 
5 
Despite progress in our understanding of the biochemistry of skin 
cancer and growing public awareness of the associated risk factors, 
malignant melanoma still poses many problems to the clinician and 
medicinal chemist alike. 
As with all cancers, malignancy indicates that the normal growth 
patterns of the cell have been corrupted, allowing unrestrained division to 
occur. In malignant melanoma this manifests itself by the appearance of dark 
nevi or lesions on the skin caused by excessive production of melanin. 
While treatment in the early stages is possible by drug administration and 
surgery, little can be done for patients in the advanced stages of the disease. 
The lack of efficacious therapy for disseminated malignant melanoma is the 
driving force behind the drug development programmes described in this 
chapter. 
5.1.1 The Epidemiology of Malignant Melanoma 
The term 'skin cancer' covers a number of manifestations of the 
disease which vary in severity and presentation. Among these are the so-
called 'non-melanotic' cancers such as basal cell carcinoma and squamous 
cell carcinoma which account for most cases (>75%) of skin cancer. These 
diseases, particularly basal cell carcinoma, have a relatively good prognosis 
since the cancers tend not to metastasise. Cure rates of 90-95% can 
regularly be achieved by surgery or radiotherapy. This is in sharp contrast to 
the more aggressive form of skin cancer, malignant melanoma, which is 
highly metastatic. By the time the disease has entered the lymph nodes 
surrounding the primary tumour, the likelihood of cure has dropped to only 
15%. The median survival time for those presenting with fully disseminated 
disease is 6 months. Four main types of the disease are known: superficial 
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spreading melanoma, which accounts for 70% of cases; nodular melanoma, 
the most rapidly growing form; lentigo maligna melanoma, which tends to 
affect the elderly, and acral melanoma which occurs on the palms, soles and 
nails.10,114 
Although malignant melanoma only accounts for 2% of all cancers, its 
rate of incidence continues to rise at an alarming pace. Independent 
statistics from Scotland, Scandinavia and Australia show that the number of 
diagnoses of the disease is doubling every decade.1 ° Mortality rates are 
also on the increase, albeit less rapidly thanks largely to earlier diagnosis. 
This elevation in the profile of the disease reflects several changes in society 
this century, the most marked of which is the amount of time we spend 
exposed to solar radiation. The link between sunlight and skin cancer has 
been known for over 100 years but it was first quantified in 1907 by William 
Dubreuilh, a French dermatologist who performed conclusive 
epidemiological studies on the subject. George Findlay, a British pathologist, 
confirmed and extended this work in 1928 by inducing skin cancer in mice 
exposed to UV radiation. 115 Although UV rays do not penetrate deeply into 
the skin, overexposure is known to cause mutagenesis and the onset of 
cancer. UVB (280-320 nm) has been identified as the most dangerous band. 
Depletion of the ozone layer has increased the amount of UVB reaching the 
earth's surface: one estimate suggests that a 1 % depletion in the ozone 
layer would increase the amount of potentially damaging UVB reaching us 
by 2%.116 
Despite these statistics, the sun-tan continues to be a Western symbol 
of health, wealth and happiness. In pursuit of brown skin, holidaymakers 
spend vast amounts of time soaking up the sun on the beach while taking 
few protective measures. Significantly, the group most at risk of contracting 
skin cancer are fair-skinned individuals who spend most of their time indoors 
but sunbathe to excess when on holiday.117 Unsurprisingly, it's those 
countries where malignant melanoma is rife which have been leading the 
way in terms of public education programmes. Australia, where the 
incidence of skin cancer is three times the world average, has taken strides 
in raising public awareness with its recent 'Slip-Slap' campaign. The light-
hearted advertisements encourage sunbathers to slip on a T-shirt or slap on 
some sun-cream. A strong emphasis is placed on protecting children from 
the sun, since early exposure seems to be a risk factor in developing the 
disease in later life. 118 
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World-wide studies have established associations between sunlight 
and the incidence of malignant melanoma, several of which are outlined 
below. 
• In a seminal paper of 1956,119 Lancaster demonstrated that within 
groups of the same skin type, risk of death increased with proximity of 
residence to the equator. This pattern has been confirmed in more recent 
studies in North America 120, England and Wales 121 and the 
Scandinavian countries.122, 123 
• Immigrants to countries with sunny climates are less likely to develop 
malignant melanoma than those of the same race born in that country. 
this indicates that childhood exposure may be a significant risk factor.118 
• The likelihood of developing melanoma increases with one's educational 
and social status.124 
• Women are more at risk from malignant melanoma than men. In the UK, 
female incidence is roughly twice than found in males. Much of this 
difference may be attributable to differences in dress codes. 47% of 
primary melanomas in women occur on the legs compared to only 10% 
of those in men.125 
• Skin colour is a key factor in assessing an individual's chances of 
developing the disease. Incidence is 12 times higher in white-skinned 
people compared to black individuals with a similar lifestyle.125 
Interestingly, certain African tribes develop melanomas on the soles of 
their feet, the area least protected by melanin.126 
• Within white-skinned races, those people with fair or red hair and blue 
eyes who do not tan readily are most at risk. A large number of moles on 
the individual's skin (> 40) may also indicate a genetic predisposition to 
the disease. 
5.1.2 Prognosis and Current Therapy 
The superficial nature of malignant melanoma makes it among the 
easiest of cancers to detect. Successful education programmes have alerted 
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the public to the classic signs of the disease: 'moles' which appear 
suddenly, change colour or start to itch or bleed. One such campaign in the 
west of Scotland increased the proportion of patients identifying the disease 
in its earliest stages by 17%.127 The importance of identifying and treating 
the disease as soon as possible cannot be overstated since there is a clear 
correlation between tumour invasiveness and prognosis. The commonest 
clinical measurement of the extent of the disease is the Breslow thickness 
(Figure 31), named after a pathologist who saw the need to quantify the 
degree of tumour invasion as an aid to prognosis.128 A section from the 
thickest part of the melanoma is excised and examined microscopically. The 
Breslow thickness is taken as the distance in millimetres from the granular 
layer in the epidermis to the deepest invasive tumour cell in the underlying 
tissue. The significance of this measurement is self-evident from Table 6.129 
Epidermal surface 
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Deepest invasive 
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Figure 31 130 
Table 6 
Breslow Thicknessl mm Actuarial 5-year survival 
(%) 
0.0 - 0.75 93 
0.76 - 1.50 82 
1.51 - 3.00 67 
3.01 - 4.50 57 
> 4.51 37 
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A variety of further classifications exist which depend on the extent to 
which the disease has metastasised. Broadly speaking, the progress of the 
cancer can be split into three stages. 
I) Primary melanoma - no metastases. 
II) Metastases in regional lymph nodes. 
III) Disseminated disease. 
Stage I tumours can be treated surgically, which involves excising the 
primary tumour to the appropriate depth with prophylactic removal of the 
surrounding tissue. A rule of thumb coined by the World Health Organisation 
is that for each mm of tumour depth, an area of diameter 1 cm should be 
excised around the primary tumour. 131 Five-year survival rates for patients 
with stage I tumours range from excellent (93% when Breslow thickness 
<1.5 mm) to moderate (38% when Breslow thickness >3.5 mm).132 
Stage " tumours can also be treated by surgery but the degree of 
excision must be extended to include the regional lymph nodes as well. At 
the moment there is no satisfactory treatment for the advanced stage of the 
disease. Of the chemotherapeutic agents used, OTIC (dacarbazine, 125) is 
the single most successful agent giving some degree of response in 22% of 
patents. 133 The anticancer activity of OTIC is ascribed to the formation of 
alkylating metabolites. 134 
CONH2 N~ N~ /~" Lr N 
H 
(125) 
Combination chemotherapy with OTIC can marginally improve 
response rates but its main advantage is in extending the duration of 
response. Despite this, most tumours are only susceptible to the drug for a 
matter of months. There is a clear need for novel anticancer agents for the 
treatment of advanced malignant melanoma. 
Several classes of phenolic compounds have shown promise as 
antimelanoma agents. Acting in a non-classical fashion, these prodrugs use 
the biochemical 'machinery' of the melanocyte to generate toxic species in 
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situ. The subsequent sections of this chapter outline the normal function of 
the melanocyte and explain how its 'machinery', particularly the enzyme 
tyrosinase, can be used to advantage in fighting malignant melanoma. 
5.2 Melanin: Function and Synthesis. 
Melanin is the dark, pigmented heteropolymer which gives skin its 
colour. The synthesis of melanin takes place within melanosomes which are 
vesicles formed in dedicated cells called melanocytes (Figure 32). These 
pigment-producing cells are mainly located in the epidermis and the retina. 
The number of melanocytes is fairly consistent across all races; what differs 
is the amount of pigment they produce and disperse. This genetic variation 
gives rise to the different skin tones and colours with which we are familiar. 
Albinism is a congenital defect which precludes melanin synthesis, resulting 
in pale skin and white hair. 
Keratinocyte 
, 
, 
@ 
Melanocyte 
Figure 32135 
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Melanin is formed as a consequence of the oxidation of tyrosine 
(126), catalysed by the enzyme tyrosinase, a process which occurs 
uniquely within melanocytes (Scheme 28). Melanin polymers are highly 
unsaturated and readily absorb the energy associated with UV radiation. 
There are two main classes of integumentary melanin - brown/black 
eumelanin and yellow/red pheomelanin. In melanocytes, tyrosinase oxidises 
tyrosine to dihydroxyphenylalanine (dopa, 127) and then dopaquinone 
(128) which is cyclised and oxidised further to give eumelanin. If 
dopaquinone encounters cysteine (129) or other related sulfhydryl 
compounds, pheomelanin is produced via cysteinyl dopas, among which 5-
S-cysteinyl dopa (130) is the major isomer. Recent evidence indicates that 
pure pheomelanins or eumelanins rarely exist and that each melanin is best 
thought of as a heteropolymer containing varying degrees of cysteinyl or 
non-cysteinyl monomer units.136 
The key biochemical feature of melanocytes is the cuproenzyme 
tyrosinase, which acts successively as a monophenol monooxygenase and 
then as an oxidase. The enzyme does not require a cofactor but uses the 
product of the hydroxylation, dopa, as the hydrogen donor. Tyrosinase is 
found only within melanocytes and as such can act as a specific biochemical 
marker for these cells. 
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5.3 Background to Antimelanoma Drug Synthesis 
The melanocyte is, in some senses, an ideal system for drug targeting 
since its function is unique but non-essential. Consequently, potential 
agents need only be able to discriminate between melanocytes and non-
melanocytes rather than between healthy and malignant cells. The most 
distinctive feature of melanocytes is tyrosinase and most attempts at rational 
design of antimelanoma agents have focused upon this enzyme. 
The common approach in tyrosinase-mediated strategy is to design a 
prodrug which is a substrate for the enzyme and which gets oxidised in situ 
to form a cytotoxic metabolite. The beauty of this approach is its specificity. 
Provided that the prodrug is non-toxic and specific for tyrosinase, cell kill 
should be limited to melanocytes only. Since the initial tyrosinase substrate 
in melanin synthesis is tyrosine, many mono- and di-hydroxybenzene 
analogues have been synthesised as potential substrates. Several of these 
are outlined below.137 
Hydroquinone (131): Depigmenting agent for black skin and hair. 
Reduced the incidence of successful transplantation of mouse melanoma. 
Increased survival of melanoma-bearing mice. 
4-lsopropylcatechol (132): Depigmenting agent for black skin and hair. 
Prolonged life span of melanoma bearing mice. 
Dopa, dopamine, 6-hydroxydopamine (133, 134, 135): Antitumour 
effect against mouse/human melanomas in vivo and in vitro. 
4-Hydroxyanisole (136): Exhibited anti-tumour activity in mice and in 
pilot clinical trials. Unfavourable pharmacokinetics mitigates against 
widespread clinical use.138 
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OH OH OH ¢ OH OH 
eOOH OH 
NH2 
(131) (132) (133) 
OH OH OH 
OH OH ¢ HO 
NH2 NH2 OMe 
(134) (135) (136) 
Wick139 has proposed a mechanism for the cytotoxicity of these 
compounds. Upon oxidation by tyrosinase to the ortho-quinone form, the 
drugs can conjugate with sulfhydryl enzymes such as DNA polymerase and 
so inhibit the cell's replication processes. Another theory, suggesting the 
involvement of quinone radicals as alkylating agents has been proposed.140 
The proposed mechanisms for the melanocytotoxic effects of phenolic 
compounds are illustrated in Scheme (29). 
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Despite their interesting biological effects, catechol-based drugs are 
unlikely to find much clinical use: instability and systemic toxicity due to non-
specific oxidation are severe limitations. With this in mind, Miura et al. 137 
have synthesised a range of sulfur-containing phenols (and catechols) as 
potential antimelanoma agents. Sulfur was incorporated to increase 
lipophilicity and hence improve uptake of the drug into the melanocyte. 4-S-
Cysteaminylphenol (137) and 4-S-cysteinylphenol (138) proved to be the 
most successful compounds. Both increased the life span of melanoma-
bearing mice and inhibited the growth of melanoma tissue. The results are 
summarised in Table 7. Significantly, the corresponding 2-S isomers of 137 
and 138 did not show any significant anti melanoma effect. 
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OH OH ¢ ¢ 
.# NH2 
8~NH2 8JCOOH 
(137) (138) 
Table 7 
COMPOUND Increase in life span Growth Inhibition 
(% I.L.S.) i% G.I.) 
137 48.7 64.2 
138 15.4 20.3 
Topical application of 137 and 138 on the skin of black guinea pigs 
caused marked depigmentation. This phenomenon was attributed to a 
decrease in the number of functioning melanocytes; a decrease in the 
number of melanosomes synthesised, and the destruction of membranous 
organelles within the melanocyte.141 
A further study142 showed that 137 and 138, unlike their 2-8 
counterparts, were excellent substrates for mushroom tyrosinase and good 
substrates for mammalian tyrosinase. Given the difference in activity 
between the 2-8 and 4-8 isomers, these findings seemed to affirm a role for 
tyrosinase in generating cytotoxic species from hydroxybenzenes. This 
discovery added weight to Wick's quinone theory.139 To this end, the ability 
of the quinone forms of 137 and 138 to conjugate with cysteine and 
cysteine residues was determined. With cysteine, both quinones performed 
better than the quinone derived from tyrosine itself. With cysteine residues in 
alcohol dehydrogenase, however, 137 was over five times as effective at 
conjugation as 138 which, it was suggested, could account for the 
difference in their activity (Table 7). 
In 1990 the same group of workers were forced to review this theory 
after discovering that 137 was, in fact, being oxidised in vitro by monoamine 
oxidase (MAO).143 This concurred with work carried out by Padgette et al.144 
which showed that phenyl aminoethyl sulfides were good substrates for 
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MAO. In this study, four phenolic derivatives were tested for in vitro 
antimelanoma effect. 
OH OH OH OH ¢ ¢ ¢ ¢ 
S S~NH2 SJNH2 S~ ./ ~NH2 N I 
(137) (139) (140) (141 ) 
The compounds 137 and 139 proved to be much more cytotoxic than 
the other two analogues, but their activity was completely negated in the 
presence of semicarbazide, an inhibitor of plasma MAO. The activity of the 
second pair of amines was not modified by administration of semicarbazide, 
catalase or phenylthiourea, a tyrosinase inhibitor. In culture medium, the 
primary amine of 137 was shown to be oxidised to the aldehyde and then 
the acid. From this work it was concluded that the activity of the straight 
chain primary amines was attributable to the formation of oxidation products 
via MAO. The activity of the other two amines was, in part, attributable to 
tyrosinase but clearly involved other mechanisms. 
In an attempt to diversify from straight-chain amines, Miura et a/. 
synthesised the N-acetyl derivative (142) of 135 .145 This compound, which 
is a substrate for mammalian tyrosinase but not for MAO, proved to be even 
more successful than its parent compound, exhibiting 74.4% growth 
inhibition of the B 16 melanoma cell line in mice. When introduced 
subcutaneously into black mice, 142 showed 98% depigmentation of black 
hair follicles. 146 Further in vivo studies proved that 142 accumulated readily 
in melanotic tissue and that its antimelanoma activity could be enhanced if 
administered in combination with buthionine sulfoximine. 147 Human 
xenografts in nude mice were also sensitive to the reagent.148 A recent in 
vitro study by the same authors has shown that a variety of cancer cell lines 
can be inhibited by 142 and its analogues, suggesting that non-tyrosinase 
mediated cytotoxicity may well be involved.149 
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OH 
o yo 
S~N~ 
H 
(142) (143) 
Thiophenols are by no means the only tyrosinase-activated prodrugs 
in development. Mascagna ef al. have been studying p-aminophenols 
concurrently, several of which show good antimelanoma activity.1S0 By 
introducing an amine function para to the phenolic hydroxyl group, the 
authors hoped to increase the susceptibility of their drugs to oxidation by 
tyrosinase. Prior work had established that phenols are more easily oxidised 
by tyrosinase when they contain electron donating substituents in the para 
position.1S1 A lead compound from this study was the di-protected catechol 
143 which exhibited an ICso of 15 I-lg/ml against the human HBL melanoma 
cell line. This class of compounds shows a fairly broad spectrum of activity 
across various cancer types, leading to the conclusion that their mode of 
action may not be entirely tyrosinase dependent. 
5.4 Melanoma Research at Glasgow University 
In 1993 the Cancer Research Group of Glasgow University chemistry 
department were approached by Professor Rona Mackie, a leading clinical 
dermatologist, and asked if we could provide a sample of compound 142 for 
her own studies. In the course of our literature search, it became clear that 
little progress had been made in refining or developing the structure of 142. 
It appeared that the researchers concerned had hit upon a successful 
compound and were content to investigate its biological properties at length. 
It seemed to us, as medicinal chemists, that there was a great deal of work 
which could be done to develop this interesting class of compounds. 
Professor Mackie was glad to lend her support and experience to our efforts. 
This was the start of an ongoing programme which has seen us match, and 
go beyond our initial target compounds. Chapter 6 details the synthesis and 
biological evaluation of these novel antimelanoma agents. 
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6 
Synthesis and Biological Evaluation 
of Antimelanoma Agents. 
6.1 Preparation. Characterisation and Development of 
Compound 142. 
Our initial target in this area was the phenolic amide 142 which had 
previously been prepared by Padgette et al. as an antihypertensive 
agent. 144 The authors used a preparation involving the reaction of 4-
hydroxythiophenol (144) with 2-methyl-2-oxazoline (145, Scheme 30). 
OH OH ¢ ~ ¢ + NyO ~ .# 0 92% S~N)lCH SH CH3 H 3 
(144) (145) (142) 
i. Reflux neat, 2h, N2 
Scheme 30 
Oxazolines are five-membered heterocycles containing one double 
bond and are designated as 2-, 3- or 4- oxazolines depending on the 
position of that bond. 2-0xazolines are the most common type. They are the 
dihydro derivatives of oxazoles and are commonly encountered as 
protecting groups for carboxylic acids (Scheme 31 ).152 
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--.. .. ,4\/ 
R N~ 
ii 
-----! .. ~ RCOOH 
i. Reflux, toluene, 70-80% ii. HCI (aq), 90% 
Scheme 31 
They are also useful synthetic reagents in their own right and many 
are now commercially available. We prepared oxazoline 145 from 
ethanolamine and acetonitrile according to the method of Witte and Seeliger 
(Scheme 32).153 
OH 0 C + CH3CN --54-
0
1c-o - .. ~ ~ACHs + NHs 
NH2 
(145) 
i. Reflux, Cd (OAch, 120°C 
Scheme 32 
The boiling point for 145 agreed with that recorded in the 
Iiterature. 154 Reaction with 4-hydroxythiophenol under the conditions 
employed by Padgette et al. (Scheme 3D), afforded 142 in excellent yield. 
The spectral data and melting point of 142 concurred with those in the 
literature.144 
6.1.1 Crystal Structure of Compound 142 
Compound 142 was recrystallised in a flat bottomed flask from 
analytical grade ethyl acetate, affording small, rhombic crystals. These were 
submitted to Dr K.W. Muir (University of Glasgow) for X-ray crystallographic 
analysis. The displacement ellipsoid structure of this compound is depicted 
overleaf (Figure 33). 
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Figure 33 
The molecule adopts a non-planar conformation, the crucial bond 
angles being the C(4)-S(1 )-C(7) angle which is 99.81 ° and S(1 )-C(7)-C(8) 
angle which is 114.7°. The C(4)-S(1)-C(7)-C(8) torsion angle is 71.5°. 
Crystallising in this form gives the molecule several stabilising hydrogen 
bonding interactions (Figure 34). The oxygen and hydrogen of the hydroxyl 
group participate in H-bonding with two different molecules. The hydroxyl 
oxygen binds to an adjacent amide hydrogen while the hydroxyl hydrogen 
associates with a carbonyl oxygen. The unit cell of the crystal is represented 
in Figure 35. 
Figure 34 
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Figure 35 
6.1.2 Proposed Structural Modifications to Compound 142 
Having prepared 142 successfully, we set about modifying the 
structure in search of more active compounds. We pinpointed five areas, 
illustrated in Figure 36, which we considered worthy of investigation. 
OH 
replace/modify 
sulphur 
replace/modify hydroxyl 
... _------ other aromatic structures 
I 
I 
I 
I 
I 
I 
modify terminal 
functional group 
introduce alkyl grC?ups 
into side-chain 
Figure 36 
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The rationale behind replacing the OH group was to test the 
hypothesis that phenols exert toxicity by oxidation to ortho-diols and then to 
ortho-quinone forms.139 If this hypothesis is correct, we would expect to see 
a diminution of activity when OH is replaced by, for example, methyl or 
halide groups. We expected that the phenol would be the active part of the 
molecule, but to affirm this we decided to replace it with heterocyclic 
moieties. A negative result would again confirm the importance of the 
phenol. 
Miura et al. 137 had incorporated sulfur in the structure of 142 to 
increase lipophilicity. We were interested in either replacing or oxidising this 
atom. The work of Mascagna et al.15o suggested that the nature of the 
heteroatom was not crucial to the efficacy of these compounds. Fina"y, we 
wanted to explore the effects of introducing alkyl groups into the thioether 
side-chain and altering the nature of the terminal amide function. 
Financial support from Professor Mackie (Department of 
Dermatology) enabled us to start this project in the summer of 1993 with the 
help of three undergraduate students, Neil Lant, Robert Campbell and Ian 
McBride. 23 novel compounds were prepared, including some where the 
hydroxyl moiety had been replaced by hydrogen, alkyl group and halides or 
derivatised as ethers and esters. A sma" number of compounds with 
different thioether side-chains were also prepared. The compounds were 
tested against murine melanoma cell lines in vitro by Professor Mackie. The 
conclusions from this work155 can be summarised in three simple 
statements. 
• An hydroxyl, or latent hydroxyl function is essential for activity. 
• Alkyl groups a-to the nitrogen improve activity. 
• Larger terminal alkyl groups improve activity. 
We were interested to find that phenolic ester derivatives were active, 
whereas a" the other compounds where the OH group had been replaced 
were much less. It seems likely that the esters are hydrolysed in vitro to 
generate the free phenol (this is what is meant by a 'latent' hydroxyl 
function). The discoveries from this work were a useful springboard for 
further development of phenolic antimelanoma agents. 
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6.2 Oxazoline Synthesis 
As a first priority, we concentrated our attention on increasing the bulk 
of the thioether side-arm. Given that we were preserving the phenolic 
portion of the molecule, the chemistry of Padgette et al. seemed eminently 
suitable for our purposes, provided that we could prepare the appropriately 
substituted oxazolines. A wide variety of preparative methods for oxazolines 
are available and have been well reviewed. 156,157 We employed two 
methods, which involved the reaction of nitriles153 or acid chlorides156 with 
2-aminoalcohols. The general schemes for these reactions are shown 
below (Scheme 33). 
Method A: 
R1 R2 R1 R2 
r NH2 R3CN .. h + NH3 + NyO 
OH R3 
L Reflux, Cd (OAch 120°C 
Method B: 
R1 R2 
R1 R2 
~NHCOR3 r NH2 + R3COCI .. HCI + OH 
OH 
J 
ii, iii 
L DCM, RT, 2h 
iL SOCI2 
R1 R2 iiLNaOH h 
NyO 
R3 
Scheme 33 - R1, R2 and R3 as specified in Table 8 
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Five oxazolines were prepared using these methods (Table 8) 
Table 8 
LABEL R1 R2 R3 METHOD 0/0 YIELD 
145154 H H CH3 A 54 
146158 H CH3 CH3 A 49 
147159 CH3 CH3 C2H5 A 68 
148160 CH3 CH3 tBu B 69 
149 CH3 CH3 C6H5 B 70 
Compounds 145, 146, 147 and 148 gave the correct boiling points 
according to the literature and showed the presence of imidic ester 
absorptions in the IR spectra (C=N at ca. 1674 cm-1 and C-O at ca. 1230 cm-
1). Compound 149 showed aromatic and aliphatic C-H stretching modes in 
the IR spectrum at 3032 and 2968 cm-1, respectively. The main features of 
the 1 H NMR spectrum of 149 were the five aromatic protons between 8 7.19 
and 7.83 and the gem-dimethyl protons at 8 1.24. 
6.3 Synthesis of Analogues of Compound 142 
Six compounds were prepared by reaction of thiophenols with the 
various oxazolines described in Section 6.2. Five of these derivatives 
formed readily under the conditions described by Padgette, but 155 could 
only be prepared in DMF under more forcing conditions. The results are 
summarised in Scheme 34 and Table 9. 
x X ¢ R1 R2 A) reflux neat, 2h, N2 ¢ h .. + NyO or 5t2O 8) reflux in DMF, 5h, N2 R3 S N)lR3 SH 
H 
Scheme 34 - X and R groups as specified in Table 9 
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Table 9 
LABEL X R1 R2 R3 METHOD % YIELD 
142 OH H H CH3 A 41 
150 F H H CH3 A 72 
151 OH CH3 H CH3 A 61 
152" OH CH3 CH3 CH3 A 52 
153 OH CH3 CH3 Et A 63 
154 OH CH3 CH3 tBu A 63 
155 OH CH3 CH3 CSH5 B 19 
" The oxazoline required in this preparation, 2,4,4-trimethyloxazoline, was purchased from Aldrich 
Chemicals. 
The fluorine derivative 150 was easily identified by the 13C/19F 
coupling in the 13C NMR spectrum. The observed coupling constants were 
245, 8 and 22 Hz for the carbons at positions 4', 3' and 2' in the benzene 
ring. The amide carbonyl carbon came into resonance at b 170.4. The IR 
spectrum of 150 showed amide stretching modes at 1637 and 1560 cm-1 
and a C-F absorption at 1242 cm-1. 
The racemic amide 151 showed an ABX system in the 1H NMR 
spectrum for the diastereotopic methylene protons in the side-chain. The 
melting point and spectral data for 151 agreed with those previously 
recorded in the Iiterature.144 
Compound 152 incorporated two methyl substituents in the side-
chain which were present as a singlet integrating for six protons in the 1 H 
NMR spectrum. The IR spectrum showed N-H stretching at 3307 cm-1 and 
amide absorptions at 1636 and 1559 cm-1. 
The propanamide 153 showed the required signals for the ethyl 
group in the 1 H NMR spectrum; the 3J coupling constant between the 
methylene and methyl protons was 7.5 Hz. The methylene carbon adjacent 
to the amide carbonyl came into resonance at b 30.2 in the 13C NMR 
spectrum. 
Compound 154 gave a large singlet at b 1.06 integrating for 9 
protons in the 1 H NMR spectrum. The tbutyl quaternary carbon came into 
resonance at b 38.6 in the 13C NMR spectrum. The IR spectrum showed 
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amide N-H and C=O stretching modes as well as strong aliphatic C-H 
absorptions at 2970 cm-1. 
The N-substituted benzamide 155 showed nine aromatic protons in 
the 1H NMR spectrum and exhibited aromatic C-H stretching modes in the IR 
spectrum. Absorptions at 817 and 715 cm-1 confirmed the presence of para 
disubstituted and monosubstituted benzene moieties. The poor yield of 155 
may be understood by considering the mechanism of the reaction (Scheme 
35). The first step is deprotonation of the thiol (pKa -7) by the oxazoline 
nitrogen. The protonated oxazoline is then susceptible to nucleophilic attack 
at the 5' position, since this pushes electrons onto the positive nitrogen 
atom. When R3 is a phenyl group, however, the positive charge can 
delocalise through the benzene ring, stabilising the intermediate and 
making it less likely to react with the thiolate anion. 
t 
Scheme 35 
6.4 Optically Active Antimelanoma Agents 
In 1991, the same group of workers who had been studying 142 as 
an antihypertensive agent published an interesting paper in which they 
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demonstrated an enantiomeric specificity in the antihypertensive activity of 
1-(phenylthio)-2-aminopropane (156).161 
(156) 
Their studies showed that the (S)- isomer of 156 was seven times 
more active then the (R)-isomer against the enzyme dopamine p-
monooxygenase. We were interested in preparing the enantiomers of 
racemate 151 for testing to determine whether tyrosinase exhibited a 
preference for one stereoisomer. 
Starting from chiral 2-aminopropanols (157a & b) we were able to 
prepare enantiomerically pure (R)-and (S)-N-{[2-( 4-hydroxyphenyl)thio-1-
methyl]ethyl}acetamides (159a & b, Scheme 36).161 
(157a) (R) (drawn) 
(157b) (5) 
i. Reflux, Cd (OAch. 120 ·C 
ii. Reflux, N2, 5h 
70% 
OH 
¢ 
SH 
Scheme 36 
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(158a) (R) 
(158b) (5) 
[a]o=+80P 
[a]o=-80.2° 
I 57% 
OH 
I~ 
(159a) (R) [a]o=-30.0° 
(159b) (5) [a]o=+30.9° 
Oxazolines 158a and b 161 ,162 and products 159a and b gave equal 
and opposite rotations but this was not sufficient proof that they were single 
enantiomers. Evidence to this effect was obtained by studying the 1 H NMR 
spectra of amides 159a and b in the presence of the chiral shift reagent 
tris[3-(heptafluoropropylhydroxy methylene)-( -)-camphorato] europium (III) 
[Eu(hfch, 160]. 
0---_ 
.......... ~ ---0--------------- ---::: Eu 
3 
(160) 
Figure 37a shows a section of the 1H NMR spectrum of 151, which is 
a racemic mixture of (R) - and (S)- enantiomers. The signal shown is due to 
the methyl group (labelled 7) borne by the carbon a- to nitrogen. 
OH 
This signal is split into a doublet by a three bond coupling to the 
proton borne by carbon 6. The (R)- and (S)- enantiomers are, of course, 
indistinguishable by NMR spectroscopy. Figures 37b and 37c show the 
same signal after addition of 1 mg and 10 mgs of Eu(hfcb, The shift reagent 
acts as a Lewis acid and forms a diastereomeric complex with both isomers 
of 151. 'As the shift reagent is added the signal moves downfield under the 
influence of the paramagnetic europium atom and becomes resolved into 
two distinct doublets. The methyl groups are no longer equivalent and come 
into resonance at different chemical shifts. Although the spectrum becomes 
distorted, it is evident that the enantiomers are present in approximately 
equal quantities. 
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151 + 
159a + 
; i , , ii' 
1.5 1.0 
(a) 
o 
" :5' , , '1.'0 
(d) 
o 
• i , , • , i ' 
1.5 
(b) 
1 
(e) 
2 
1.0 
Fi ure 37 
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i , • , , i ' 
2.0 
(e) 
10 
(f) 
6 
1.5 
mg Eu(hfe)3 
mg Eu(hfe)J 
159b + 
, I ••• ii' i 
1.5 1.0 
(g) 
o 
••• I' i •• Iii 
1.5 1.0 
(h) 
5 
Figure 37 
mg Eu(hfch 
Figure 37d shows the lH NMR spectrum for the same methyl group in 
the (R) -isomer 159a. Even after addition of 6 mg of shift reagent the signal 
for the methyl group remains a clear doublet, indicating the presence of only 
one enantiomer. The same observation was made for 159b (Figure 37g 
and 37h). Although these experiments do not prove that the absolute 
configurations assigned to 159a and 159b are correct, they indicate the 
presence of only one stereoisomer in each case. The proposed mechanism 
for the reaction is shown in Scheme 37. 
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'~0 rNH2 + H3C-C~N-CdOAC 
OH 
Scheme 37 
H2N-CdOAc 
I 
-8 
AcO 
If this mechanism is correct then the stereochemistry of the starting 
amino alcohol is preserved throughout the reaction. Labelling studies would 
be of use in determining the reaction pathway. If acetonitrile labelled with 
15N were reacted with 2-aminopropanol as in Scheme 32, one would expect 
to find none of the radioactive nitrogen in the oxazoline according to the 
proposed mechanism. 
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6.5 Novel Heterocyclic Derivatives 
2-Methyl-2-oxazoline was reacted with three fused heterocyclic thiols 
to produce the novel compounds 161, 162 and 163. We thought it unlikely 
that the benzimidazole, benzoxazole and benzthiazole rings would be 
substrates for tyrosinase and were interested to discover whether any 
activity remained in the absence of the phenol moiety. The preparative 
details are summarised in Scheme 38 and Table 10. 
o:N I }-SH # X 
i. 2-methyl-2-oxazoline, reflux 2h, N2 
Scheme 38 
Table 10 
LABEL X % YIELD 
161 N-H 45 
162 0 97 
163 S 40 
The benzimidazole derivative 161 showed some interesting spectral 
features. A broad absorption at 3155 cm- 1 in the IR spectrum indicated 
hydrogen-bonded N-H stretching modes which could either be from the N-H 
of the imidazole or the amide. Examination of the 1 H NMR spectrum showed 
that the coupling constant for the methylene protons of the side-chain was 
higher than normal by -1-1.5 Hz. This suggested that the side chain may be 
twisting back on itself for the amide carbonyl to hydrogen bond with the 
imidazole N-H. Molecular modelling has shown that conformations which 
allow this interaction force the two methylene groups in the side chain to 
adopt a conformation with the protons eclipsed (so raising the observed 
coupling constant). If hydrogen bonding of this type is involved one would 
expect to see a concomitant lowering of the amide C=O stretching 
absorption by -15-40 cm-1. Although the main absorption is at 1666 cm-1, 
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there is also a significant peak at 1626 cm-1 which may be due to a 
hydrogen bonded carbonyl. Whether or not 161 crystallises in this form 
could be determined by X-ray studies. 
The benzoxazole derivative 162 exhibited strong N-H and C=O 
stretching modes in the IR spectrum and a large absorption at 744 cm-1 
indicating an ortho disubstituted benzene moiety. An absorption for CoS 
stretching was also observed at 1236 cm-1. The 13C NMR spectrum showed 
two highly deshielded Sp2 carbons (0 170.6 and 164.8) corresponding to the 
carbonyl carbon and position 2' of the benzoxazole ring. Two methylene 
carbons were also present in the spectrum. 
Benzothiazole 163 showed similar spectral features to the other 
fused ring compounds, including N-H stretch (3298 cm-1), amide carbonyl 
stretch (1642 cm-1) and CoS stretching absorptions at 1236 cm-1 in the IR 
spectrum. 
6.6 Nitrile. Primary Amide and Carboxylic Acid 
Derivatives 
Having explored various modifications to the side-chain while 
preserving the secondary amide moiety, we now prepared compounds 
containing other functional groups. We considered the nitriles 165 and 164 
to be good starting points and successfully hydrolysed these to form primary 
amide and acid groups (Scheme 39). 
Nitrile 165 has been prepared previously163 and the melting point 
and spectral data for our sample correlated well with those in the literature. 
The clearest indication of product formation was the aliphatic nitrile 
absorption at 2266 cm-1 in the IR spectrum and the nitrile carbon resonance 
at 0 118.2 in the 13C NMR spectrum. Compound 164 was prepared during 
the initial summer vacation work and was kindly donated by Robert 
Campbell. 
Partial hydrolysis 164 of 165 and 164 led to the primary amides 167 
and 166. Both compounds showed two N-H stretching modes at ca. 3400 
and 3180 cm-1 and amide C=O stretching absorptions at ca. 1660 cm-1. The 
carbonyl carbon came into resonance at ca. 0 171. 
Complete hydrolysis165 of 164 afforded acid 168. The carboxylic acid 
OH group gave a very broad absorption at 3160 cm-1 in the IR spectrum and 
the frequency of the carbonyl absorption increased by 23 cm-1 to 1693 cm-1 
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confirming the transformation from amide to acid. The carboxylic acid proton 
was also evident in the 1 H NMR spectrum as a broad signal at 3 12.56. 
OH OH Q+ Br-(CH2)n-CN .. ¢ + NaBr ~e 40-50% n = 1 or 2 S Na S" (CH2)n- CN 
i. Reflux, 3h n=1 (164) 
ii. 35% HCI, 40 ·C, 30 min n=2 (165) 
iii. H2O 
OH 
50%! iv. Reflux, 30% NaOH, 3h 
¢ v. H2O/HCI OH 
S, (CH2)n- CONH2 ¢ 
n=1 (166) S~COOH 
n=2 (167) (168) 
Scheme 39 
6.7 Preparation of a Solubilised Antimelanoma 
Compound 
In attempting to prepare a solubilised version of 142 we made use of 
the hydroxyl group which was the most accessible functional 'handle'. We 
chose to esterify the phenol with MPEG succinate (169), formed by reaction 
of succinic anhydride with MPEG (Scheme 40).105 The crude product of this 
reaction was purified from succinic anhydride by gel filtration 
chromatography but the 1 H NMR spectrum showed the presence of 
unreacted MPEG. Comparison of the integral for the polyethyleneglycol 
protons with that for the succinate protons gave the amount of starting 
material as -16%. This figure was confirmed by titration of a solution of 169 
with standard sodium hydroxide. 9.7 ml of 4.16 mM NaOH solution were 
required to neutralise a solution of 0.1 g 169 in 10 ml water. Since the 
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stoichiometry of the reaction between MPEG succinate and NaOH is 1:1, we 
can say: 
% by weight of = 
unreacted MPEG 
= 
= 
i. Toluene, reflux 5h 
no. moles 169 - no. moles NaOH used 
no. moles 169 
0.1/2100 - (9.7/1000 x 4.16/1000) 
0.1/2100 
15% 
ii. DCM, Compound 142, DCC, DMAP, stir, RT, 24h 
ii 
53% 
(170) 
Scheme 40 
X100 
Crude 169 was esterified with 142 using dicyclohexylcarbodiimide 
(DCC) and dimethylaminopyridine (DMAP) to effect the reaction. 
Precipitation of dicyclohexylurea (DCU) confirmed that coupling had taken 
place and the 1 H NMR spectrum of the crude product 170 showed it to be 
approximately 75% of the desired product. The aromatic region of the 13C 
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NMR spectrum showed that the carbon at position 4' of the ring (ortho- to the 
ester function) had shifted downfield from () 116.2 in 142 to () 122.5 in 170. 
This was because the carbonyl group in 170 lessened the shielding effect 
of the oxygen's lone pair on positions 4' and 2' in the ring. The IR spectrum, 
although dominated by aliphatic C-H and C-O stretching modes, showed 
absorptions for ester and amide carbonyl groups (1730 & 1660 cm- 1 
respectively). Figure 38 shows the ESMS for MPEG, 169 and 170. The 
distribution for MPEG shows that the polymer tends to lose three electrons 
under the ionising conditions employed. Although the peaks are flat and 
broad, there is a clear shift to the right as the average molecular weight 
increases from 2000 to 2112 to 2281. The expected m/z values for these 
three compounds are 666, 704 and 760 respectively. 
50% 76.2 
MPEG - MW 2000 
~(7.8 592.4 §36.4 .680.6 
o· IlILl ~~~~J,..~'~.~!!!!I' "TT "Ti' 11 I 'iii' .1 "'I 
200 400 600 800 1000 1200 
50% 
73.2 MPEG succinate 
117.7 (169) MW2112 
I 
0 il~l ,l.l~ 
200 400 600 800 1000 1200 
50% 76.7 
MPEG succinate - 142 conjugate 
127.6 (170) MW 2281 
o II 212.1 .1 ,.I, 
200 400 600 800 1000 1200 
Figure 38 
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The ESMS spectrum for 170 is shown in clearer detail in Figure 39. 
The centre of the distribution lies somewhere between an mlz of 750-770 
which is in the correct region for the desired product. 
(170) 
% expected m/z = 228113 = -760 
212.1 
Figure 39 
Solubility testing showed the conjugate to be readily soluble in water 
with gentle heating. 
6.8 Biological Evaluation of Antimelanoma Compounds 
The compounds described in this chapter were tested for us by Dr 
Lloyd Kelland at the CRC Institute of Cancer Research, Royal Marsden NHS 
Trust. Each compound was tested against six human melanoma cell lines 
and the human ovarian carcinoma SKOV-3 as a control. The cells were 
plated in 96-well plates at a concentration of 4000 cells/well and allowed to 
incubate overnight before the addition of the drugs at concentrations of 25, 
10, 2.5 and 0.25 JlM. The drugs were present for five days, after which time 
the cells were subjected to a sulforhodamine B (SRB) staining assay to 
determine the proportion of living cells. The results are expressed as the 
percentage of growth inhibition (%GI) observed at a concentration of 25 JlM 
(Table 11). Large values indicate successful inhibition of cancer growth. 
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Table 11 
Growth Inhibition of Antimelanoma Compounds 
No. B008 B0010 HT144 G631 SK-Mel- SK-Mel- SKOV-3 
2 24 
142 13.5 4.1 0 2.9 0 5.6 1.7 
150 7.4 6.7 0 0 2.6 0 6.6 
151 16.9 1.3 0 14.1 0 7.9 1.4 
159b 26.0 7.0 0 11 .5 0 14.7 1.2 
159a 8.3 2.4 0 12.6 5.8 0 2.2 
163 0 0 0 0 0 0 0 
165 9.0 6.7 0 14.4 0 5.2 3.5 
167 11.7 3.1 0 7.3 0 10.8 6.7 
166 4.0 0 0 5.2 0 0 0 
168 3.8 20.4 0 0 0 4.2 0 
170 15.6 1.4 0 1.6 2.7 0 0 
OH COMPOUND R 
152 Methyl 
153 Ethyl 
154 tSutyl 
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The success of compounds 152, 153 and 154 (dark shading) in 
comparison with 142 (lighter shading) is noteworthy. 154 was the most 
consistently potent compound, inhibiting the growth of melanoma cells 
between five and ten times more effectively than 142. As expected, the 
fluorobenzene derivative 150 and the benzothiazole 163 showed poor 
inhibition. The nitrile 165 exhibited similar inhibition to 142, as did the 
primary amide 167 derived from it. The shorter chain amide 166 and its 
related acid 168 were relatively inactive. 
The racemic compound 151 showed comparable activity to 142, 
which is largely attributable to the influence of the (S) isomer 159b which 
performs as well as, if not better than the (R) isomer 159a in six out of the 
seven cell lines. It was encouraging that the solubilised compound 170 
showed similar activity to 142. 
The N-substituted benzamide derivative 155 was not tested at this 
stage but was later screened against the same panel of cell lines. The 
compound did not inhibit effectively and gave IC50 values of >50 IlM in each 
case. 
The fact that several of the most active compounds also inhibited the 
SKOV-3 ovarian carcinoma confirms that these compounds are able to exert 
toxicity by non-tyrosinase mediated routes. 
Professor Rona Mackie contributed valuable information by testing 
the compounds against murine melanoma lines in vitro and in vivo. 80th 
152 and 153 out-performed 142 against the highly metastatic 816F-10 cell 
line in vitro, exhibiting %GI values of 79 and 81% compared to 51% for 142. 
The in vivo testing was performed on C-57 black mice which were injected 
with 816F-1 or 816F-1 0 melanoma cells and given a dose of the appropriate 
drug at a concentration of 3 mg/g body weight seven days later. The mice 
were sacrificed after a further seven days and the tumours were excised and 
weighed. The results are recorded in Table 12. Empirical observations also 
showed a decrease in the extent of ulceration exhibited at the tumour sites 
compared to animals which had not been treated with the drug. 
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% Growth reduction in weight 
COMPOUND of tumour tissue 
816 F1 cell 816 F10 cell 
line line 
OH ¢ (142) I~ 39 16 0 
S~N)lCH 
H 3 
OH ¢ (152) 
I~ 43 45 0 
sYNJlCH H 3 
OH ¢ (153) I~ 46 48 0 
sYNJlC H H 2 5 
Table 12 
6.9 Discussion and Suggestions for Future Work 
Of our initial strategies in modifying the parent compound 142, 
increasing the bulk in the side-chain while preserving the secondary amide 
has produced the most encouraging results. Altering the nature of the 
terminal functional group was not beneficial, and removing the phenol 
moiety brought a complete loss of activity. It is significant that drug potency 
seems to rise dramatically with the inclusion of two methyl groups in the 
side-chain. This is obvious from a comparison of the activity of 142 and 151 
with 154, 1 52 and 1 53. Is there a limit to this effect? An obvious 
progression would be to increase the size of these groups to ethyl or propyl 
units, or possibly cyclic spiro compounds. The slight enantiomeric specificity 
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evidenced for 15gb suggests that it may be worth introducing different akyl 
groups at this position. 
The nature of the terminal alkyl group also seems to have a bearing 
on activity. Taking the average %GI across all the cell lines, apart from 
SKOV-3, we find that 154 averages 42.9%, 153, 29.1 % and 152, 24.7%. 
The only difference between these compounds is the nature of the terminal 
amide, which suggests that bulky groups are advantageous in this position. 
It is unclear whether this is a 'spacing' effect or whether it is to do with the 
lipophilicity of the compounds. This warrants further investigation, 
particularly as the phenyl derivative 155, which one would expect to be 
active on the basis of these arguments, is actually a poor inhibitor. A more 
conclusive pattern could be established by preparing oxazolines from 
longer chain aliphatic acids such as butyric, isobutyric, hexanoic and 
palmitic acids and reacting these with 4-hydroxythiophenol. Alternatively, 
the parent compound 142 could be esterified by reaction with a long chain 
fatty acid to form a lipophilic equivalent of 170. This work should be 
prioritised since the increase in activity provided by relatively minor 
structural alterations has been impressive. The X-ray structures of 152, 153 
and 154 should be elucidated to determine whether their crystal structures 
differ significantly from that of 142. 
Another area which could be explored is introducing chirality into the 
terminal amide group. This could readily be achieved by preparing 
oxazolines from chiral acids, acid chlorides or nitriles (Figure 41). 
Rl R2 * Rl R2 R3CN h > r NH2 * NyO + R3COOH OH 
*R3 * R3COCI 
Figure 41 
Although the phenyl derivative 155 was inactive, it would be 
instructive to prepare a small number of substituted phenyl derivatives to 
determine whether functionality in the ring alters activity. Two which would 
be worth pursuing are the substituted phenols 171 and 172. 
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OH 
o YJN~O "" 
H I 
# OH 
(171 ) (172) 
At one level, these compounds are interesting simply because of their 
different electronic character, but it is possible that each may exert an 
unusual mode of cytotoxicity. Most melanomas are solid tumours and, as 
has already been described (Section 4.8), under these conditions reductase 
enzymes are overexpressed. By incorporating a nitro group, while retaining 
the active phenol structural unit, it may be possible to take advantage of this 
factor in malignant tissue. This compound may have two modes of action. 
Where malignant melanocytes are functioning, the phenol could inhibit 
using the normal tyrosinase pathways and where hypoxic conditions are in 
evidence, the nitro group might be reduced to form cytotoxic radical species. 
Incorporating two phenol moieties in the drug raises the possibility 
that both could be hydroxylated and oxidised by tyrosinase to form quinones 
such as 173. Such species may have the ability to crosslink DNA. 
o 
(173) 
The poor results for 150 and 163 confirm the importance of the 
phenol moiety and suggest that other aromatic groups may not be 
acceptable substitutes. It may be possible, however, to form ring-constrained 
analogues if suitably functionalised thianaphthenes can be prepared (e.g. 
174). Thianaphthenes SUbstituted at the 2'- and 3'- positions are 
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commercially available and may provide useful building blocks for structures 
similar to that shown below. 
OH 
(174) 
Summary of Future Work 
• The X-ray structures of 159b, 159a, 152, 153 and 154 should be 
obtained. 
• The ability of the most active antimelanoma agents to act as substrates 
for mammalian tyrosinase should be established. 
• Labelling studies should be carried out to determine the mechanism of 
oxazoline formation as described by Witte and Seeliger (Scheme 32). 
• The optimal substitution pattern for the side-chain should be determined, 
including an investigation of chirality a- to the nitrogen and in the acyl 
position. 
• The two novel substituted phenyl compounds 171 and 172 should be 
prepared and tested. 
• Alkylation on the amide nitrogen to remove H-bonding and oxidation of 
the sulfur atom should be explored. The possibility of replacing sulfur 
with another heteroatom should be investigated. 
• The chemistry of thianaphthenes should be researched and suitable 
compounds prepared. 
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7 
Experimental to Chapters 3-6 
7.1 General Preamble to Experimental Section: 
All chemicals were purchased from Aldrich Chemical Company 
(Gillingham, Dorset, UK). Organic solutions were dried with anhydrous 
MgS04 or Na2S04 and solvents were removed under reduced pressure 
below 40°C. Melting points (m.p.) were measured with a Gallenkamp 
apparatus and are uncorrected; the abbreviation 'd.' denotes compounds 
which decomposed before melting. 1H and 13C NMR spectra were obtained 
on a Bruker WP200-SY spectrometer operating at 200 MHz and 50 MHz 
respectively. All coupling constants quoted are measured in Hz. The 
numbering schemes shown are used for ease of assigning the NMR spectra. 
Mass spectra (MS) were recorded on AEI MS12 or MS902 spectrometers. 
Infra-red (IR) spectra were obtained for KBr discs on a Perkin Elmer 983 
spectrophotometer or a Perkin Elmer PU 9800 FT-IR spectrophotometer. 
Ultra-violet (UV) spectra were recorded on a Shimadzu UV-1601 
spectrophotometer. Thin layer chromatography (TLC) was carried out on 
silica gel G plates of 0.25 mm thickness developed with petroleum ether (40-
60°C) - EtOAc (1: 1) unless stated otherwise and compounds were 
visualised by UV and with iodine. Column chromatography was carried out 
on silica gel, 70-230 mesh with the same solvent system. Gel filtration 
chromatography was carried out on Sephadex LH-20 (10 g) with water as 
eluent. 
7.2 Experimental to Chapter 3: 
7.2.1 General Procedures 
The majority of tyrphostins in this set were synthesised using the 
methodology employed by Gazit et al. 25 
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Method A:25 Quinolinecarbaldehyde (2-3 mmol) was dissolved in EtOH (2 
ml) in a 25 ml round-bottomed flask. To the stirred solution was added an 
equimolar amount of the appropriate malononitrile derivative, solid 
compounds being pre-dissolved in EtOH (2 ml). A catalytic amount of EtOH-
piperidine solution (10:1, 2 drops) was introduced and the reaction stirred at 
RT until a solid precipitate formed. The solid was filtered off, washed with 
petroleum ether (40-60 °C) and dried under suction. 
In reactions where TLC indicated that the reaction had gone to 
completion but precipitation did not occur, water was added to the reaction 
mixture and the precipitated solid was filtered, dried and purified by column 
chromatography. 
Method 8:89 The tbutyl cyanoacetate derivatives with 3- and 4-quinoline 
carbaldehyde (59 & 60) were stirred in formic acid at RT for 4 h. After this 
time the solution was evaporated to dryness and the solid products were 
purified from starting material by column chromatography. 
7.2.2 Numbering System 
The numbering system has been based on the quinolinyl 
propenenitrile unit which is common to all the structures in chapter 3 and to 
many in chapter 4. Numbering starts at the nitrile moiety and continues 
along the side arm, proceeding anti-clockwise around the quinoline rings. 
Where the quinoline has been substituted at the (formal) 3- or 4-position, the 
ring carbons keep the same number as they have in the 2-substituted 
compounds. This introduces a slight discontinuity in the flow of the 
numbering but allows easier comparison between structures. 
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7.2.3 Experimental Data 
2-Cyano-3-(2-quinolinyl)propenenitrile (43). 
8 
9 
10 
6 
3 
1 
CN 
Compounds 43,44 and 45 have been prepared previously8S.87 but have 
only been reported in obscure journals. The spectral data for these 
compounds are presented in full here. Method A afforded nitrile 43 as a 
brown powder which was recrystallised to give orange needles (0.297 g, 
68%), m.p. 168-170 °c (from EtOAc); Rt 0.67; Vmax (KBr) 3050w (unsaturated 
C-H), 2220m (CN), 1590, 1500s (aromatic C=C & C=N) cm-1; OH (Ds-DMSO) 
8.64 (1 H, s, 3-H), 8.52 (1 H, d, 3J= 8.4, 6-H), 8.02 (2 H, m, 8-H & 11-H), 7.78 
(1 H, d, 3J= 8.5, 5-H), 7.84 (1 H, m, 4J= 1.6, 10-H) and 7.71 (1 H, m, 4J= 1.3, 
9-H); Oc (Ds-DMSO) 158.5 (C-3), 148.7 (C-4), 146.9 (C-12), 137.8 (C-6), 
131.1 (quin C-H), 129.3 (quin C-H), 129.1 (quin C-H), 128.9 (C-7), 128.1 
(quin C-H), 124.1 (C-5), 114.4 (C-1), 112.9 (CN) and 80.1 (C-2); m/z 205 
(M+, 100), 179 (12.5), 154 (35.2), 129 (25.7) and 101 (22.3%) (Found: M+, 
205.0629; C, 76.02; H, 3.49; N, 20.39%. C13H7N3 requires M, 205.0639; C, 
76.07; H, 3.44; N, 20.49%). 
2-Cyano-3-(3-quinolinyl)propenenitrile (44).8S.87 
10 
11 
CN 
1 
Method A afforded nitrile 44 as a brown powder, the reaction proceeding 
quickly without addition of catalyst. Recrystallisation afforded fawn coloured 
needles (0.334 g, 81 %), m.p. 199-201 °c (from isopropanol); Rt 0.52; Vmax 
(KBr) 3040w (unsaturated C-H), 2215m (CN), 1595 and 1490 (aromatic 
C=C) cm-1; OH (Ds-DMSO) 9.21 (1 H, d, 4J= 2.2, 4-H), 8.87 (1 H, d, 4J - 1.9, 
6-H), 8.69 (1 H, s, 3-H), 8.12-8.02 (2 H, m, 8-H & 11-H), 7.93 (1 H, ddd, 10-H) 
and 7.71 (1 H, ddd, 9-H); Oc (D6-DMSO) 158.8 (C-3), 149.9 (C-4), 148.8 (C-
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12),138.8 (C-6), 133.1 (quin C-H), 129.7 (quin C-H), 128.9 (quin C-H), 128.8 
(quin C-H), 126.3 (C-7), 124.8 (C-5), 113.9 (C-1), 113.1 (CN) and 83.4 (C-2); 
m/z 205 (M+, 14.0), 151 (27.5),127 (31.6), 99 (41.9) and 75 (95.3%) (Found: 
M+, 205.0648; C, 76.01; H, 3.18; N, 20.43%. C13H7N3 requires M, 205.0639; 
C, 76.07; H, 3.44; N, 20.49%). 
2-Cyano-3-(4-quinolinyl)propenenitrile (45).86.87 
eN 
1 
9 
10 
11 
Method A afforded nitrile 45 as a yellow powder which was recrystallised to 
give yellow needles (0.163 g, 40%), m.p. 145-146 °c (from isopropanol); Rt 
0.51; Vmax (KBr) 3060w (unsaturated C-H), 2217m (CN), 1590 and 1500m 
(aromatic C=C) cm-1; OH (D6-DMSO) 9.40 (1 H, s, 3-H), 9.12 (1 H, d, 3J= 4.5, 
4-H), 8.22 (1 H, dd, 3J= 8.6, 11-H), 8.14 (1 H, dd, 3J= 8.6, 8-H), 7.97-7.83 (2 
H, m, 5-H & 10-H) and 7.75 (1 H, ddd, 9-H); oc (D6-DMSO) 158.9 (C-3), 
150.4 (C-4), 147.9 (C-12), 136.3 (C-6), 130.6 (quin C-H), 129.7 (quin C-H), 
128.2 (quin C-H), 124.4 (quin C-H), 124.3 (C-7), 120.2 (C-5), 113.2 (C-1), 
112.2 (CN) and 89.8 (C-2); m/z 205 (M+, 92.4), 178 (100.0), 151 (31.9), 100 
(21.4) and 75 (34.1%) (Found: M+, 205.0630; C, 75.72; H, 3.58; N, 20.31%. 
C13H7N3 requires M, 205.0639; C, 76.07; H, 3.44; N, 20.49%). 
(Z)-2-Amino-4-(2-quinolinyl)-1 ,3-butadiene-1, 1 ,3-tricarbonitrile 
!!§1.86 
10 
11 3 
1 
eN eN 
eN 
Compounds 46,47 and 48 have been prepared previously but have only 
been reported in obscure journals. The spectral data for these compounds 
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are presented in full here. Method A afforded nitrile 46 as a yellow solid 
(0.326 9, 70%), m.p. 180°C (d.); Rf 0.24; "-max (EtOH)/nm 203 (E/dm3 mol-1 
cm-1 49000), 230 (28000), 269 (31700) and 316 (18400); Vmax (KBr) 3320m 
(NH2), 3190w, 2220, 2210 (CN), 16505 (alkene C=C) and 1610 (aromatic 
C=C) cm-1; BH (D6-DMSO) 9.38 and 9.31 (2 H, 2 br 5, NH2), 8.62 (1 H, d, 3J= 
8.4, 6-H), 8.29 (1 H, 5, 3-H), 8.12 (2 H, m, 8-H & 11-H), 7.93 (1 H, m, 4J= 1.2, 
10-H), 7.91 (1 H, d, 3J= 8.5, 5-H) and 7.77 (1 H, m, 4J= 1.0, 9-H); Be (D6-
DMSO) 165.7 (-C (NH2)=C(CNb), 150.3 (C-3), 149.5 (C-4), 147_1 (C-12), 
137.8 (C-6), 131.0 (quin C-H), 129.1 (quin C-H), 128.8 (quin C-H), 128.4 (C-
7),128.1 (quin C-H), 123.6 (C-5), 115.6 (CN), 114.5 (2 x CN), 106.6 (C-2) 
and 50.2 (-C (NH2)=C(CNb); m/z 271 (M+, 88.6), 245 (87.5), 206 (61.4), 179 
(38.8) and 129 (100%) (Found: M+, 271.0856; C, 70.56; H, 3.16; N, 25.62%. 
C16HgNS requires M, 271.0857; C, 70.83; H, 3.35; N, 25.83%). 
(ZJ-2-Amino-4-(3-quinolinyl)-1 ,3-butadiene-1, 1 ,3-tricarbonitrile 
~86 
11 
eN eN 
1 
eN 
Method A afforded nitrile 47 as a yellow solid (0.261 9, 48%), m.p. 195°C 
(d.); Rf 0.51 (EtOAc); "-max (EtOH)/nm 205 (E/dm3 mol-1 cm-1 64900), 231 
(55300), 246 (48000) and 276 (43100); Vmax (KBr) 3414 and 3327 (NH2), 
2218, 2202m (CN), 16435 (alkene C=C), 1601 and 1491 (aromatic C=C) cm-
1; BH (D6-DMSO) 9.31 (1 H, d, 4J= 2.2, 4-H), 9.31 & 9.25 (2 H, 2 br 5, NH2), 
8.97 (1 H, 4J= 2.0, 6-H), 8.39 (1 H, 5, 3-H), 8.22-8.08 (2 H, m, 8-H & 11-H), 
7.97 (1 H, ddd, 4J= 1.3, 10-H) and 7.77 (1 H, ddd, 4J= 1.0, 9-H); Be (D6-
DMSO) 165.0 (-C (NH2)=C(CNh), 150.8 (C-3), 150.2 (C-4), 148.6 (C-12), 
137.8 (C-6), 136.3 (quin C-H), 129.6 (quin C-H), 129.0 (quin C-H), 128.2 
(quin C-H), 126.7 (C-7), 125.1 (C-5), 115.5, 114.8, 114.7 (all CN), 104.3 (C-
2) and 50.2 (-C (NH2)=C(CN)2); m/z 271 (M+, 78.7), 245 (44.8), 206 (72.1), 
142 (95.9) and 115 (30.3%) (Found: M+, 271.0847; C, 70.75; H, 3.12; N, 
25.77%. C16HgNS requires M, 271.0857; C, 70.83; H, 3.35; N, 25.83%). 
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(ZJ-2-Amino-4-(4-quinolinyl)-1 ,3-butadiene-1, 1 ,3-tricarbonitrile 
L4.ru....86 
CN 
11 
Method A afforded nitrile 48 as a yellow solid (0.379 g, 70%), m.p. 180°C 
(d.); Rt 0.55 (EtOAc); Amax (EtOH)/nm 212 (E/dm3 mol-1 cm-1 85900), 252 
(40100) and 307 (24900); Vmax (KBr) 3443 and 3335 (NH2), 3177, 2228, 
2220 (CN), 1660 (alkene C=C), 1608 and 1504 (aromatic C=C) cm-1; OH (06-
OMSO) 9.46 and 9.35 (2 H, 2 br s, NH2), 9.17 (1 H, d, 3J= 4.4, 4-H), 8.95 (1 
H, 5, 3-H), 8.29 (1 H, d, 3J= 8.1, 11-H), 8.19 (1 H, d, 3J= 8.2, 8-H), 7.96-7.88 
(2 H, m, 5-H & 10-H) and 7.73 (1 H, ddd, 9-H); oe (06-0MSO) 164.2 (-C 
(NH2)=C(CNh), 151.0 (C-3), 150.9 (C-4), 147.9 (C-12), 137.6 (C-6), 130.7 
(quin C-H), 129.8 (quin C-H), 128.0 (quin C-H), 125.1 (C-7), 124.9 (quin C-
H), 120.3 (C-5), 115.8 (CN), 114.5 (C-1), 113.9 (CN), 109.9 (C-2) and 50.7 (-
C (NH2)=C(CNh); m/z 271 (M+, 100.0), 245 (84.6), 206 (53.4), 142 (32.7) 
and 75 (33.6%) (Found: M+, 271.0856; C, 70.61; H, 3.16; N, 25.80%. 
C16HgNS requires M, 271.0857; C, 70.83; H, 3.35; N, 25.83%). 
Methyl (EJ-2-cyano-3-(2-quinolinyl)propenoate (49). 
10 
11 
1 
CN 
~2 COOCH3 
3 
Method A afforded ester 49 as a cream solid which was recrystallised to 
give cream needles (0.132 g, 18%), m.p. 126-127 °c (from EtOAc); Rt 0.68; 
Vmax (KBr) 3050w (unsaturated C-H), 2950w (aliphatic C-H), 2220m (CN), 
1720s (ester C=O), 1625m (alkene C=C) and 1270 (C-O) cm-1; OH (COCI3) 
8.48 (1 H, s, 3-H), 8.32 (1 H, d, 3J= 8.5, 6-H), 8.22 (1 H, dd, 3J= 8.5, 11-H), 
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8.02 (1 H, d, 3J= 8.5, 5-H), 7.88 (1 H, dd, 3J= 8.4, 8-H), 7.81 (1 H, ddd, 4J= 
1.6, 10-H), 7.66 (1 H, ddd, 4J= 1.3, 9-H) and 3.99 (3 H, s, COOCH3); ()c 
(CDCI3) 162.6 (COOCH3), 154.1 (C-3), 149.7 (C-4), 148.2 (C-12), 137.2 (C-
6),130.7 (C-10), 130.4 (C-11), 129.0 (C-9), 128.6 (C-7), 127.7 (C-8), 122.1 
(C-5), 114.8 (C-1), 107.2 (C-2) and 53.7 (COOCH3); m/z 238 (M+, 11.3),208 
(70.4), 180 (100), 128 (61.5) and 101 (33.5%) (Found: M+, 238.0740; C, 
70.50; H, 4.32; N, 11.77%. C14H1ON202 requires M, 238.0740; C, 70.56; H, 
4.23; N, 11.76%). 
Methyl (E)-2-cyano-3-{3-quinolinyl)propenoate (50). 
3 ~2 COOCH3 
CN 
1 
11 
Method A afforded ester 50 as a white powder (0.367 g, 77%), m.p. 155-156 
°C; Rt 0.44; V max (KBr) 3050w (unsaturated C-H), 2960w (aliphatic C-H), 
2220m (CN), 1730s (ester C=O), 1620m (alkene C=C) and 1270s (C-O) cm-
1; ()H (CDCI3) 9.13 (1 H, d, 4-H), 9.00 (1 H, d, 4J= 2.1, 6-H), 8.39 (1 H, s, 3-H), 
8.11 (1 H, d, 3J= 8.4, 11-H), 7.90 (1 H, d, 3J= 8.0, 8-H), 7.82 (1 H, m, 4J= 1.4, 
10-H), 7.60 (1 H, m, 4J= 1.0, 9-H) and 3.94 (3 H, s, CH3); ()C (CDCI3) 162.4 
(COOCH3), 151.5 (C-4), 151.4 (C-3), 149.4 (C-12), 138.1 (C-6), 132.7 (C-
10), 129.4 (C-11), 129.4 (C-8), 128.0 (C-9), 127.0 (C-7), 124.4 (C-5), 115.2 
(C-1), 104.4 (C-2) and 53.6 (COOCH3); m/z 238 (M+, 51.6), 223 (38.2), 179 
(44.2), 152 (100) and 75 (75.8%) (Found: M+, 238.0743; C, 70.41; H, 4.02; 
N, 11.68%. C14Hl0N202 requires M, 238.0740; C, 70.56; H, 4.23; N, 
11.76%). 
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Methyl (EJ-2-cyano-3-(4-quinolinyl)propenoate (51 ). 
COOCH3 
1 
11 
Method A afforded ester 51 as a white crystalline solid (0.262 g, 36%), m.p. 
140-141 °c (from EtOAc); Rf 0.44; Vmax (KBr) 3050w (unsaturated C-H), 
2950w (aliphatic C-H), 2220m (CN), 1720s (ester C=O), 1600m (aromatic 
C=C) and 1270s (C-O) cm-1; BH (D6-DMSO) 9.13 (1 H, d, 3J= 4.5, 4-H), 9.10 
(1 H, s, 3-H), 8.19 (1 H, d, 3J= 8.4, 11-H), 8.11 (1 H, d, 3J= 7.7, 8-H), 7.95-
7.87 (2 H, m, 5-H & 10-H), 7.75 (1 H, m, 9-H) and 3.98 (3 H, s, CH3); Be (D6-
DMSO) 161.2 (COOCH3), 152.1 (C-3), 150.3 (C-4), 147.8 (C-12), 137.3 (C-
6), 130.4 (quin C-H), 129.8 (quin C-H), 127.9 (quin C-H), 124.6 (C-7), 124.3 
(quin C-H), 120.3 (C-5), 114.4 (C-1), 110.7 (C-2) and 53.6 (COOCH3); m/z 
238 (M+, 37.0), 207 (10.2), 179 (100), 152 (58.6) and 75 (17.2%) (Found: 
M+, 238.0743; C, 70.46; H, 4.14; N, 11.67%. C14H10N202 requires M, 
238.0740; C, 70.56; H, 4.23; N, 11.76%). 
Ethyl (EJ-2-cyano-3-(2-quinolinyl)propenoate (52). 
Method A afforded ester 52 as a white powder which was recrystallised to 
yield cream coloured needles (0.349 g, 69%), m.p. 108-109 °c (from EtOAc); 
Rf 0.73; vmax (KBr) 3060w (unsaturated C-H), 2980w (aliphatic C-H), 2220m 
(CN), 1730s (ester C=O), 1620m (alkene C=C) and 1250s (C-O) cm-1; BH 
(CDCI3) 8.47 (1 H, s, 3-H), 8.29 (1 H, d, 3J= 8.6, 6-H), 8.22 (1 H, dd, 11-H), 
8.05 (1 H, d, 3J= 8.5, 5-H), 7.87 (1 H, dd, 3J= 8.2, 4J= 1.2, 8-H), 7.79 (1 H, 
ddd, 4J= 1.6, 10-H), 7.65 (1 H, ddd, 4J= 1.2, 9-H), 4.43 (2 H, q, 3J= 7.1, 
COOCH2CH3) and 1.43 (3 H, t, 3J= 7.1, COOCH2CH3); Be (CDCI3) 162.0 
(COOCH2CH3), 153.8 (C-3), 149.9 (C-4), 148.2 (C-12), 137.2 (C-6), 130.6 
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(C-10), 130.3 (C-11), 129.0 (C-9), 128.6 (C-7), 127.6 (C-8), 121.9 (C-5), 
114.8 (C-1), 107.8 (C-2), 63.0 (GOOCH2CH3) and 14.2 (GOOGH2CH3); mlz 
252 (M+, 3.1), 208 (58.9),180 (100) and 128 (42.5%) (Found: M+, 252.0903; 
C, 71.18; H, 4.66; N, 11.03%. G15H12N202 requires M, 252.0896; C, 71.40; 
H, 4.79; N, 11.10%). 
Ethyl (E)-2-cyano-3-(3-quinolinyl)propenoate (53). 
10 
11 
Method A afforded ester 53 as a white powder. Recrystallisation of the 
product yielded cream coloured needles (0.194 g, 76%), m.p. 173-174 °C 
(from EtOAc); Rt 0.54; Vmax (KBr) 3060w (unsaturated C-H), 2980w (aliphatic 
C-H), 2220m (CN), 1720s (ester C=O), 1605 (aromatic C=G) and 1250 (C-O) 
cm-1; OH (CDCI3) 9.19 (1 H, d, 4J= 2.4, 4-H), 9.07 (1 H, d, 4J= 2.3, 6-H), 8.42 
(1 H, 5, 3-H), 8.15 (1 H, dd, 3J= 8.4, 4J= 1.0, 11-H), 7.98 (1 H, dd, 3J= 8.2 4J= 
1.4, 8-H), 7.87 (1 H, ddd, 4J= 1.5, 10-H), 7.65 (1 H, ddd, 4J= 1.2, 9-H), 4.44 
(2 H, q, 3J= 7.1, COOGH2GH3) and 1.44 (3 H, t, 3J= 7.1, COOGH2CH3); oe 
(CDCI3) 162.0 (COOCH2GH3), 151.7 (C-4), 151.3 (G-3), 149.6 (G-12), 138.0 
(C-6), 132.6 (C-10), 129.6 (C-11), 129.4 (G-8), 128.0 (C-9), 127.1 (G-7), 
124.6 (C-5), 115.3 (C-1), 105.0 (C-2), 63.1 (GOOCH 2CH 3 ) and 14.2 
(COOCH2CH3); m/z 252 (M+, 78.3), 208 (100), 179 (44.0) and 152 (49.5%) 
(Found: M+, 252.0897; C, 71.29; H, 4.64; N, 10.97%. C15H12N202 requires 
M, 252.0896; C, 71.40; H, 4.79; N, 11.10%). 
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Ethyl (EJ-2-cyano-3-(4-quinolinyl)propenoate (54). 
10 
11 
Method A afforded ester 54 as a white powder. Recrystallisation of the 
product gave rhombic crystals (0.198 g, 39%), m.p. 97-98 °c (from EtOAc); Rt 
0.51; Vmax (KBr) 3060w (unsaturated C-H), 2230m (CN), 1725s (ester C=O), 
1620s (alkene C=C) and 1270s (C-O) cm-1; DH (CDCI3) 9.07 (1 H, d, 3J= 4.5, 
4-H), 8.99 (1 H, s, 3-H), 8.23 (1 H, dd, 3J= 8.6, 11-H), 7.98 (1 H, dd, 8-H), 
7.95 (1 H, dd, 3J= 4.5, 5-H), 7.84 (1 H, ddd, 10-H), 7.69 (1 H, ddd, 9-H), 4.47 
(2 H, q, 3J= 7.2, COOCH2CH3) and 1.45 (3 H, t, 3J= 7.2, COOCH2CH3); DC 
(CDCI3) 161.2 (COOCH2CH3), 150.7 (C-3), 150.1 (C-4), 148.5 (C-12), 136.3 
(C-6), 130.6 (quin C-H), 130.4 (quin C-H), 128.2 (quin C-H), 125.4 (C-7), 
122.9 (quin C-H), 120.1 (C-5), 114.1 (C-1), 110.3 (C-2), 63.4 (COOCH2CH3) 
and 14.1 (COOCH2CH3); m/z 252 (M+, 52.0), 207 (16.5), 180 (43.1) and 179 
(100%) (Found: C, 71.50; H, 4.76; N, 11.14%. C15H12N202 requires C, 71.40; 
H, 4.79; N, 11.10%). 
n Butyl (E)-2-cyano-3-(2-quinolinyl)propenoate (55). 
10 
11 
1 
eN 
Method A afforded ester 55 as a white powder which was recrystallised to 
give large rhombic crystals (0.375 g, 45%), m.p. 71-72 °c (from EtOAc); Rt 
0.81; Vmax (KBr) 3060w (unsaturated C-H), 2980w (aliphatic C-H), 2215m 
(CN), 1720s (ester C=O), 1630w (alkene C=C) and 1280s (C-O) cm-1; DH 
(Da-DMSO) 8.60 (1 H, d, 3J= 8.5, 6-H), 8.56 (1 H, s, 3-H), 8.15-8.05 (3 H, m, 
5-H, 8-H & 11-H), 7.92 (1 H, ddd, 4J= 1.4, 10-H), 7.77 (1 H, ddd, 4J= 1.2, 9-
- 151 -
H), 4.35 (2 H, t, 3J= 6.6, COOCH2-), 1.75 (2 H, m, COOCH2CH2-), 1.46 (2 H, 
m, -CH2C H3) and 0.98 (3 H, t, 3J= 7.2, CH3); Oc (06-0MSO) 161.9 
(COO(CH2hCH3), 153.6 (C-3), 149.8 (C-4), 148.1 (C-12), 137.0 (C-6), 130.5 
(quin C-H), 130.2 (quin C-H), 128.8 (quin C-H), 128.4 (C-7), 127.5 (quin C-
H), 121.8 (C-5), 114.6 (C-1), 107.7 (C-2), 66.7 (COOCH 2-), 30.4 
(COOCH2CH2-), 18.9 (-CH2CH3) and 13.6 (-CH3); m/z 280 (M+, 10.5),236 
(15.8), 208 (49.8), 180 (100) and 128 (49.6%) (Found: M+, 280.1216; C, 
72.86; H, 5.81; N, 10.01%. C17H16N202 requires M, 280.1208; C, 72.82; H, 
5.75; N, 10.00%). 
n Butyl (EJ-2-cyano-3-(3-quinolinyl)propenoate (56). 
10 
11 
eN 
1 
Method A gave ester 56 as a white powder. Recrystallisation of the product 
gave large rhombic crystals (0.400 g, 71 %), m.p. 87-88 °c (from EtOAc); Rt 
0.68; V max (KBr) 3060w (unsaturated C-H), 2980w (aliphatic C-H), 2220m 
(CN), 1720s (ester C=O), 1620s (alkene C=C) and 1280s (C-O) cm-1; OH (06-
acetone) 9.40 (1 H, d, 4J= 2.3, 4-H), 9.01 (1 H, d, 4J= 2.2, 6-H), 8.53 (1 H, s, 
3-H), 8.10 (2 H, m, 8-H & 11-H), 7.91 (1 H, ddd, 4J= 1.4, 10-H), 7.70 (1 H, 
ddd, 4J= 1.2 9-H), 4.36 (2 H, t, 3J= 6.5, COOCH2(CH2bCH3), 1.75 (2 H, m, 
COOCH2CH2CH2CH3), 1.49 (2 H, m, COO(CH2bCH2CH3) and 0.98 (3 H, t, 
3J= 7.2, COO(CH2hCH3); Oc (06-acetone) 162.4 (COO(CH2hCH3), 152.3 (C-
3),151.6 (C-4), 150.1 (C-12), 139.4 (C-6), 133.1 (C-10), 130.2 (C-11), 130.1 
(C-8), 128.7 (C-9), 127.8 (C-7), 125.9 (C-5), 116.0 (C-1), 105.7 (C-2), 67.0 
(COOCH2(CH2)2CH3), 31.2 (COOCH2CH 2CH 2CH 3 ), 19.6 
(COO(CH2)2CH2CH3) and 13.9 (COO(CH2hCH3); m/z 280 (M+, 47.9), 224 
(69.6), 207 (61.2), 180 (85.4) and 152 (69.4%) (Found: M+, 280.1208; C, 
72.93; H, 5.74; N, 10.08%. C17H16N202 requires M, 280.1208; C, 72.82; H, 
5.75; N, 10.00%). 
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nButyl (EJ-2-cyano-3-(4-guinolinyl}propenoate (57). 
11 
After 24 h reaction time using Method A, TLC indicated the formation of a 
new product with Rt 0.63. This product was precipitated and purified by 
column chromatography to yield ester 57 as a fawn coloured solid (0.370 g, 
53%), m.p. 42-43 °C; Rt 0.63; Vmax (KBr) 3060w (unsaturated C-H), 2961w 
(aliphatic C-H), 2231m (CN), 1724s (ester C=O) and 1273s (C-O) cm-1; bH 
(CDCI3) 9.07 (1 H, d, 3J= 4.5, 4-H), 8.99 (1 H, s, 3-H), 8.24 (1 H, d, 3J= 8.5, 
11-H), 8.00-7.95 (2 H, m, 5-H and 8-H), 7.81 (1 H, m, 10-H), 7.68 (1 H, m, 9-
H), 4.40 (2 H, t, 3J= 6.6, COOCH2-), 1.76 (2 H, m, COOCH2CH2-), 1.50 (2 H, 
m, -CH2CH3) and 1.00, (3 H, t, 3J= 7.2, CH3); be (CDCI3) 161.3 (C=O), 150.7 
(C-4), 150.2 (C-3), 148.6 (C-12), 136.2 (C-6), 130.7 (quin C-H), 130.3 (quin 
C-H), 128.2 (quin C-H), 125.4 (C-7), 122.9 (quin C-H), 120.1 (C-5), 114.1 (C-
1), 110.3 (C-2), 67.2 (COOCH2-), 30.5 (COOCH2CH2-), 19.1 (-CH2CH3) and 
13.7 (CH3); m/z 280 (M+, 9.2), 224 (21.1), 207 (22.9), 179 (89.7) and 152 
(68.2%) (Found: M+, 280.1212. C17H16N202 requires M, 280.1208). 
tButyl (EJ-2-cyano-3-(2-guinolinyl}propenoate (58). 
9 
10 
Method A afforded ester 58 as a cream precipitate which was recrystallised 
to give large rhombic crystals (0.432 g, 70%), m.p. 169-170 °C (from EtOAc); 
Rt 0.84 (EtOAc); Vmax (KBr) 3060w (unsaturated C-H.), 2970w (aliphatic C-H), 
2220m (CN), 1734s (ester C=O) and 1280s (C-O) cm-1; bH (CDCI3) 8.39 (1 H, 
s, 3-H), 8.29 (1 H, d, 3J= 8.6, 6-H), 8.20 (1 H, d, 3J= 8.3, 11-H), 8.07 (1 H, d, 
3J= 8.5, 5-H), 7.87 (1 H, d, 3J= 8.1, 8-H), 7.80 (1 H, m, 4J= 1.6, 10-H), 7.64 (1 
H, m, 4J= 1.2, 9-H) and 1.62 (9 H, s, C(CH3b); be (CDCI 3 ) 160.7 
- 153-
(COOC(CH3b), 153.0 (C-3), 150.1 (C-4), 148.2 (C-12), 137.1 (C-6), 130.5 
(C-10), 130.2 (C-11), 128.7 (C-9), 128.4 (C-7), 127.5 (C-8), 121.7 (C-5), 
115.0 (C-1), 109.5 (C-2), 84.2 (COOC(CH3b) and 27.9 (COOC(CH3b); m/z 
280 (M+, 5.0), 236 (9.6), 208 (38.5),180 (100) and 128 (78.2%) (Found: M+, 
280.1213; C, 72.87; H, 5.84; N, 10.03%. C17H16N202 requires M, 280.1208; 
C, 72.82; H, 5.75; N, 10.00%). 
tButy! (EJ-2-cyano-3-(3-quinoliny!)propenoate (59). 
3 t H ~2 COOC4 9 
10 CN 
1 
11 
Method A gave ester 59 as a cream precipitate which was recrystallised, 
giving large rhombic crystals (1.104 g, 78%), m.p. 125-126 °c (from EtOAc); 
Rt 0.67; V max (KBr) 3051 w (unsaturated C-H), 2982m (aliphatic C-H), 2228m 
(CN), 17095 (ester C=O) and 1608m (aromatic C=C) cm·1; 3H (CDCI3) 9.13 
(1 H, d, 4J= 2.3, 4-H), 8.96 (1 H, d, 4J= 2.3, 6-H), 8.28 (1 H, s, 3-H), 8.09 (1 H, 
d, 3J= 8.5, 11-H), 7.92 (1 H, d, 3J= 8.2, 8-H), 7.81 (1 H, ddd, 4J= 1.5, 10-H), 
7.60 (1 H, ddd, 4J= 1.1, 9-H) and 1.58 (9 H, s, C(CH3b); 3c (CDCI3) 160.6 
(COOC(CH3b), 151.5 (C-4), 150.2 (C-3), 149.3 (C-12), 137.7 (C-6), 132.3 
(C-10), 129.4 (C-11), 129.3 (C-8), 127.8 (C-9), 127.0 (C-7), 124.6 (C-5), 
115.4 (C-1), 106.6 (C-2), 84.2 (COOC(CH3b) and 27.9 (COOC(CH3b); m/z 
280 (M+, 7.1), 224 (39.2), 207 (38.3), 180 (60.0) and 152 (56.6%) (Found: 
M+, 280.1218; C, 73.01; H, 5.79; N, 10.04%. C17H16N202 requires M, 
280.1208; C, 72.82; H, 5.75; N, 10.00%). 
lButy! (EJ-2-cyano-3-(4-quinolinyl)propenoate (60). 
11 
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Method A afforded ester 60 as a cream precipitate which was recrystallised, 
giving large rhombic crystals (1.188 g, 85%), m.p. 110-111 °c (from EtOAc); 
Rt 0.61; V max (KBr disc) 3065w (unsaturated C-H), 2991 m (aliphatic C-H), 
2229m (CN), 1714s (ester C=O) and 1618m (alkene C=C) cm-1; OH (CDCI3) 
9.03 (1 H, d, 3J= 4.5, 4-H), 8.87 (1 H, s, 3-H), 8.17 (1 H, d, 3J= 8.3, 11-H), 
7.97-7.89 (2 H, m, 5-H & 8-H), 7.78 (1 H, m, 10-H), 7.63 (1 H, m, 9-H) and 
1.61 (9 H, s, C(CH3b); oe (CDCI3) 159.9 (C=O), 150.1 (C-4), 149.7 (C-3), 
148.5 (C-12), 136.4 (C-6), 130.6 (quin C-H), 130.2 (quin C-H), 128.0 (quin 
C-H), 125.4 (C-7), 122.9 (quin C-H), 120.0 (C-5), 114.2 (C-1), 111.8 (C-2), 
84.8 (C(CH3b) and 27.9 (C(CH3b); m/z 280 (M+, 11.0), 224 (21.8), 207 
(35.1),179 (69.9) and 152 (50.3%) (Found: M+, 280.1217; C, 73.00; H, 5.81; 
N, 9.98%. C17H1SN202 requires M, 280.1208; C, 72.82; H, 5.75; N, 10.00%). 
(E)-2-cyano-3-(3-guinolinyl)propenamide (62). 
3 ~2 CONH2 
10 CN 
1 
11 
Method A afforded amide 62 as a white solid (0.273, 81%), m.p. 245°C (d.); 
Rt 0.46 (EtOH); V max (KBr) 3100m (NH2), 2225m (CN), 1710s (amide I), 
1640s (amide "), 1585s and 1500m (aromatic C=C) cm-1; OH (Ds-DMSO) 
9.32 (1 H, d, 4J= 2.2, 4-H), 8.95 (1 H, d, 4J= 2.0, 6-H), 8.45 (1 H, s, 3-H), 8.16-
8.11 (2 H, m, 8-H & 11-H), 8.10-7.90 (3 H, m, 10-H & NH2) and 7.57 (1 H, m, 
4J= 1.1, 9-H); oe (Ds-DMSO) 162.3 (CONH2), 150.5 (C-4), 148.3 (C-12), 
147.8 (C-3), 137.5 (C-6), 132.0 (quin C-H), 129.3 (quin C-H), 128.9 (quin C-
H), 127.8 (quin C-H), 126.7 (C-7), 125.5 (C-5), 116.3 (C-1) and 108.7 (C-2); 
m/z 223 (M+, 76.6), 222 (100), 206 (60.0), 179 (27.9) and 152 (35.8%) 
(Found: M+, 223.0731; C, 69.92; H, 3.84; N, 18.77%. C13HgN30 requires M, 
223.0744; C, 69.93; H, 4.07; N, 18.83%). 
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(E)-2-Cyano-3-(4-quinolinyl)propenamide (63). 
10 
11 
Method A yielded amide 63 as a white solid (0.354 g, 79%), m.p. 195 °c (d.); 
Rt 0.47 (EtOAc); Vmax (KBr) 3439s, 3400m (NH2), 2218m (CN), 1701s (amide 
I), 1608m, 1583m and 1504s (aromatic C=C) cm-1; BH (D6-DMSO) 9.11 (1 H, 
d, 3J= 4.4, 4-H), 8.87 (1 H, s, 3-H), 8.36 (1 H, br s, NH2), 8.20 (2 H, m, 8-H & 
11-H), 8.04 (1 H, br s, NH2), 7.92 (2 H, m, 5-H & 10-H) and 7.72 (1 H, m, 9-
H); Be (D6-DMSO) 162.1 (CONH2), 150.5 (C-4), 147.9 (C-12), 146.8 (C-3), 
138.0 (C-6), 130.4 (quin C-H), 129.9 (quin C-H), 127.9 (quin C-H), 125.0 (C-
7),124.4 (quin C-H), 120.4 (C-5), 115.3 (C-1) and 114.9 (C-2); m/z 223 (W, 
100),222 (41.8), 206 (18.1),194 (9.4),179 (58.9) and 153 (37.1%) (Found: 
M+, 223.0741; C, 69.86; H, 3.99; N, 18.95%. C13HgN30 requires M, 
223.0744; C, 69.93; H, 4.07; N, 18.83%). 
(EJ-2-Cyano-3-(3-quinolinyl)propenethioamide (65). 
3 ~2 CSNH2 
10 CN 
1 
11 
Method A afforded thioamide 65 as an orange solid which recrystallised to 
give needles (0.311 g, 65%), m.p. 179 °c (from EtOAc, d.); Rt 0.25; vmax (KBr) 
3312s (CSNH2), 3022w (unsaturated C-H), 2210m (CN), 1616 (amide II), 
1491 (aromatic C=C) and 1269 (amide I) cm-1; BH (D6-DMSO) 10.31 and 
9.99 (2 H, 2 br s, CSNH2), 9.32 (1 H, d, 4J= 2.2, 4-H), 9.01 (1 H, d, 4J= 2.2,6-
H), 8.44 (1 H, s, 3-H), 8.15-8.11 (2 H, m, 8-H & 11-H), 7.94 (1 H, ddd, 10-H) 
and 7.74 (1 H, ddd, 9-H); Be (D6-DMSO) 194.4, (C=S), 150.7 (C-4), 148.1 (C-
12), 143.2 (C-3), 137.4 (C-6), 131.9 (quin C-H), 129.2 (quin C-H), 128.9 
(quin C-H), 127.8 (quin C-H), 126.7 (C-7), 125.5 (C-5), 116.2 (C-1) and 
114.3 (C-2); m/z 239 (M+, 100),206 (63.6), 179 (30.1), 152 (37.5) and 75 
- 156-
(54.8%) (Found: M+, 239.0514; C, 65.02; H, 3.98; N, 17.34%. C13HgN3S 
requires M, 239.0516; C, 65.25; H, 3.79; N, 17.57%). 
(EJ-2-Cyano-3-(4-quinolinyl)propenethioamide (66). 
10 
11 
Method A afforded thioamide 66 as an orange powder (0.334 g, 69%), m.p. 
189°C (d.); Rt 0.26; Amax (EtOH)/nm 212 (E/dm 3 mol-1 em-1 81600), 251 
(32700) and 327 (16700); Vmax (KBr) 3355s (CSNH2), 3017w (unsaturated 
C-H), 2213m (CN), 1650 (amide II), 1621 (alkene C=C), 1503 (aromatic 
C=C), 1263 (amide I) em-1; BH (D6-DMSO) 10.59 and 10.44 (2 H, 2 br s, 
CSNH2), 9.10 (1 H, d, 3J= 4.2, 4-H), 8.70 (1 H, s, 3-H), 8.28 (1 H, d, 3J= 8.2, 
11-H), 8.17 (1 H, d, 3J= 8.2, 8-H), 7.94-7.87 (2 H, m, 5-H & 10-H) and 7.76 (1 
H, ddd, 9-H); Be (D6-DMSO) 192.5 (C=S), 150.5 (C-4), 147.9 (C-12), 142.0 
(C-3), 138.2 (C-6), 130.4 (C-H), 129.9 (C-H), 127.8 (C-H), 125.3 (C-7), 124.7 
(C-H), 120.4 (C-5), 119.5 (C-2) and 115.3 (C-1); m/z 239 (M+, 100.0),206 
(29.6), 179 (27.6) and 152 (22.3%) (Found: M+, 239.0508; C, 65.32; H, 3.91; 
N, 17.43%. C13HgN3S requires M, 239.0516 C, 65.27; H, 3.77; N, 17.57%). 
(EJ-2-Cyano-3-(3-quinolinyl)propenoic acid (69). 
3 ~2 eOOH 
10 eN 
1 
11 
Using ester 59 as the starting material, Method B afforded acid 69 as a 
white powder (0.524,83%), m.p. 198°C (d.); Rt 0.70 (EtOH); Vmax (KBr) 3400-
3200s (COOH), 3030w (unsaturated C-H), 2224m (CN), 1707s (acid C=O), 
1610s and 1496s (aromatic C=C) cm-1; BH (D6-DMSO) 9.41 (1 H, d, 4J=2.2, 
4-H), 9.05 (1 H, d, 4J= 2.2, 6-H), 8.60 (1 H, S, 3-H), 8.18-8.16 (2 H, m, 8-H & 
- 157-
11-H), 7.97 (1 H, m, 10-H) and 7.76 (1 H, m, 9-H); Be (D6-DMSO) 163.0 
(C=O), 151.6 (C-3), 150.7 (C-4), 148.3 (C-12), 138.8 (C-6), 132.7 (quin C-H) 
129.6 (quin C-H), 128.8 (quin C-H), 128.2 (quin C-H), 126.8 (C-7), 125.2 (C-
5), 116.1 (C-1) and 106.0 (C-2); m/z 224 (M+, 33.2),180 (100.0), 153 (50.7), 
129 (32.9) and 75 (28.6%) (Found: M+, 224.0579. C13HsN202 requires M, 
224.0584). 
(EJ-2-Cyano-3-(4-quinolinyl)propenoic acid (70). 
eOOH 
1 
10 
11 
Using ester 60 as the starting material, Method B afforded acid 70 as a 
white powder (0.374 g, 75%), m.p. 200 DC (d.); Rf 0.70 (EtOH): vmax (KBr) 
3400-3300s (COOH), 3038w (unsaturated C-H), 2224m (CN), 1701 s (acid 
C=O), 1610s and 1499m (aromatic C=C) cm-1; BH (D6-DMSO) 9.05 (1 H, d, 4-
H), 9.01 (1 H, s, 3-H), 8.16 (1 H, d, 3J= 8.3, 11-H), 8.08 (1 H, d, 3J= 8.2, 8-H), 
7.93-7.86 (2 H, m, 5-H & 10-H) and 7.74 (1 H, m, 9-H); Be (D6-DMSO) 162.3 
(C=O), 151.1 (C-3), 150.4 (C-4), 147.8 (C-12), 137.7 (C-6), 130.5 (quin C-H), 
129.8 (quin C-H), 128.0 (quin C-H), 124.8 (C-7), 124.3 (quin C-H), 120.4 (C-
5), 115.0 (C-1) and 112.3 (C-2); m/z 224 (M+, 7.8), 180 (58.6), 179 (100), 
153 (33.4) and 75 (40.1 %) (Found: M+, 224.0592. C13HsN202 requires 
224.0584). 
- 158-
7.3 Experimental to Chapter 4 
N-[4-(cyanomethyl)phenyl]acetamide (73). 
1 
CN 
The title compound was prepared using conditions described for the 
acetylation of aniline.92 4-Aminobenzyl cyanide (0.733 g, 5.5 mmol), water 
(12.5 ml) and conc. HCI (35%, 0.45 ml) were stirred together until the solid 
dissolved. Acetic anhydride (0.639 g, 6.3 mmol) was added with stirring until 
a heterogeneous mixture was obtained. Immediately, a solution of sodium 
acetate (0.825 g, 12 mmol) in water (2.5 ml) was added. The mixture was 
stirred vigorously and then cooled in ice. A cream preCipitate formed which 
was filtered off, washed with petroleum ether and dried under suction giving 
amide 73 (0.910 g, 95%), m.p. 84-85 °C (1it.,93 85-87 °C), Rt 0.58 (EtOAc); 
V max (KBr) 3345, 3318 (NH), 3055, 2960, 2247 (unconjugated CN), 1669 
(amide I), 1600 (aromatic C=C), 1523 (amide II) and 814 (para-disubstituted 
benzene) cm-1; DH (06-acetone) 9.37 (1 H, br s, N-H), 7.68 (2 H, AA'BB', 5-H), 
7.29 (2 H, AA'BB', 4-H), 3.88 (2 H, s, 2-H) and 2.08 (3 H, s, 8-H); DC (06-
acetone) 168.5 (C=O), 138.9 (C-6), 128.6 (C-4), 125.6 (C-3), 119.5 (C-5), 
114.7 (CN), 24.1 (C-8) and 21.9 (C-2); m/z 174 (M+, 26.3),132 (100),104 
(11.6) and 77 (11.1%) (Found: M+, 174.0794. Cl0Hl0N20 requires M, 
174.0791). 
Condensation product (74) of 2-guinolinecarbaldehyde with 
compound 73. 
8 
11 3 
1 
CN 
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o 
16N~18 
15 H 
Compound 73 (0.255 g, 1.46 mmol) was dissolved in EtOH (2 ml) and 
added to a stirred solution of 2-quinolinecarbaldehyde (0.236 g, 1.5 mmol) 
in EtOH (2 ml). After 30 min the cream precipitate was filtered off, washed 
with petroleum ether and dried under suction. Amide 74 (0.338 mg, 74%) 
was obtained as a white powder, m.p. 193-195 °C; Rt 0.49 (EtOAc); Vmax 
(KBr) 3056, 2925, 1667 (amide I), 1588 (C=C), 1514 (amide II), 836 (para-
disubstituted benzene) and 755 (ortho-disubstituted benzene) cm-1; OH (06-
OMSO) 10.26 (1 H, br s, N-H), 8.45 (1 H, d, 3J= 8.5, 6-H), 8.08-7.96 (3 H, m), 
7.87-7.72 (6 H, m), 7.63 (1 H, ddd, 9-H) and 2.08 (3 H, s, 18-H); Oc (06-
OMSO) 168.7 (C-17), 152.0 (C-4), 147.1 (C-12), 140.9 (C-16), 138.7 (C-3), 
137.0 (C-6), 130.4 (quin C-H), 128.8 (quin C-H), 128.0 (C-7), 127.8 (quin C-
H), 127.5 (C-13), 127.5 (quin C-H), 126.9 (C-14), 122.6 (C-5), 119.1 (C-15), 
117.3 (C-2), 114.2 (CN) and 24.1 (C-18); m/z 313 (M+, 93.9), 270 (100), 255 
(18.3) and 243 (11.2%) (Found: M+, 313.1185. C2oH1SN30 requires M, 
313.1212). 
N-1Butoxycarbonyl-4-cyanomethylaniline (75). 
1 2 
NC 
4-Aminobenzyl cyanide (0.66 g, 5 mmol) and (BOC)20 (1.2 g, 5.5 mmol) 
were stirred together in dioxane-water (1: 1, 6 ml) for 18 h. Ethanol (10 ml) 
was added and the solvents removed under reduced pressure to give 
carbamate 75 (1.160 g, 99%), m.p. 117.5-118.5 °C; Rt 0.46; Vmax (KBr) 3388 
(N-H), 2983, 2248 (unconjugated CN), 1700 (carbamate C=O), 1597 (C=C), 
1238 (carbamate C-O) and 820 (para-disubstituted benzene) cm-1; OH (06-
OMSO) 9.44 (1 H, br s, N-H), 7.50 (2 H, AA'BB', 3J= 8.6, 5-H) 7.25 (2 H, 
AA'BB', 3J= 8.6, 4-H), 3.96 (2 H, s, 2-H) and 1.51 (9 H, s, 9-H); Oc (06-0MSO) 
152.7 (C-7), 139.1 (C-6), 128.5 (C-4), 124.5 (C-3), 118.5 (C-5), 114.9 (C-1), 
79.2 (C-8), 28.2 (C-9) and 21.8 (C-2); m/z 232 (M+, 6.0), 176 (30.7), 132 
(34.7) and 104 (6.7%) (Found: M+, 232.1217; C, 67.17; H, 7.09; N, 12.13%. 
C13H16N202 requires M, 232.1208; C, 67.20; H, 6.95; N, 12.07%). 
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Condensation product (76) of 2-guinolinecarbaldehyde with 
compound 75. 
8 
11 3 
1 
CN 
~ 0 ~ 19 
16)l k'\ ~ N 17 0 18 
15 H 
Carbamate 75 (0.464 g, 2 mmol) was dissolved in EtOH (2 ml) and added to 
a stirred solution of 2-quinolinecarbaldehyde (0.314 g, 2 mmol) in EtOH (2 
ml). KOtBu (0.224 g, 2 mmol) was added and after 5 min a light brown 
precipitate formed. This was filtered off, washed with petroleum ether and 
dried under suction to give carbamate 76 (0.527 g, 71 %) as a beige 
powder, m.p. 180-182 °C; RI 0.85 (EtOAc); Vmax (KBr) 3058, 2975, 1715 
(carbamate C=O), 1588 (C=C), 1522, 1231 (carbamate C-O), 1158,832 
(para-disubstituted benzene) and 756 (ortho-disubstituted benzene) cm-1; OH 
(D6-DMSO) 9.77 (1 H, br s, N-H), 8.50 (1 H, d, 3J= 8.5, 6-H), 8.12 (1 H, s, 3-
H), 8.10-8.00 (2 H, m), 7.93-7.82 (4 H, m), 7.73-7.65 (3 H, m) and 1.53 (9 H, 
s, 19-H); Oc (D6-DMSO) 152.7 (C-17), 152.2 (C-4), 147.3 (C-12), 141.5 (C-
16), 138.4 (C-3), 137.1 (C-6), 130.5 (quin C-H), 128.9 (quin C-H), 128.0 
(quin C-H), 127.7 (quin C-H), 127.6 (C-7 or C-13), 127.3 (C-13 or C-7), 
127.1 (C-14), 122.7 (C-5), 118.3 (C-15), 117.5 (C-2), 114.4 (CN), 79.7 (C-18) 
and 28.2 (C-19); m/z 371 (M+, 4.5),315 (23.1), 297 (36.6), 270 (100) and 
242 (15.7%) (Found: M+, 371.1598; C23H21 N302 requires M, 371.1629). 
2-(4-Aminophenyl)-3-(2-guinolinyl)propenenitrile (77). 
8 
11 
1 
CN 
15 
Carbamate 76 (0.216 g, 0.6 mmol) was dissolved in EtOAc (10 ml) and HCI 
gas was bubbled through the solution for 30 min. The orange precipitate 
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was filtered off, dissolved in water and treated with NaOH solution (1 M) to 
pH 8. The aqueous solution was extracted with EtOAc (3 x 25 ml), dried and 
the organic solvents were removed under reduced pressure to give crude 
compound 77 (0.142 g, 90%). The 1H NMR showed the presence of a small 
amount «5%) of 76 in this crude mixture. This compound was used in a 
further experiment without further characterisation. The NMR spectra are 
quoted for the deprotected amine 77; m.p (crude, 174-175°C), Rt 0.46 
(EtOAc); OH (06-acetone) 8.25 (1 H, d, 3J= 8.6, 6-H), 7.96 (1 H, dd, 11-H), 7.83 
(1 H, dd, 8-H), 7.79 (1 H, d, 3J= 8.6, 5-H), 7.65 (2H, m, 3-H & 10-H), 7.49 
(3H, m, 14-H & 9-H), 6.67 (2H, d, 3J= 8.7, 15-H) and 5.16 (2 H, br s, NH2); oe 
(06-acetone) 153.9 (C-16), 151.6 (C-4), 148.6 (C-12), 137.4 (C-3 or C-6), 
135.5 (C-6 or C-3), 131.1 (C-7), 130.8 (quin C-H), 130.1 (quin C-H), 128.6 
(quin C-H), 128.5 (C-14), 128.0 (quin C-H), 123.0 (C-13), 122.7 (C-5), 116.6 
(C-2), 115.1 (C-15) and 114.7 (CN). 
N-[(4-cyanomethyl}phenyl]-2-guinolinealdimine (78). 
2 
1 
eN 
2-Quinolinecarbaldehyde (0.470 g, 3 mmol) and 4-aminobenzyl cyanide 
(0.396 g, 3 mmol) were dissolved in EtOH (3 ml) with stirring. Within 5 
minutes a brown precipitate formed which was recovered and recrystallised 
from EtOAc to afford nitrile 78 (0.523 g, 65%) as brown plates, m.p. 131-132 
°C; Rt 0.58 (EtOAc); Vmax (KBr) 3063 (aromatic C-H), 2943 (aliphatic C-H), 
2246 (unconjugated CN), 1624 (C=N), 1593, 1501 (aromatic C=C), 1417 
(CH2 deformation), 834 (para-disubstituted benzene) and 759 (ortho-
disubstituted benzene) cm-1; OH (COCI3) 8.75 (1 H, s, 7-H), 8.32 (1 H, d, 3J= 
8.5, 10-H), 8.20 (1 H, d, 3J= 8.6, 9-H), 8.17 (1 H, dd, 3J= 8.5, 15-H), 7.82 (1 H, 
dd, 12-H), 7.71 (1 H, ddd, 14-H), 7.57 (1 H, ddd, 4J= 1.1, 13-H), 7.34 (4 H, m, 
4-H & 5-H) and 3.75 (2 H, s, 2-H); oe (COCb) 161.5 (C-7), 154.5 (C-6), 150.7 
(C-8), 147.9 (C-16), 136.7 (C-10), 130.0 (quin C-H), 129.8 (quin C-H), 128.9 
(C-4), 128.3 (C-11), 127.9 (quin C-H), 127.8 (quin C-H), 121.9 (C-5), 118.6 
(C-9), 117.8 (C-3) 115.2 (CN) and 23.2 (C-2); m/z 271 (M+, 97.6), 243 (100), 
204 (23.7), 155 (25.7) and 129 (74.0%) (Found: M+, 271.1097; C, 79.54; H, 
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4.92; N, 15.53%. C1SH 13N3 requires M, 271.1107; C, 79.67; H, 4.83; N, 
15.50%). 
Condensation product (79) of 2-quinolinecarbaldehyde with 78. 
20 22 
2-Quinolinecarbaldehyde (0.118 g, 0.75 mmol) was dissolved in EtOH (2 ml) 
with stirring. A solution of nitrile 78 (0.203 g, 0.75 mmol) in EtOH (2 ml) was 
added, followed by an equivalent of tBuOK (84 g, 0.75 mmol) in EtOH (2 ml). 
After stirring for 30 min a solid had precipitated which was filtered, washed 
and dried to afford nitrile 79 (0.217 g, 71%) as a yellow powder, m.p. 145°C 
(d.); Rf 0.50 (EtOAc); Amax (EtOH)/nm 205 (E/dm 3 mol-1 cm-1 85300), 233 
(66400) and 370 (41000); Vmax (KBr) 3042 (unsaturated C-H), 2214 (a,f3-
unsaturated CN), 1616 (C=N), 1504 (C=C), 834 (para-disubstituted 
benzene) and 752 (ortho-disubstituted benzene) cm-1; OH (CDCI3) 8.70 (1 H, 
s, 7-H), 8.36 (2 H, 2 d, 10-H & 20-H), 8.23 (1 H, d, 3J= 8.6, 9-H), 8.04 (2 H, 2 
dd, 15-H & 25-H), 8.01 (1 H, s, 17-H), 7.95-7.85 (2 H, m, 12-H & 22-H), 7.92 
(2 H, AA'BB', 3J= 8.8, 4-H), 7.85 (1 H, d, 3J= 8.6, 19-H), 7.76-7.66 (2 H, 2 
ddd, 14-H & 24-H), 7.62-7.50 (2 H, 2 ddd, 13-H & 23-H) and 7.45 (2 H, 
AA'BB', 3J= 8.8, 5-H); Oc (CDCI3) 161.9 (C-7), 154.2 (C-6), 151.6 (C-8 or C-
18), 151.3 (C-18 or C-8), 147.3 (C-16 or C-20), 147.2 (C-20 or C-16), 140.3 
(C-17), 137.3 (C-10 or C-20), 135.3 (C-20 or C-10), 130.5, 129.4, 129.0 (all 
C-H), 128.7 (C-11), 128.3, 128.1, 127.8, 127.6, 126.1, 123.1, 122.4, 121.8, 
118.4 (all C-H) 117.2 (C-2) and 113.9 (CN); m/z 410 (M+, 21.8), 270 (100), 
253 (18.3), 242 (10.4) and 135 (16.8%) (Found: M+, 410.1525. C2sH1sN4 
requires M, 410.1528) 
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N-[(4-cyanomethyl)phenyl]-2-guinolinemethylamine (80). 
13 
14 
2 
1 
eN 
The conditions for the borohydride reduction were the same as those 
employed by Moriarty et al.95 Nitrile 78 (0.540 g, 2 mmol) was dissolved in 
dry MeOH (5 ml) and the solution stirred at 0 DC under N2. NaBH4 (0.756 g, 
20 mmol) was added in small quantities over a period of 10 min and the 
reaction was allowed to stir for a further 2 h. After this time the mixture was 
diluted with brine (15 ml) and extracted with CHCI3 (3 x 10 ml). After drying, 
the solvent was removed under reduced pressure to afford nitrile 80 (0.432 
g, 79%) as a fawn coloured solid, m.p. 79-81 DC; Rt 0.88 (EtOAc); Vmax (KBr) 
3348 (N-H), 3054 (aromatic C-H), 2912 (aliphatic C-H), 2244 (unconjugated 
CN), 1614, 1522 (aromatic C=C), 824 (para-disubstituted benzene) and 748 
(ortho-disubstituted benzene) cm-1; OH (Ds-DMSO) 8.33 (1 H, d, 3J= 8.5, 10-
H), 8.04 (1 H, dd, 3J= 8.4, 15-H), 7.97 (1 H, dd, 3J= 8.1, 12-H), 7.79 (1 H, ddd, 
14-H), 7.59 (1 H, ddd, 13-H), 7.56 (1 H, d, 3J= 8.5, 9-H), 7.05 (2 H, dd, 
AA'BB', 4-H), 6.67 (3 H, m, N-H & 5-H), 4.57 (2 H, d, 3J=6.1, 7-H) and 3.80 (2 
H, s, 2-H); oe (Ds-DMSO) 160.7 (C-6), 147.9 (C-8), 147.1 (C-16), 136.7 (C-
10),129.6 (quin C-H), 128.9 (C-4), 128.4 (quin C-H), 127.9 (quin C-H), 127.0 
(C-11), 126.1 (quin C-H), 119.6 (C-9), 117.9 (CN), 112.6 (C-5), 49.1 (C-7) 
and 21.5 (C-2); m/z 273 (M+, 40.8), 157 (40.3), 145 (74.3), 129 (84.7) and 
116 (97.7%) (Found: M+, 273.1271. ClsH15N3requires M,273.1263). 
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Condensation product (81) of 2-quinolinecarbaldehyde with 80. 
14 
15 7 
4 
20 22 
Nitrile 80 (0.165 g, 0.6 mmol) was dissolved in EtOH (2 ml) with stirring. To 
this solution was added tBuOK (67 mg, 0.6 mmol) in EtOH (2 ml) and, after 
stirring for 1 min, 2-quinolinecarbaldehyde (94 mg, 0.6 mmol) in EtOH (1 ml). 
After 2 h, TLC indicated formation of a new product. The reaction solution 
was adsorbed onto silica and was purified by column chromatography with 
petroleum ether-EtOAc (2:1) as eluent to give nitrile 81 (83 mg, 34%) as a 
yellow solid, m.p. 214°C (d.); A, 0.86 (EtOAc); Vmax (KBr) 3387 (N-H), 3054 
unsaturated C-H), 2961 (aliphatic C-H), 2213 (conjugated CN), 1608, 1522 
(C=C), 823 (para-disubstituted benzene) and 755 (ortho-disubstituted 
benzene) cm-1; OH (D6-DMSO) 8.35 (1 H, d, 3J= 8.5, 10-H or 20-H), 8.25 (1 H, 
d, 3J= 8.5, 20-H or 10-H), 8.00-7.86 (4 H, m), 7.79 (1 H, s, 17-H), 7.75-7.64 (3 
H, m), 7.58-7.45 (5 H, m), 6.70 (2 H, AA'BB', 3J= 8.6, 5-H) and (2 H, d, 7-H); 
Oc (D6-DMSO) 160.2 (C-6), 152.7 (C-18 or C-8), 150.3 (C-8 or C-18), 147.4 
(C-16 or C-26), 147.1 (C-26 or C-16), 136.9 (C-10 or C-20), 134.5 (C-20 or 
C-10), 130.3, 129.8, 128.8, 128.5 (all C-H), 128.0 (C-4), 127.7, 127.4 (both 
C-H), 126.8 (C-11 & C-21), 126.3 (C-H), 122.5 (C-19), 121.4 (C-3), 119.7 (C-
9), 117.5 (C-2), 115.0 (CN), 112.6 (C-5) and 48.9 (C-7); m/z 412 (M+, 1.8), 
270 (100), 245 (10.2) and 135 (17.0%) (Found: M+, 412.1703. C2sH2oN4 
requires M,412.1684). 
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2,4-0iamino-6-cyanomethyl-3,S-pyridinedicarbonitrile (82). 
NC 
Trinitrile 82 was prepared as previously described in the literature.96 A 
mixture of malononitrile (3.0 g, 45 mmol) and anhydrous ZnCI2 (1 g, 7.4 
mmol) in DMF (5 ml) was heated with stirring for 15 min at 95°C and for 15 
min at RT. The yellowish solution was diluted with MeOH to give a pale 
yellow precipitate. This was filtered off and recrystallised from dioxane to 
give compound 82 (1.148 g, 38%) m.p. 329-331 °C (lit.,96 330-332 °C); Rt 
0.61; Vmax (KBr) 3411, 3335 (NH2), 2262 (unconjugated CN), 2214 
(conjugated CN), 1649 (C=N), 1573 and 1553 cm-1; OH (D6-DMSO) 7.51 and 
7.34 (4 H, 2 br s, 2 x NH2) and 4.14 (2 H, s, 6-H); Oc (D6-DMSO) 161.5 (C-5), 
158.9 (C-1), 158.2 (C-3), 116.5, 115.2, 114.7 (all CN), 81.4 (C-4), 70.9 (C-2) 
and 25.8 (C-6); m/z 198 (M+, 100), 171 (11.0),144 (17.9) and 67 (18.0%) 
(Found: M+, 198.0655. C9H6N6 requires M, 198.0654). 
2-[6-(2,4-0 i am i no-3 .S-d i cyanopyridyl)]-3-(2-q ui nol i nyl) 
propenenitrile (83). 
10 
11 
1 
CN 
CN 
To a solution of 2-quinolinecarbaldehyde (0.314 g, 2 mmol) in DMF (2 ml) 
was added a catalytic amount of piperidine and a solution of trinitrile 82 
(0.396 g, 2 mmol) in DMF (2 ml). A small quantity of tBuOK was introduced 
and the reaction was stirred at RT for 4 h. The reaction mixture was diluted 
with EtOAc and washed with water (2 x 10 ml), brine (2 x 10 ml) and water (2 
x 10 ml). After drying, most of the EtOAc was removed under reduced 
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pressure, leaving a slurry of the precipitated product. This slurry was filtered, 
washed with petroleum ether and dried under suction to afford nitrile 83 
(0.323 g, 48%) as a fawn coloured solid, m.p. 230°C (d.); Rt 0.34 (EtOAc); 
Vmax (KBr) 3642, 3367 (NH2), 2208 (CN), 1662 (alkene C=C), 1566, 1543 
(aromatic C=C & C=N) cm-1; DH (D6-DMSO) 8.60 (1 H, d, 3J= 8.5, 6-H), 8.23 
(1 H, s, 3-H), 8.17-8.06 (2 H, m, 8-H & 11-H), 7.99-7.85 (2 H, m, 5-H & 10-H) 
and 7.83-7.47 (5 H, m, 9-H & 2 x NH2); DC (D6-DMSO) 161.5 (C-17), 159.3 
(C-13), 158.9 (C-15), 150.7 (C-4), 148.4 (C-3), 147.3 (C-12), 137.7 (C-6), 
130.9, 129.3, 128.5, 128.2 (all quin C-H), 128.1 (C-7), 122.9 (C-5), 115.9, 
115.5,114.7 (all CN), 112.7 (C-2), 81.8 (C-16) and 71.9 (C-14); m/z 337 
(M+, 100),311 (86.5),198 (19.9),179 (30.1),128 (45.8) and 101 (21.3%). 
(Found: M+, 337.1093. C19HllN7 requires M, 337.1075). 
2-Cyanomethyl-propene-1,1.3.3-tetranitrile. sodium salt (84). 
2 1 
NC~CN 4 3 
5 -
NC 6 CN 
CN N~ 
A solution of malononitrile (1.98 g, 30 mmol) in Na2C03 solution (1 M, 20 ml) 
was stirred for 17 h at room temperature. The solution was acidified to pH3 
with concentrated HCI and extracted with EtOAc (4 x 50 ml). Anhydrous 
NaHC03 (2.5 g) was added to the combined extracts and the slurry was 
stirred for 2 h. The precipitate was recovered by filtration and washed with 
EtOAc-CHCI3 (3:2, 2 x 50 ml). The filtrate and washings were combined and , 
diluted with CHCI3 to precipitate an oil which crystallised giving nitrile 84, 
(53%) m.p. 249-250 °c (lit.,99 248-250 °C); Rt 0.23 (EtOAc); Vmax (KBr) 2200 
(conjugated CN), 1648 (aliphatic C=C) and 1492 cm-1; DH (D6-DMSO) 3.64 
(2 H, s, 2-H); Dc (D6-DMSO) 156.6 (C-3), 117.6 (C-1), 115.6 (CN). 115.2 
(CN), 53.7 (C-4 & C-6) and 23.0 (C-2). This compound was used in 
subsequent reaction without further characterisation. 
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2-Amino-6-chloro-4-cyanomethyl-3,5-pyridinedicarbonitrile (85). 
CN 
NC 
CI 
Nitrile 84 (0.880 g, 4.33 mmol) was dissolved in acetone (15 ml), 
concentrated HCI (0.5 ml) was added and the reaction was heated at 60°C 
for 20 min. The reaction mixture was concentrated under reduced pressure 
and dissolved in water (20 ml). NaOH (1 M) was added to pH 8. The organic 
product was extracted with EtOAc and the solution was dried before 
removing the organic solvents under reduced pressure. The crude product 
was purified by column chromatography to afford nitrile 85 (0.131 g, 14%), 
Rf 0.42; ()H (D6-DMSO) 8.85 and 8.50 (2 H, 2 br s, NH2) and 4.27 (2 H, s, 
CH2CN); m/z 217 (M+, 100), 181 (24.5), 155 (23.9), 128 (18.4) and 101 
(8.2%). This product was used in a subsequent reaction without further 
characterisation. 
3-(4-Quinolinyl)-2-propenal (87). 
9 
10 
11 
1 
CHO 
Compound 87 was prepared as described previously in the literature.1oo To 
a suspension of triphenylphosphoranylideneacetaldehyde (0.608 g, 2 mmol) 
in nitrobenzene (2 ml) under N2 in dry conditions was added 4-
quinolinecarbaldehyde (0.314 g, 2 mmol). After the initial exotherm had 
subsided, the mixture was stirred, excluding light and air, for 24 h at RT. Hel 
(2 M, 5 x 2 ml) was added and the aqueous phase separated and washed 
with ether (3 x 20 ml) and pentane (3 x 20 ml) until the smell of nitrobenzene 
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had disappeared. The acid solution was carefully treated with Na2C03 until 
a precipitate formed and the pH became alkaline. The crude product was 
filtered off, dried and purified by flash column chromatography to yield 87 
(0.335 g, 54%) as a mixture of E- and Z- isomers (92:8 by 1 H NMR 
spectroscopy), m.p. 68.5-70 °c (lit.,100 91-92 °c for E- isomer); Rt 0.31 
(EtOAc); V max (KBr) 3052, 1682 (a,fJ-unsaturated aldehyde C=O), 1612 
(a,fJ- unsaturated C=C), 1506 (aromatic C=C) and 760 (ortho-disubstituted 
benzene) cm-1; NMR data quoted for E-isomer; OH (D6-acetone) 9.94 (1 H, d, 
3J1F7.6, 1-H), 8.96 (1 H, d, 3J= 4.5, 4-H), 8.56 (1 H, d, 3J2s=15.9, 3-H), 8.35 
(1 H, dd, 3J=8.0, 11-H), 8.12 (1 H, dd, 3J=7.8, 8-H), 7.80 (2 H, m, 5-H & 10-
H), 7.67 (1 H, ddd, 4J= 1.3, 9-H) and 6.98 (1 H, dd, 3J1F7.6, 3J2s=15.9, 2-H); 
oe (D6-acetone) 194.2 (C-1), 151.1 (C-4), 149.7 (C-12), 146.9 (C-3), 139.8 
(C-6), 134.6 (C-2), 131.0 (quin C-H), 130.4 (quin C-H), 128.2 (quin C-H), 
126.4 (C-7), 124.1 (quin C-H) and 119.1 (C-5); m/z 183 (M+, 56.2) 154 
(100), 127 (34.3) and 75 (16.9%) (Found: M+, 183.0679. C12H9NO requires 
183.0682). 
4-(4-quinolinyl)-1 ,3-butadiene-1, 1-dicarbonitrile (88). 
CN 
~ CN 
11 
Malononitrile (36.1 mg, 0.55 mmol) was dissolved in EtOH (2 ml) and added 
to a solution of aldehyde 87 (100 mg, 0.55 mmol) in EtOH (2 ml). EtOH-
piperidine solution (10: 1, 2 drops) was added and the reaction was stirred 
for 48 h. The solvents were removed under reduced pressure and the crude 
product was subjected to column chromatography in pet. ether-EtOAc (1: 1), 
affording nitrile 88 (83 mg, 66%), Rt 0.55; Vmax 2963, 2221 (CN), 1603, 
1563 (C=C and C=N) and 1504; OH (D6-DMSO) 9.04 (1 H, d, 3J= 4.61, 4-H), 
8.59 (1 H, d, 3J= 15.0, 3-H), 8.46 (1 H, d, 3J= 11.4, 1-H), 8.36 (1 H, dd, 3J= 
8.2, 11-H), 8.19-8.07 (2 H, m, 8-H & 5-H), 7.95 - 7.75 (2 H, m, 9-H & 10-H) 
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and 760 (1 H, dd, 3J= 15.0, 3J=11.3, 2-H); m/z 270 (M+, 3.3), 257 (5.2), 231 
(100), 204 (43.2) and 166 (91.2%). 
2-Amino-6-(4-quinolinyl)-1 ,3,5-hexatriene-1, 1 ,3-tricarbonitrile 
ru.1. 
eN 
11 
Malononitrile dimer (72 mg, 0.55 mmol) was dissolved in EtOH (2 ml) and 
added to a stirred solution of aldehyde 87 (0.100 g, 0.55 mmol) in EtOH (2 
ml). After 1 h a yellow precipitate had formed which was filtered off and 
purified by flash column chromatography to give nitrile 89 (101 mg, 62%) 
(>90% of one isomer by 1H NMR spectroscopy), m.p. 140°C (d.); Rf 0.08 
(EtOAc); Vmax (KBr) 3324, 3210 (NH2), 2960, 2215 (conjugated CN), 1647 
(alkene C=C), 1607, 1575 (aromatic C=C & C=N) and 761 (ortho-
disubstituted benzene) cm-1; NMR data quoted for major isomer (E,Z- shown 
above); DH (D6-DMSO) 9.15 (2 H, br 5, NH2), 9.02 (1 H, d, 4-H), 8.56 (1 H, d, 
3J2~ 15.0, 3-H), 8.39 (1 H, d, 3J= 8.5, 11-H), 8.20-8.05 (3 H, m, 1-H, 8-H & 5-
H), 7.95-7.75 (2 H, m, 10-H & 9-H) and 7.57 (1 H, dd, 3J2~ 15.0, 3J1F11.2, 
2-H); DC (D6-DMSO) 164.3 (C(NH2)), 153.7 (C-1), 150.6 (C-4), 148.5 (C-12), 
142.2 (C-3), 139.2 (C-6), 130.0 (quin C-H), 129.9 (quin C-H), 128.2 (quin C-
H), 127.7 (C-2), 125.4 (C-7), 123.3 (quin C-H), 118.4 (C-5), 115.5, 114.8, 
113.6 (all CN), 105.6 (=C(CN)-C(NH2)=C(CN)2), 49.8 (C(CN)2); mlz 297 (M+, 
100), 269 (26.2), 205 (27.9) and 166 (47.9%) (Found: M+, 297.1010. 
C1sH11Ns requires M, 297.1013). 
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lButyl-2-Cyano-5-(4-quinolinyl)-2,4-pentadieneoate (90). 
10 
11 
~ eN 
1 
3# 2 
tButyl cyanoacetate (66 mg, 0.47 mmol) was added to a stirred solution of 
aldehyde 87 (86 mg, 0.47 mmol) in EtOH (2 ml). After 18 h a yellow 
precipitate had formed which was filtered off and purified by flash column 
chromatography to give ester 90 (79 mg, 57%), (>90% one isomer by 1 H 
NMR spectrospcopy), m.p. 131-133 °C; Rt 0.53 (EtOAc); Vmax (KBr) 2978, 
1724 (ester C=O), 1654 (alkene C=C), 1586 (aromatic C=C) and 1260 (ester 
C-O) cm-1; NMR quoted for major isomer (E,E- shown above); OH (D6-DMSO) 
8.94 (1 H, d, 3J= 4.6, 4-H), 8.58 (1 H, d, 3J2~15.1, 3-H), 8.38 (1 H, dd, 3J= 
8.4, 11-H), 8.28 (1 H, d, 3J1F11.5, 1-H), 8.07 (1 H, dd, 3J= 8.3, 8-H), 7.95 (1 
H, d, 3J= 4.6, 5-H), 7.82 (1 H, ddd, 10-H), 7.70 (1 H, ddd, 9-H), 7.45 (1 H, dd, 
3J12=11.5, 3J23=15.1, 2-H) and 1.57 (9 H, s, CH3b); Oc (D6-DMSO) 160.6 
(C=O), 154.4 (C-1), 150.6 (C-4), 148.5 (C-12), 142.9 (C-3), 139.2 (C-6), 
130.0 (quin C-H), 129.9 (quin C-H), 128.2 (quin C-H), 127.5 (C-2), 125.5 (C-
7), 123.6 (quin C-H), 118.2 (C-5), 114.4 (CN), 107.6 (=C(CN», 83.8 
(C(CH3b) and 27.6 (CH3); m/z 306 (M+, 12.5),250 (22.5),233 (11.9), 205 
(90.1) and 166 (37.3%) (Found: M+, 306.1354. C19H1SN202 requires M, 
306.1364). 
3-(2-Thienyl)propenal (91 ). 
6 5 
7GJ--~HO 
S 4 3 
Aldehyde 91 was prepared as previously described in the literature.102 
NaOH (1 g, 25 mmol) was added to a solution of EtOH-water (1 :2, 18 ml) and 
over a period of 15 min, freshly distilled 2-thienaldehyde (4.5 g, 40 mmol) 
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was added dropwise. To this mixture a solution of acetaldehyde in water 
(40% vlv, 10 ml) was added at 0 °c over 3.5 h with vigorous stirring. 
Following neutralisation with ice-cold acetic acid the mixture was extracted 
with benzene, washed with water and dried. Distillation afforded aldehyde 
91 (1.158g, 34%) as a colourless liquid, b.p. 131-135 °c (lit.,102 105-108 °c 
(0.4 atm.)); Rt 0.79 (EtOAc); V max (KBr) 3040 (aromatic C-H), 1672 (a,{3--
unsaturated aldehyde C=O), 1612, 1421, 1226 (C=C in-plane vibration), 
1118 and 711 (monosubstituted thiophene) cm-1; BH (neat) 9.46 (1 H, d, 
3J,~7.7, 1-H), 7.47 (1 H, d, 3J2J=15.6, 3-H), 7.37 (1 H, d, 3J= 5.0, 7-H), 7.24 
(1 H, d, 3J= 3.4, 5-H), 6.95 (1 H, m, 6-H) and 6.35 (1 H, dd, 3J'2=7.7, 
3J2J=15.6, 2-H); Be (neat) 192.9 (C-1), 144.5 (C-3), 139.1 (C-4), 132.2 (C-5), 
130.5 (C-7), 128.5 (C-6) and 127.0 (C-2); m/z 138 (M+, 86.3),109 (66.8), 84 
(70.0) and 65 (66.8%). 
2-Amino-6-(2-thienyl)-1 ,3,5-hexatriene-1, 1 ,3-tricarbonitrile (92). 
NC 
6 NC 5 CN 
f 2 7 
1 NH2 
3 
Aldehyde 91 (124 mg, 0.89 mmol) was added to a stirred solution of 
malononitrile dimer (118 mg, 0.89 mmol) in EtOH (5 ml). After 1 h the EtOH 
was removed under reduced pressure and the solid product was purified by 
column chromatography twice on silica with petroleum ether-EtOAc (1:1) 
and diethyl ether as eluents. This afforded compound 92 (0.153 g, 68%) as 
a yellow solid, m.p. 212°C (d.); Rt 0.88 (EtOAc); Vmax (KBr) 3334, 3217 (NH2), 
2212 (CN), 1658 (alkene C=C), 1599, 1575 and 1533 cm-1; BH (Ds-DMSO) 
8.83 (2 H, br s, NH2), 7.82 (1 H, d, 3J'F11.2, 1-H), 7.80 (1 H, d, 3J= 5.0, 7-H), 
7.68 (1 H, d, 3J2J=14.9, 3-H), 7.56 (1 H, d, 3J= 3.4, 5-H), 7.16 (1 H, dd, 6-H) 
and 6.81 (1 H, dd, 3J23=14.9, 3J'2=11.3, 2-H); Be (Ds-DMSO) 165.0 {-C 
(NH2)=C(CNh), 154.0 (C-1), 141.3 (C-3), 139.9 (C-4), 133.4 (C-5), 132.0 (C-
7), 129.4 (C-6), 121.3 (C-2), 115.8, 115.7, 115.1 (all CN), 101.5 (-
C(NH2)=C(CNh) and 52.7 (-C(NH2)=C(CN)2); m/z 252 (M+, 100),226 (24.8), 
197 (10.5) 160 (30.3) and 122 (30.7%) (Found: M+, 252.0473. C13HSN4S 
requires M, 252.0469). 
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Methyl (Z)-3-amino-2.4-dicyano-2-butenoate (93). 
Sodium methoxide (3.51 g, 65 mmol) was suspended in dry toluene (30 ml) 
and heated to reflux. A solution of methylcyanoacetate (6.44 g, 65 mmol) 
and malononitrile (4.292 g, 65 mmol) was added dropwise over 10 min. The 
solution was refluxed for a further 50 min. The coloured sodium salt was 
filtered off, dissolved in water (30 ml) and the pH adjusted to 5 with 
concentrated HCI. After cooling overnight a solid had precipitated which 
consisted of malononitrile dimer and the desired product. The solid was 
filtered off and purified by column chromatography, yielding 93 (0.072 g, 
<1 %), m.p. 95-96 °c (lit.,103 95-96 °C); Rt 0.27; OH (Ds-DMSO) 9.12 (2 H, br s, 
NH2), 3.87 (2 H, s, 5-H) and 3.72 (3 H, s, 1-H); rn/z 165 (75.1), 138 (54.3), 
133 (100), 107 (25.9) and 68 (95.6%). 
Dimethyl-3-amino-2-cyano-pent-2-enedioate (94). 
6 7 
H2N COOCH3 3~ /CN 
COOCH3 
2 1 
To a solution of sodium (1.15 g, 50 mmol) in dry MeOH (22 ml) was added 
methyl cyanoacetate (10.7 g, 100 mmol) and the solution was heated at 
reflux for 1 h. Upon cooling to RT, a colourless precipitate formed which was 
recovered and stirred in ice cooled HCI (0.5 M, 50 ml). The crystals were 
filtered off, washed with water and recrystallised from MeOH-water giving 
diester 94 (6.403 g, 61%) as white crystals m.p. 132-133 °c (lit.,104 131°C); 
Rt 0.31 (EtOAc); Vmax (KBr) 3402, 3320 (NH2), 2206 (CN), 1708 (ester C=O), 
1636 (alkene C=C) and 1280 (ester C-O) cm-1; OH (Ds-DMSO) 9.13 and 8.94 
(2 H, 2 br s, NH2), 3.71 (3 H, s, 1-H or 7-H), 3.70 (3 H, s, 7-H or 1-H) and 3.63 
(2 H, s, 3-H); Oc (Ds-DMSO) 167.8 (C-6 or C-2), 167.2 (C-2 or C-6), 165.8 (C-
4), 118.3 (CN), 70.5 (C-5), 52.5 (C-7 or C-1), 51.2 (C-1 or C-7) and 39.8 (C-
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3); m/z 198 (M+, 29.7), 166 (39.8), 138 (100), 123 (18.0) and 79 (21.1%) 
(Found: M+, 198.0628; C, 48.60; H, 5.09; N, 14.39%. CsH1QN204 requires M, 
198.0638; C, 48.47; H, 5.09; N, 14.14%). 
Condensation product (95) of 2-guinolinecarbaldehyde with 
diester 94. 
14 
15 COOCH3 
2 1 
To a solution of 2-quinolinecarbaldehyde (0.314 g, 2 mmol) in DMF (2 ml) 
was added a catalytic amount of piperidine and a solution of diester 94 
(0.396 g, 2 mmol) in DMF (2 mI). A small quantity of tBuOK was introduced 
and the reaction was stirred at 90°C for 16 h. The reaction mixture was 
cooled, diluted with EtOAc and washed with water (2 x 10 ml), brine (2 x 10 
ml) and water (2 x 10 mI). After drying, most of the EtOAc was removed 
under reduced pressure, leaving a slurry of the precipitated product. This 
slurry was filtered, washed with petroleum ether and dried under suction to 
afford 95 (0.323 g, 46%) as a fawn-coloured solid, m.p. 185°C (d.); Rt 0.86 
(EtOAc); Vmax (KBr) 3422 (NH2), 2208 (CN), 1726 (ester C=O), 1628 (alkene 
C=C), 1522 (aromatic C=C) and 1266 (ester C-O) cm-1; OH (D6-DMSO) 9.19 
and 9.14 (2 H, 2 br s, NH2), 8.45 (1 H, d, 3J= 8.5, 11-H), 8.32 (1 H, s, 8-H), 
8.01 (2 H, m), 7.82 (2 H, m), 7.65 (1 H, m, 14-H), 3.89 (3 H, s, 7-H or 1-H) and 
3.81 (3 H, s, 1-H or 7-H); Oc (D6-DMSO) 167.4 (C-2 or C-6), 167.3 (C-6 or C-
2),164.2 (C-4), 151.2 (C-9), 147.5 (C-17), 142.0 (C-8), 137.2 (C-11), 130.6 
(quin C-H), 129.4 (quin C-H), 129.2 (C-5), 128.2 (quin C-H), 128.0 (quin C-
H), 127.5 (C-12), 123.2 (C-10), 118.9 (CN), 70.7 (C-3), 53.0 (C-7 orC-1) and 
51.2 (C-1 or C-7); m/z 337 (M+, 1.5), 278 (100), 246 (10.7), 203 (10.9) and 
128 (20.7%) (Found: M+, 337.1048. C1SH15N304 requires M, 337.1059). 
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Condensation product (96) of 4-quinolinecarbaldehyde with 
diester 94. 
2 1 
COOCH3 
8 ~5 COOCH3 
6 7 
14 
15 
16 17 
Diester 96 was prepared using the method described for the preparation of 
compound 95. Recrystallisation from EtOAc afforded compound 96 (0.108 
g, 16%) as a fawn-coloured solid, m.p. 179°C (d.); Rt 0.57 (EtOAc); Vmax 
(KBr) 3406, 3308 (NH2), 2214 (CN), 1720 (ester C=O), 1664 (alkene C=C), 
1620, 1528 (aromatic C=C & C=N), 1240 (ester C-O) and 754 (para-
disubstituted benzene) cm-1; OH (D6-DMSO) 9.11 and 9.04 (2 H, 2 br s, NH2), 
8.87 (1 H, d, 3J= 4.4, 9-H), 8.46 (1 H, s, 8-H), 7.99 ( 2 H, m, 13-H & 16-H), 
7.75 (1 H, ddd, 15-H), 7.62 (1 H, ddd, 14-H), 7.40 (1 H, d, 3.): 4.3, 10-H), 3.81 
(3 H, s, 7 -H) and 3.52 (3 H, s, 1-H); oc (D6-DMSO) 166.6 (C-2 or C-6), 164.7 
(C-6 or C-2), 163.5 (C-4), 150.3 (C-9), 147.8 (C-17), 140.5 (C-8), 138.7 (C-
11), 131.3 (C-5), 130.2 (quin C-H), 129.6 (quin C-H), 127.4 (quin C-H), 125.4 
(C-12), 125.1 (quin C-H), 119.5 (C-5), 118.0 (CN), 71.7 (C-3), 53.2 (C-7) and 
51.3 (C-1); m/z 337 (M+, 5.9), 278 (56.7), 246 (100),191 (15.1) and 128 
(50.5%) (Found: M+, 337.1079. C1sH15N304 requires M, 337.1059). 
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(Z}-2-Amino-4-(4-guinolinyl)-1 ,3-butadiene-1, 1 ,3-tricarbonitrile, 
hydrochloride salt (97). 
eN 
HCI gas was bubbled through a solution of compound 48 (0.1 g, 0.37 mmol) 
in EtOH (5 ml). A yellow precipitate formed instantly and it was filtered off 
and dried under suction giving compound 97 (110 mg, 97%), m.p. 231°C 
(d.); Rt 0.77 (EtOH-acetic acid, 1:1); Vmax (KBr) 3426, 3344 (NH2), 2430 (+N-
H), 2208 (CN), 1650 (alkene C=C) and 1596 (aromatic C=C) cm-1; ~H (Ds-
DMSO) 10.49 (1 H, br s, +N-H), 9.81 and 9.35 (2 H, 2 br s, NH2), 9.27 (1 H, d, 
3J4s=5.1, 4-H), 8.91 (1 H, s, 3-H), 8.34 (2 H, m, 8-H & 11-H), 8.03 (2 H, m, 
3J4s=5.1, 5-H &10-H) and 7.84 (1 H, ddd, 9-H); ~c (Ds-DMSO) 163.5 (-C 
(NH2}=C(CN)2), 149.2 (C-4), 147.0 (C-3), 143.4 (C-12), 141.5 (C-6), 133.2 
(quin C-H), 129.4 (quin C-H), 125.7 (C-7), 125.3 (quin C-H), 124.5 (quin C-
H), 120.9 (C-5), 115.5, 114.1, 113.2 (all CN), 111.5 (C-2) and 50.3 (-
C(NH2)=C(CNh); m/z 271 (M-36+, 69.0),245 (54.8), 217 (16.3), 206 (36.0) 
and 142 (22.1%) (Found C, 62.62; H, 3.35; N, 22.57%. C1SH10CINs requires 
C, 62.53; H, 3.28; N, 22.80%). 
(Trimethyleneglycol methyl ether) cyanoacetate (99). 
2 
4 1 
5 3 o~A y NCll \'; °I
n 
o 
Cyanoacetic acid (4.155 g, 49 mmol) and triethyleneglycol methyl ether 
(7.990 g, 49 mmol) were heated at reflux in toluene (100 ml) for 24 h under 
Dean-Stark conditions. After removal of the toluene under reduced pressure 
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the clear liquid product was subjected to flash column chromatography with 
EtOAc as eluent. This afforded 99 (7.523 g, 66%) as a viscous, clear oil, Rt 
0.14 (EtOAc); Vmax (KBr) 2891s (aliphatic C-H), 2261 (unconjugated CN), 
1749 (ester C=O), 1257 (ester CoO) and 1104 (ether CoO) cm-1; BH (CDCI3) 
4.17 (2 H, m, ester terminal ethylene glycol unit, 2a-H), 3.56-3.34 (12 H, m) 
and 3.20 (3 H, s, 1-H); Be (CDCb) 161.9 (C-3), 112.0 (CN), 69.9, 68.6, 68.5, 
66.6, 63.7 (all CH2), 56.9 (C-1) and 22.7 (C-4); m/z 232 (M+1, 0.2), 186 
(3.0), 156 (4.1), 112 (92.8) and 68 (55.9%) (Found: M+, 232.1209. 
C1 oH 17N05 requires M, 231.1102). 
(Polyethyleneglycol methyl ether) cyanoacetate (101 ). 
2 
4 1 N~~00o~ 
o 
Cyanoacetic acid (0.637 g, 7.4 mmol) and polyethyleneglycol methyl ether 
(15 g, 7.5 mmol) were heated at reflux in toluene (100 ml) with a catalytic 
amount of PTSA for 24 h under Dean-Stark conditions. After removal of the 
toluene under reduced pressure the white solid was taken up in acetone 
and precipitated by addition to ice-cooled diethyl ether. The precipitate was 
recovered by filtration and purified from residual cyanoacetic acid by 
filtration through Sephadex LH-20 beads (50 g) with water as eluent giving 
ester 101 (10.994 g, 71 %), m.p. 48-50 °C; Rt 0.05 (EtOH); BH (CDCI3) 4.26 (2 
H, m, ester terminal polyethylene glycol unit, 2a-H), 3.90 (2 H, m, ester 
terminal polyethyleneglycol unit, 2b-H), 3.56 (178 H, m, 2-H and 4-H) and 
3.23 (3 H, s, 1-H); Be (CDCI3) 165.3 (C-3), 115.3 (CN), 83.0, 77.1, 72.7, 71.2 
(strong), 69.3, 66.2,65.3,59.4 (C-1) and 24.9 (C-4) 
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(Trimethyleneglycol methyl ether)-2-cyano-3-(4-guinolinyl) 
propenoate (102). 
14 
o b 15 130~Or 
3 
8 1 
10 
11 
4-Quinolinecarbaldehyde (0.471 g, 3 mmol) was dissolved in diethyl ether (5 
ml) and a catalytic amount of EtOH-piperidine solution (10:1) was added. 
Compound 99 (0.693 g, 2.9 mmol) was introduced and the reaction was 
stirred for 18 h. After this time TLC indicated formation of a new product. After 
removing the solvent under reduced pressure, the crude oil was twice 
purified by column chromatography on silica with EtOAc as eluent to afford 
ester 102 (0.318 g, 29%), At 0.24 (EtOAc); Vmax (KBr) 2878s (aliphatic C-H), 
2230 (CN), 1734 (ester C=O), 1272 (ester C-O), 1103 (ether C-O), 754 
(ortho-disubstituted benzene) cm-1; BH (D6-acetone) 8.91 (1 H, d, 3J=4.5, 4-
H), 8.86 (1 H, s, 3-H), 7.97 (1 H, d, 3J= 8.5, 11-H), 7.85 (1 H, d, 3J= 8.3, 8-H), 
7.76 (1 H, d, 3J= 4.5, 5-H), 7.66 (1 H, ddd, 4J= 1.4, 10-H), 7.50 (1 H, ddd, 4J= 
1.3, 9-H), 4.36 (2 H, m, terminal ethylene glycol unit, 14a-H), 3.71-3.22 (10 
H, m) and 3.06 (3 H, s, 15-H); Bc (D6-acetone) 161.9 (C-13), 152.1 (C-3), 
151.2 (C-4), 149.3 (C-12), 137.7 (C-6), 131.2 (quin C-H), 131.0 (quin C-H), 
128.8 (quin C-H), 125.9 (C-7), 124.5 (quin C-H), 121.1 (C-5), 114.9 (CN), 
111.6 (C-2), 72.6, 71.4, 71.3, 71.1, 69.3, 67.0 (all ethylene glycol CH2) and 
58.9 (C-15); m/z 371 (M+, 0.3), 294 (1.2), 251 (8.4), 207 (25.3) and 152 
(25.0%) (Found: M+, 370.1510; C, 64.54; H, 6.19; N, 7.59%. C2oH22N20s 
requires M, 370.1523; C, 64.83; H, 5.99; N, 7.57%). 
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(Trimethyleneglycol methyl ether)-2-cyano-3-(4-dimethylamino 
phenyl)-2-propenoate (103). 
9 
b 10 
O~Or 
3 
eN 
1 
4-Dimethylaminobenzaldehyde (0.298 g, 2 mmol) was dissolved in EtOAc (5 
ml) and a catalytic amount of neat piperidine was added. Compound 99 
(0.462 g, 2 mmol) was introduced, giving a rapid colour change to orange. 
After stirring for 1 h, TLC indicated the formation of a new product. The 
solvent was removed under reduced pressure and the crude oil was 
subjected to column chromatography with EtOAc as eluent to afford 103 
(0.52 g, 72%) as an orange oil, Rt 0.55 (EtOAc); Vmax (KBr) 2878s (aliphatic 
C-H), 2212 (CN), 1714 (ester C=O), 1614 (C=C), 1574, 1520 (aromatic 
C=C), 1278 (ester C-O) and 1188s (ether C-O) cm-1; OH (CDCI3) 7.87 (1 H, s, 
6-H), 7.74 (2 H, d, 3J= 9.0, 4-H), 6.52 (2 H, d, AA'BB', 3J= 9.1, 3-H), 4.30 (2 H, 
ester terminal ethylene glycol unit, 9a-H), 3.73-3.39 (10 H, m), 3.22 (3 H, s, 
10-H) and 2.95 (6 H, s, 1-H); oe (CDCI3) 163.9 (C-8), 154.3 (C-6), 153.4 (C-
2), 133.9 (C-4), 118.8 (C-5), 117.2 (CN), 111.3 (C-3), 92.8 (C-7), 71.7, 70.5, 
70.4, 70.3, 68.6, 64.7 (all ethylene glycol CH2), 58.7 (C-10) and 40.1 (C-1); 
m/z 362 (M+, 77.5), 304 (13.9), 260 (17.3),216 (67.9), 199 (100%) and 171 
(56.7%) (Found: M+, 362.1835; C2oH26N205 requires M, 362.1835). 
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(Polyethyleneglycol methyl ether)-2-cyano-3-(4-quinolinyl)-2-
propenoate (104). 
11 
To a solution of 4-quinolinecarbaldehyde (0.079 g, 0.5 mmol) in EtOH (2 ml) 
was added a solution of compound 101 (1.034 g, 0.5 mmol) in EtOH (5 ml). 
After 18 h, the solvent was removed under reduced pressure and the solid 
product was taken up in acetone and precipitated with by addition to ice-
cooled diethyl ether. The cream-coloured product was filtered off and dried 
under suction. TLC indicated no residual aldehyde but the presence of -6% 
unreacted 101. Compound 104 (0.583 g, 56%), m.p. 49-50 °C; Rt 0.05 
(EtOH); Vmax (KBr) 2887 (aliphatic C-H), 2214 (CN), 1738 (ester C=O), 1562 
(aromatic C=C), 1241 (ester C-O) and 1112 (ether C-O) cm-1; NMR data 
quoted for the major product; bH (CDCI3) 9.12 (0.96 H, d, 4-H), 9.11 (0.96 H, 
s, 3-H), 8.15 (1.92 H, m, 8-H & 11-H), 7.95 (0.96 H, d, 5-H), 7.91 (0.96 H, 
ddd, 10-H), 7.75 (0.96 H, ddd, 9-H), 4.52 (2 H, m, PEG ester terminal unit 
14a-H) and 3.95-3.20 (181 H, m, PEG CH2 & 15-H); be (CDCI3) 161.9 (C-13), 
152.4 (C-3), 151.3 (C-4), 149.4 (C-12), 137.9 (C-6), 131.2 (quin C-H), 131.1 
(quin C-H), 128.8 (C-7), 126.0, 124.7, 111.8 (CN), 100.8 (C-2), 84.5, 77.1, 
72.6, 71.2 (strong), 69.2, 66.9, 65.3 and 58.8 (C-15); ESMS showed a broad 
molecular weight distribution centred on approximately 2200 (Chapter 4, 
Section 4.5). 
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4-Hydroxy-3-quinolinecarbaldehyde (105). 
o 
Compound 105 was prepared as described previously in the literature. 1 06 
Quinolinol (2.0 g, 13.4 mmol) and powdered NaOH (2.0 g, 50 mmol) were 
mixed and CHGI3 (4 ml) was added. While heating under reflux and shaking 
vigorously, water (4 ml) was added in four equal portions, the reaction being 
allowed to subside after each addition. The mixture was heated under reflux 
and from time to time was shaken vigorously during 1 h when further GHGI3 
(2 ml) and water (1 ml) were added. The mixture was then heated under 
reflux for 5 h. The solvent was removed under reduced pressure and the 
remaining aqueous solution and insoluble gum were cooled. The aqueous 
solution was separated and filtered and the residual gum was extracted 
twice by boiling with aqueous NaOH solution (2 M, 5 ml), followed by COOling 
and filtering. The combined aqueous extract was acidified to pH 6 with 
glacial acetic acid and cooled in ice. After several hours the precipitated 
product was collected, washed with cold water and dried. Recrystallisation 
from EtOH gave colourless crystals of aldehyde 105 (1.342 g, 58%), m.p. 
271-273 °C (lit.,1 06 272-275 °G); Rf 0.38 (EtOAc); Vmax (KBr) 3444, 3078, 
3050,2992,2946, 1704 (a,p-unsaturated aldehyde), 1682, 1616 (amide I), 
1586, 1554 (amide II) and 774 (ortho-disubstituted benzene) cm-1; OH (06-
OMSO) 10.22 (1 H, s, CHO) and 8.50-7.45 (6-H, m); Oc (06-0MSO) 188.8 
(C=O), 176.3 (C-3), 143.4 (G-1), 139.4 (G-9), 133.1 (G-7), 127.8 (G-4), 125.4 
(G-5 & C-6), 119.5 (C-8) and 116.4 (G-2); m/z 173 (M+, 100), 144 (13.2),127 
(13.0), 116 (25.8) and 104 (35.1 %) (Found: M+, 173.0472; C, 69.02; H, 3.96; 
N, 7.94%. G10H7N02 requires M, 173.0475; G, 69.36; H, 4.05; N, 8.09%). 
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Condensation product of 105 with 1butyl cyanoacetate (107). 
o 
3 ~2 COOtSu 
CN 
1 
11 
To a stirred solution of compound 105 (0.198 g, 1.1 mmol) in DMF (2 ml) 
was added tbutylcyanoacetate (0.161 g, 1.1 mmol). After 16 h the reaction 
mixture was diluted with EtOAc (20 ml) and washed with water (2 x 10 ml), 
brine (2 x 10 ml) and water (2 x 10 ml). After drying, most of the EtOAc was 
removed under reduced pressure, leaving a slurry of the precipitated 
product. This slurry was filtered, washed with petroleum ether and dried 
under suction. The crude product was purified by column chromatography 
on silica with EtOAc as the eluent, affording amide 107 (46 mg, 14%) as a 
cream powder, m.p. 260-262 °C (d.); Rf 0.84 (EtOAc); Vmax (KBr) 3426 (N-H), 
3063,2930,2216 (CN), 1719 (ester C=O), 1621 (amide I), 1553 (amide II) 
and 1253 (ester C-O) cm-1; BH (D6-DMSO) 9.02 (1 H, s, 4-H), 8.63 (1 H, s, 3-
H), 8.23 (1 H, dd, 3J= 8.1, 8-H), 7.81 (1 H, ddd, 4J= 1.5, 10-H), 7.70 (1 H, d, 
11-H), 7.54 (1 H, ddd, 4J= 1.2, 9-H) and 1.58 (9 H, s, (CH3h); Be (D6-DMSO) 
174.9 (C-6), 161.9 (ester C=O), 148.2 (C-4), 142.1 (C-3), 138.4 (C-12), 133.3 
(C-10), 125.9 (C-8 or C-9), 125.8 (C-9 or C-8), 125.6 (C-7), 119.6 (C-11), 
117.0 (CN), 112.0 (C-5), 97.1 (C-2), 82.6 (C(CH3h) and 27.8 (C(D-hh); m/z 
296 (M+, 2.8), 195 (100), 140 (16.6) and 113 (4.7%) (Found: M+, 296.1146. 
C17H16N203 requires M, 296.1157). 
2-Cyano-3-(4-hydroxyphenyl)propenenitrile (108).80 
2 3 NC 
CN 
HO 
To a solution of 4-hydroxybenzaldehyde (0.366 g, 3 mmol) in EtOH (2 ml) 
was added a solution of malononitrile (0.198 g, 3 mmol) in EtOH (2 ml). A 
catalytic amount of piperidine was added and the reaction was stirred for 16 
h. The product, a yellow precipitate, was recovered by filtration, then washed 
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and dried under suction giving nitrile 108 (0.360 g, 71 %), m.p. 175-177 °C; 
Rf 0.89 (EtOAc); V max (KBr) 3350 (OH), 2228 (CN), 1610, 1580, 1564 
(aromatic C=C & C=N) and 1298 (C-O) cm-1; OH (Ds-DMSO) 8.36 (1 H, s, 0-
H), 8.30 (1 H, s, 5-H), 7.92 (2 H, AA'BB', 3J= 8.7, 3-H) and 7.01 (2 H, AA'BB', 
2-H, 3J= 8.7, 2-H); oe (Ds-DMSO) 164.6 (C-1), 160.5 (C-5), 134.0 (C-3), 
122.6 (C-4), 116.9 (C-2), 115.3 and 114.4 (both CN), 74.7 (C-6); m/z 170 
(M+, 100), 142 (40.7), 119 (43.3) and 91 (25.5%) (Found: M+, 170.0474; C, 
70.39; H, 3.64; N, 16.42%. C1oHsN20 requires M, 170.0479; C, 70.57; H, 
3.56; N, 16.47%). 
2-Cyano-3-(4-dimethylaminophenyl)propenenitrile (109). 
3 4 
CN 
NC 
Malononitrile (0.198 g, 3 mmol) was dissolved in EtOH (2 ml) and added to a 
stirred solution of 4-dimethylaminobenzaldehyde (0.447 g, 2 mmol) in EtOH 
(4 mI). A catalytic amount of EtOH-piperidine solution (10:1) was added and 
after 2 h an orange precipitate had formed. The crude product was filtered, 
washed and dried to yield nitrile 109 (0.346 g, 58%), m.p. 175-177 °c ; Rf 
0.55 (EtOAc); Vmax (KBr) 2208 (CN), 1612, 1522 (aromatic C=C), 1388 (CH3 
symmetrical deformation) and 816 (para-disubstituted benzene) cm-1; OH 
(Ds-DMSO) 8.06 (1 H, s, 6-H), 7.86 (2 H, AA'BB', 3J= 9.2, 4-H), 6.88 (2 H, 
AA'BB', 3J= 9.2, 3-H) and 3.14 (6 H, s, 1-H); Oc (Ds-DMSO) 158.9 (C-6), 
154.4 (C-2), 133.7 (C-4), 118.8 (C-5), 115.7 (2 x CN), 111.9 (C-3), 68.9 (C-7) 
and 39.6 (C-1); m/z 197 (M+, 83.9), 196 (100), 180 (13.7) and 126 (13.5%) 
(Found: M+, 197.0945; C, 73.02; H, 5.68; N, 21.44%. C12HllN3 requires M, 
197.0951; C, 73.06; H, 5.62; N, 21.31%). 
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2-Amino-4-(4-dimethylaminophenyl)-1 ,3-butadiene-1, 1,3-
tricarbonitrile (110), 
3 4 
NC CN 
NC 
Malononitrile dimer (0.264 g, 2 mmol) was dissolved in EtOH (2 ml) and 
added to a stirred solution of 4-dimethylaminobenzaldehyde (0.298 g, 2 
mmol) in EtOH (2 ml). A catalytic amount of EtOH-piperidine solution (10:1) 
was added and after 4 h an orange precipitate formed. The crude product 
was filtered off and purified by column chromatography on basic alumina to 
yield nitrile 110 (68 mg, 13%), m.p. 190°C (d.); Rt 0.26 (EtOAc); Amax 
(EtOH)/nm 202 (£/dm3 mol-1 cm-1 16800), 251 (10500) and 432 (22300); 
Vmax (KBr) 3339, 3207 (NH2), 2225, 2221 (CN), 1679 (alkene C=C), 1614, 
1516 (aromatic C=C) and 810 (para-disubstituted benzene) cm-1; OH (06-
OMSO) 8.71 (2 H, br s, NH2), 7.83 (2 H, d, AA'BB', 3J= 9.1, 4-H), 7.70 (1 H, s, 
6-H), 6.78 (2 H, d, AA'BB', 3J= 9.1, 3-H) and 3.02 (6 H, s, CH3); oe (06-
OMSO) 167.0 (C-8), 153.6 (C-2), 152.9 (C-6), 133.3 (C-4), 118.6 (C-5), 
116.7 (CN), 116.0 (CN), 115.6 (CN), 111.6 (C-3), 92.3 (C-7), 48.4 (C-9) and 
39.6 (C-1); m/z 263 (M+, 100),237 (61.4), 219 (21.4),196 (32.1) and 134 
(80.2) (Found: M+, 263.1162. C15H13N5 requires M, 263.1169). 
2-Cyano-3-(4-dimethylaminophenyl)propenethioamide (111 ). 
3 4 
NC 
Cyanothioacetamide (0.300 g, 3 mmol) was dissolved in EtOH (3 ml) and 
added to a stirred solution of 4-dimethylaminobenzaldehyde (0.447 g, 3 
mmol) in EtOH (4 ml). A catalytic amount of EtOH-piperidine solution (10:1) 
was added and after 3.5 h a dark red precipitate had formed. The crude 
product was filtered off, washed with petroleum ether and dried to yield 
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thioamide 111 (0.294 g, 33%), m.p.160 °c (d.); Rt 0.56 (EtOAc); Amax 
(EtOH)/nm 202 (£/dm3 mol-1 cm-1, 32300), 238 (16200), 261 (15200) and 
439 (45300); vmax(KBr) 3331, 3285 (NH2), 2215 (CN), 1608, 1563, 1519 
(C=C), 1370 (CH3 symm. deformation) and 810 (para-disubstituted 
benzene) cm-1; OH (D6-DMSO) 9.74 and 9.13 (2 H, 2 br s, NH2), 8.10 (1 H, s, 
6-H), 7.13 (2 H, AA'BB', 3J= 9.0, 4-H), 6.85 (2 H, AA'88', 3J= 9.0, 3-H) and 
3.10 (6 H, s, 1-H); Oc (D6-DMSO), 193.1 (C-8), 153.2 (C-2), 148.9 (C-6), 
133.4 (C-4), 118.4 (C-5), 118.1 (CN), 111.9 (C-3), 103.9 (C-7) and 39.7 (C-1) 
; m/z 231 (M+, 100), 198 (67.2), 187 (27.1), 155 (39.5) and 128 (20.3%) 
(Found: M+, 231.0826; C, 62.46; H, 5.56; N, 18.01%. C12H13N3S requires M, 
231.0828; C, 62.31; H, 5.67; N, 18.18%). 
2-(3-pyridyl)-3-(4-dimethylaminophenyl)propenenitrile (112). 
'" N / 
3 4 
11 
12 
3-Pyridylacetonitrile (0.295 g, 2.5 mmol) was added to a stirred solution of 4-
dimethylaminobenzaldehyde (0.372 g, 2.5 mmol) in EtOH (4 ml). A catalytic 
amount of KOtBu was added and after 10 min a yellow precipitate had 
formed. The crude product was filtered off, washed with petroleum ether and 
dried to yield nitrile 112 (0.347 g, 55%), m.p. 129-130 °C; Rt 0.31 (EtOAc); 
Amax (EtOH)/nm 202 (£/dm3 mol-1 cm-1, 28000), 260 (9960) and 408 (38000); 
Vmax (KBr) 3022, 2199 (CN), 1613, 1586, 1529 (aromatic C=C & C=N), 1378 
(CH3 symm. deformation) and 811 (para-disubstituted benzene) cm-1; OH 
(D6-DMSO) 8.91 (1 H, d, 4J= 2.4, 12-H), 8.57 (1 H, dd, 3J= 4.7, 11-H), 8.06 (1 
H, m, 9-H), 7.92 (2 H, d, AA'88', 3J= 8.9, 4-H), 7.92 (1 H, s, 6-H), 7.50 (1 H, 
dd, 3J= 4.8, 10-H), 6.82 (2 H, d, AA'BB', 3J= 9.0, 3-H) and 3.04 (6 H, s, 1-H); 
Oc (D6-DMSO) 152.0 (C-2), 148.7 (C-12), 146.2 (C-11), 144.4 (C-6), 132.4 
(C-9), 131.5 (C-4), 131.0 (C-8), 123.9 (C-10), 120.7 (C-5), 118.8 (CN), 111.6 
(C-3), 98.9 (C-7) and 39.6 (C-1); m/z 249 (M+, 100),234 (55.2), 220 (28.2), 
206 (52.5) and 177 (16.8%) (Found: M+, 249.1260; C, 77.33; H, 6.03; N, 
16.61%. C16H15N3requires M, 249.1263; C, 77.07; H, 6.07; N, 16.86%). 
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Quinaldine N-oxide monohydrate (113). 
1 
Glacial acetic acid (75 ml), quinaldine (31.74 g, 0.222 mol) and hydrogen 
peroxide solution (27.5%, 23 ml, 0.186 mol) were heated at 70°C for 30 min. 
More peroxide solution (20 ml) was introduced and the mixture was heated 
at reflux for a further 3 h. The excess acid was removed under reduced 
pressure and the remaining solution was neutralised with saturated Na2C03 
solution. The mixture was filtered and the filtrate extracted with CHCI3 (2 x 
100 ml). The filtered solid was also extracted with hot CHCI3 (2 x 50 ml). 
After combining these extracts and removing the solvent under reduced 
pressure the dark brown liquid was diluted with OCM and pre-adsorbed onto 
silica. Flash column chromatography with EtOAc removed the residual 
quinaldine and the desired quinaldine N-oxide was eluted with MeOH. 
Removal of the solvent under reduced pressure and recrystallisation from 
MeOH afforded compound 113 (12.86 g, 36%) as fawn-coloured needles, 
m.p. 76-78 °c (1it.,109 77-78 °C); R, 0.56 (EtOH); Vmax (KBr) 3416 (water of 
crystallisation), 1566, 1516 (C=C & C=N), 1242s (N-O) and 734 (ortho-
disubstituted benzene) cm-1; SH (06-0MSO) 8.55 (1 H, d, 3J= 8.7, 4-H), 7.97 
(1 H, dd, 4J= 1.0, 3J= 8.0, 9-H), 7.74 (2 H, m, 6-H & 8-H), 7.62 (1 H, ddd, 4J= 
1.0, 7-H), 7.48 (1 H, d, 3J= 8.6, 3-H) and 2.56 (3 H, s, 1-H); Sc (06-0MSO) 
145.2 (C-2), 140.7 (C-10), 130.2 (C-8), 129.0 (C-5), 128.5 (C-7), 127.7 (C-6), 
124.5 (C-4), 123.4 (C-3), 118.7 (C-9) and 18.32 (C-1); m/z 159 (M+, 52.2), 
143 (60.3) and 115 (53.0%) (Found: M+, 159.0688; C10HgNO requires M, 
159.0684). 
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2-Quinolinecarbaldehyde N-oxide (114). 
7 
8 
CHO 
1 
To a solution of 8e02 (1.109 g, 10 mmol) in dioxane (10 ml) at 70-80 °c, a 
solution of compound 113 (1.305 g, 9.0 mmol) in dioxane (1.5 ml) was 
added dropwise. The mixture was heated at reflux for 1 h to deposit 
selenium metal which was filtered off. Upon addition of MeOH a white solid 
precipitated which was also removed by filtration. Chromatography of the 
residue afforded aldehyde 114 (0.851 g, 55%) as a yellow solid, m.p. 98-
100 °c (lit.,110 95-96 °C); Rt 0.41 (EtOAc); Vmax (KBr) 3058 (aromatic C-H), 
1694 (aldehyde C=O) and 1206 (N-O) cm-1; OH (CDCI3) 10.82 (1 H, s, 1-H), 
8.75 (1 H, d, 4-H) and 7.90-7.69 (5 H, m); Oc (CDCI3) 186.5 (C-1), 142.0 (C-
2), 140.0 (C-10), 131.9 (C-5), 130.9 (C-8 & C-7), 128.4 (C-6), 124.7 (C-4), 
119.8 (C-3 or C-9) and 118.9 (C-9 or C-3); m/z 173 (M+, 7.0), 156 (13.4), 
128 (100) and 101 (26.9%) (Found: M+, 173.0469; C10H7N02 requires M, 
173.0476). 
(Z)-2-Amino-4-(2-quinolinyl)-1 .3-butadiene-1. 1 .3-tricarbonitrile. 
N-Oxide (115). 
10 
11 3 
1 
CN CN 
CN 
Compound 114 (0.140g, 8.1 mmol) and malononitrile dimer (0.106 g, 8.0 
mmol) were dissolved in EtOH (2 mI). While stirring for 2 h, a yellow 
precipitate formed which was filtered off and purified by column 
chromatography to give compound 115 as a yellow solid (0.089 g, 39%), 
m.p. 140 °c (d.); Rt 0.1 (EtOAc); vmax (KBr) 3204, 3070 (unsaturated C-H), 
2962 (aliphatic C-H), 2216 (CN), 1666, 1620 (alkene C=C), 1564, 1540 
(aromatic C=C & C=N) and 1262 (N-O) cm-1; OH (D6-DMSO) 9.35 and 9.30 (2 
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H, 2 br s, NH2), 8.60 (1 H, d, 6-H), 8.43 (1 H, 5, 3-H), 8.18-8.13 (3 H, m) and 
7.95-7.91 (2 H, m); Dc (D6-DMSO) 164.3 (-C (NH2)=C(CN)2), 143.3 (C-3), 
141.1 (C-4), 138.7 (C-12), 131.7 (C-10), 130.8 (C-8 or C-9), 130.7 (C-7), 
129.1 (C-8 or C-9), 125.2 (C-6), 120.7 (C-5), 119.3 (C-11), 115.3, 114.5, 
113.9 (all CN) 107.8 (C-2) and 50.6 (-C (NH2)=C(CNh); m/z 287 (M+, 16.5), 
273 (23.2), 271 (57.0), 245 (73.3) and 207 (100%) (Found: M+, 287.0823; 
C16H9NsO requires M, 287.0806) 
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7.4 Experimental to Chapter 6 
7.4.1 General Procedures: 
Method A-Preparation of oxazolines from nitriles:153 The nitrile (1 
mol) was heated at reflux with the appropriate amino alcohol (1-1.5 mol) and 
cadmium acetate (0.025 mol) for 25 h. Ammonia was evolved during the 
course of the reaction and progress was monitored by taking the pH of the 
exit gases from the condenser. The oxazolines were recovered by distillation 
of the reaction mixture at atmospheric pressure. 
Method B(i)-Preparation of 2-hydroxyamides:156.166 The acid 
chloride (50 mmol) was dissolved in OCM (25 ml) and added dropwise with 
stirring to an ice-cooled solution of the appropriate amino alcohol (0.1 mol) 
in OCM (25 ml). After stirring at RT for 4 h, the reaction mixture was filtered 
and the solvent removed under reduced pressure to give the amide in good 
to excellent yields. 
Method B(ii)-Preparation of oxazolines by cyclisation of 2-
hydroxyamides:156.166 Thionyl chloride (60 mmol) was added dropwise 
with stirring to an ice-cooled solution of the 2-hydroxyamide (20 mmol) in 
OCM (20ml). After 2 h reaction time, during which HCI was evolved, the 
solvent was removed under reduced pressure leaving the oxazoline as its 
hydrochloride salt. The oily solid was dissolved in water (5 ml), neutralised 
with NaOH (1 M) and extracted with EtOAc (3 x 10 ml). The organic extracts 
were dried and concentrated under reduced pressure to yield the desired 
oxazoline as a yellow oil. 
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2-Methyl-2-oxazoline (145).154 
4 3 
n NrO 
1 
Acetonitrile (20.5 g, 0.5 mol), ethanolamine (39.7 g, 0.65 mol) and cadmium 
acetate (3.33 g, 12 mmol) were reacted according to method A. Distillation of 
the reaction mixture at atmospheric pressure yielded oxazoline 145 (22.720 
g, 54%) as a colourless liquid, b.p. 108-110 °c (1it.,154 109.5-110.5 °C); Rt 
0.32 (EtOAc); V max (KBr) 2976, 2938 (aliphatic C-H), 1674 (C=N) and 1228 
(imidic ester C-O) cm-1; OH (CDCI3) 3.48 (2 H, t, 3J= 9.5, 3-H), 3.05 (2 H, t, 3J= 
9.4, 4-H) and 1.21 (3 H, s, 1-H); oe (CDCI3) 164.4 (C-2), 66.5 (C-3), 53.8 (C-
4) and 12.8 (C-1); m/z 85 (M+, 40.7),55 (100) and 43 (20.4%) (Found: M+, 
85.0528. C4H7NO requires M, 85.0532). 
N-{2-[( 4-Hydroxyphenyl)thiolethyl}acetamide (142). 
OH 
The title compound was synthesised as described previously in the 
literature. 144 4-Hydroxythiophenol (3.402 g, 27 mmol) and oxazoline 145 
(2.55 g, 30 mmol) were heated at reflux under N2 for 2 h at 130 °c. Upon 
cooling, the viscous reaction mixture was dissolved in hot EtOH (20 ml) and 
diluted with water (50 ml) to precipitate a white solid which was filtered off 
and recrystallised to yield white crystals of amide 142 (5.24 g, 92%), m.p. 
124-125 °c (from EtOAc, lit.,144 123-125 °C); Rt 0.2 (EtOAc); V max (KBr) 
3418m (N-H), 3038 (aromatic C-H), 2960 (aliphatic C-H), 1636s (amide I), 
1580 (C=C), 1522 (amide II) and 834 (para-disubstituted benzene) cm-1; OH 
(D6-acetone) 7.34 (2 H, AA'BB', 3J= 8.7, 3-H), 6.83 (2 H, AA'BB', 3J= 8.7, 2-
H), 3.34 (2 H, t, 3J= 6.6, 6-H), 2.90 (2 H, t, 3J= 6.5, 5-H) and 1.89 (3 H, s, 8-H); 
oe (D6-acetone) 170.8 (C-7), 157.9 (C-1), 134.5 (C-3), 124.6 (C-4), 116.8 (C-
2), 39.5 (C-6), 35.53 (C-5) and 22.7 (C-8); m/z 211 (M+, 19.5), 152 (90.6), 
139 (16.3),125 (23.1) and 107 (16.7%) (Found: M+, 211.0666; C, 56.87; H, 
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6.17; N, 6.62%. C10H13N02S requires M, 211.0666; C, 56.85; H, 6.21; N, 
6.63%). 
(R,SJ-2,4-Dimethyl-2-oxazoline (146).158 
5 
H Nit 
1 
Acetonitrile (1.845 g, 45 mmol), 2-amino-propan-1-ol (4.506 g, 60 mmol) and 
cadmium acetate (0.300 g, 1.1 mmol) were reacted according to method A to 
yield oxazoline 146 (2.182 g, 49%) as a colourless oil, b.p. 115-117 °C 
(lit.,158 116-117 DC); Rt 0.38 (EtOAc); Vmax (KBr) 2970, 2930 (aliphatic C-H), 
1674 (C=N) and 1234 (imidic ester C-O) cm-1; SH (neat) 4.41-3.62 (3 H, m, 4-
Hand 3-H), 1.86 (3 H, s, 1-H) and 1.16 (3 H, d, 3J= 6.0, 5-H); m/z 99 (M+, 
0.6), 86 (22.8), 60 (10.0) and 44 (100%). 
2-Ethyl-4,4-dimethyl-2-oxazoline (147). 
/! ~ 
N~1 
Propanonitrile (11.016 g, 0.2 mol), 2-amino-2-methyl-1-propanol (18.00 g, 
0.2 mol) and cadmium acetate (1.332 g, 5 mmol) were reacted together 
according to method A. The reaction mixture was distilled at atmospheric 
pressure to yield oxazoline 147 (17.36 g, 68%) as a colourless liquid, b.p. 
125-127 °C (lit.,159 129-130 DC); Rt 0.56 (EtOAc); Vmax (KBr) 2971 (aliphatic C-
H), 1667 (C=N) and 1195 (imidic ester C-O) cm-1; SH (CDCI3) 3.60 (2 H, s, 4-
H), 1.94 (2 H, q, 3J= 7.6, 2-H), 0.96 (6 H, s, 6-H) and 0.87 (3 H, t, 3J= 7.6, 1-
H); Sc (CDCI3) 166.6 (C-3), 78.5 (C-4), 66.3 (C-5), 27.9 (C-6), 21.1 (C-2) and 
9.9 (C-1); m/z 127 (M+, 12.5), 112 (72.4), 97 (44.4) and 84 (23.9%) (Found: 
M+, 127.1004; C7H13NO requires M, 127.0997). 
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2-t Butyl-4,4-dimethyl-2-oxazoline (148). 
~ ~ }: 
~ 
1 
Pivaloyl chloride (6.029 g, 50 mmol) and 2-amino-2-methyl-1-propanol 
(8.903 g, 0.1 mol) were reacted according to method B(i) to give a 
quantitative yield of N-( 1, 1-dimethyl-2-hydroxyethyl)-2,2-dimethyl 
propanamide. This amide (3.0 g, 17.3 mmol) was cycJised according to 
method B(ii) by reaction with thionyl chloride (6.54 g, 55 mmol) yielding 
oxazoline 148 (1.805 g, 69%) as a yellow oil, b.p. 131-135 DC (1it.,160 135 
DC); Rf 0.65 (EtOAc); Vmax (KBr) 2970 (aliphatic C-H), 1658 (C=N) and 1122 
(imidic ester C-O) cm-1; 3H (CDCI3) 3.45 (2 H, s, 4-H), 0.83 (6 H, s, 6-H) and 
0.78 (9 H, s, 1-H); 3c (CDCI3) 171.7 (C-3), 78.5 (C-4), 66.3 (C-5), 59.8 (C-2), 
27.8 (C-6) and 27.3 (C-1); m/z 155 (M+, 17.8), 140 (100),125 (16),110 
(12.5) and 84 (57.6%). 
4,4-Dimethyl-2-phenyl-2-oxazoline (149).160 
x SH 
N~ 0 
5 
1 
Benzoyl chloride (7.025 g, 50 mmol) and 2-amino-2-methyl-1-propanol (8.90 
g, 0.1 mol) were reacted according to method B(i) to give a quantitative yield 
of N-(1, 1-dimethyl-2-hydroxyethyl)-benzamide. This amide (5 g, 26 mmol) 
was cyclised according to method B(ii) by reaction with thionyl chloride 
(9.282 g, 78 mmol) yielding oxazoline 149 (3.18 g, 70%) as a pleasant 
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smelling orange oil; Rt 0.59 (EtOAc); Vmax (KBr) 3032 (aromatic C-H), 2968 
(aliphatic C-H), 1650 (C=N) and 696 (monosub. benzene) and 1062 (C-O) 
cm-1; DH (CDCI3) 7.83 (2 H, dd, 3-H), 7.33-7.19 (3 H, m, 2-H and 1-H), 3.93 (2 
H, s, 6-H) and 1.24 (6 H, s, 8-H); Dc (CDCI3) 161.9 (C-5), 131.1 (C-1), 128.3 
(C-2 & C-3), 127.9 (C-4), 78.9 (C-6), 67.3 (C-7) and 28.3 (C-8); m/z 175 (M+, 
2.0), 162 (30.5), 122 (5.8) and 105 (100%). 
N-{2-[(4-Fluorophenyl)thio]ethyl}acetamide (150). 
F 
4-Fluorothiophenol (1.154 g, 9.2 mmol) and oxazoline 145 (1.507 g, 17.7 
mmol) were heated at reflux under N2 for 2 h at 120 °C. Upon cooling, an 
orange solid precipitated which was recrystallised twice to yield large white 
crystals of amide 150 (1.526 g, 70%), m.p. 96-97.5 °C (from EtOAc); Rt 0.23 
(EtOAc); Vmax (KBr) 3287 (N-H), 2980 (aliphatic C-H), 1637 (amide I), 1560 
(amide II), 1494 (C=C), 1242 (C-F) and 822 (para-disubstituted benzene) 
cm-1; DH (CDCI3) 7.38 (2 H, m, 3-H ) 7.00 (2 H, m, 2-H ) 6.53 (1 H, br s, N-H), 
3.39 (2 H, m, 6-H), 3.00 (2 H, t, 3J= 6.6, 5-H) and 1.94 (3 H, s, 8-H); DC 
(CDCI3) 170.4 (C-7), 164.3 and 159.4 (d, JCF=245 , C-1), 132.6 and 132.5 (d, 
4JCF=8, C-3), 129.9 (C-4), 116.3 and 115.9 (d, 3JCF=22, C-2) 38.6 (C-6), 34.4 
(C-5) and 23.0 (C-8); m/z 213 (M+, 11.4),154 (100),141 (12.6),127 (19.6) 
and 109 (17.8%) (Found: M+, 213.0607; C, 56.21; H, 5.68; N, 6.59%. 
C1QH12FNOS requires M, 213.0623; C, 56.32; H, 5.67; N, 6.57%). 
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(R.S)-N-{[(2-( 4-Hyd roxyphenyl)th io )-l-methyl]ethyl}acetam ide 
(151). 
OH 
The title compound has been prepared previously144 but has not been fully 
characterised. 4-Hydroxythiophenol (1.134 g, 9 mmol) and oxazoline 146 
(0.99 g, 10 mmol) were heated at reflux under N2 for 2 h at 130°C. After 
cooling, the crude product was precipitated by addition of DCM (10 ml), 
filtered and dried under suction. Recrysta"isation yielded amide 151 (1.375 
g, 61%) as w.hite crystals, m.p. 118-119 °C (from EtOAc, 1it.,144 120-122 °C); 
Rf 0.21 (EtOAc); Vmax (KBr) 3311 (N-H), 2976 (aliphatic C-H), 1632 (amide I), 
1598, 1581 and 1494 (C=C), 1548 (amide II) and 833 (para-disubstituted 
benzene) cm-1; OH (D6-acetone) 8.91 (1 H, s, O-H), 7.28 (2 H, AA'BB', 3J= 8.8, 
3-H), 7.18 (1 H, s, N-H), 6.76 (2 H, AA'BB', 3J= 8.8, 2-H), 4.01 (1 H, m, 6-H), 
2.86 (2 H, ABX, 2J= 13.4, 3J= 6.2 and 6.7, 5-H), 1.85 (3 H, s, 9-H) and 1.15 (3 
H, d, 3J= 6.7, 7-H) ; Oc (D6-acetone) 170.3 (C=O), 157.6 (C-1), 133.9 (C-3), 
124.9 (C-4), 116.5 (C-2), 45.3 (C-6), 41.9 (C-5), 22.8 (C-9) and 19.46 (C-7); 
m/z 225 (M+, 28.2), 166 (100), 140 (19.5), 125 (25.3) and 100 (34.6%). 
(Found: M+, 225.0824; C, 58.52; H, 6.42; N, 6.13%. C11H15N02S requires M, 
225.0823; C, 58.64; H, 6.72; N, 6.22%). 
N-{[(2-(4-Hydroxyphenyl)thio)-1. 1-dimethyl]ethyl}acetamide 
(152). 
OH 
4-Hydroxythiophenol (2.268 g, 18 mmol) and 2,4,4-trimethyloxazoline(2.260 
g, 20 mmol) were heated at reflux under N2 for 5 h at 120°C. After cooling, 
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the reaction mixture was dissolved in EtOH (10 ml) and diluted with water 
(20 ml) to give a white precipitate. This was filtered off, dissolved in acetone 
and pre-adsorbed onto silica. Flash column chromatography on silica with 
EtOAc as eluent, followed by recrystallisation afforded white crystals of 
compound 152 (2.249 g, 52%), m.p. 108-110 °c (from EtOAc); Rf 0.40 
(EtOAc); V max (KBr) 3307 (N-H), 2966 (aliphatic C-H), 1636 (amide I), 1601, 
1583, 1559 (amide II), 1494 and 823 (para-disubstituted benzene) cm-1; OH 
(Ds-acetone) 9.04 (1 H, br s, N-H), 7.12 (2 H, AA'BB', d, 3J= 8.6, 3-H), 7.02 (1 
H, br s, O-H), 6.59 (2 H, AA'BB', 3J= 8.6, 2-H), 3.19 (2 H, s, 5-H), 1.59 (3 H, s, 
9-H) and 1.18 (6-H, s, 7-H); oe (Ds-acetone)171.6 (C=O), 157.8 (C-1), 134.3 
(C-3), 126.5 (C-4), 116.9 (C-2), 55.0 (C-6), 45.8 (C-5), 27.1 (C-7) and 23.7 
(C-9); m/z 239 (M+, 3.8), 180 (29.5), 140 (4.0), 125 (8.9) and 100 (10.9%) 
(Found: M+, 239.0984; C12H17N02S requires M, 239.0979). 
N-{[(2-(4-Hydroxyphenyl)thio)-1. 1-dimethyl]ethyl}propanamide 
(153). 
OH 
1 
~2 ~ 137 
, . · 0 S~N~10 
H 9 
4-Hydroxyphenol (1.80 g, 14 mmol) and 4,4-dimethyl-2-ethyl oxazoline (2.00 
g, 15 mmol) were heated at reflux under N2 for 4 h at 120 °c. Upon cooling, 
the reaction mixture was dissolved in EtOH (10 ml) and diluted with water 
(20 ml) to give a white precipitate of the crude product. This was filtered off 
and recrystallised to give white crystals of amide 153 (1.788 g, 52%), m.p. 
112-113 °C (from EtOAc); Rf 0.37 (EtOAc); Vmax (KBr) 3321 (N-H), 1636 
(amide I), 1598, 1579, 1558 (amide II), 1494 (C=C) and 822 (para-
disubstituted benzene) cm-1; OH (CDCI3) 9.01 (1 H, br s, O-H) 7.20 (2 H, 
AA'BB', 3J= 8.5, 3-H) 6.70 (2 H, AA'BB', 3J= 8.5, 2-H) 5.61 (1 H, br s, N-H) 
3.25 (2 H, s, 5-H) 1.93 (2 H, q, 3J= 7.6, 9-H), 1.31 (6 H, s, 7-H) and 0.93 (3 H, 
t, 3J=7.5, 10-H); oe (CDCI3) 174.6 (C=O), 156.5 (C-1), 133.4 (C-3), 125.1 (C-
4), 116.2 (C-2), 54.5 (C-6), 45.5 (C-5), 30.2 (C-9), 26.8 (C-7) and 9.8 (C-10); 
m/z (Found: M+, 253.1158; C, 61.47; H, 7.58; N, 5.49%. C13H 19N02S 
requires M, 253.1132; C, 61.63; H, 7.57; N, 5.53%). 
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N-{[(2-(4-Hydroxyphenyl)thio)-1. 1-dimethyl]ethyl}2.2-dimethyl 
propanamide (154). 
OH 
1 
~2 ~ 137 
s~~~/o 
4-Hydroxythiophenol (0.731 g, 5.8 mmol) was heated at reflux with 
oxazoline 148 (1.00 g, 6.4 mmol) under N2 for 2 h at 130°C. TLC indicated 
residual thiol, so the reaction mixture was dissolved in EtOAc (10 ml) and 
shaken twice with Na2C03 solution (1 M, 2 x 10 ml). After drying, the organic 
extract was concentrated yielding the crude product (1.145 g, 70%). 
Recrystallisation gave colourless rhombic crystals of compound 154 (0.771 
g, 47%), m.p. 170-172 °C (from EtOH); Rf 0.69 (EtOAc); v max (KBr) 3397m (N-
H), 2970 (aliphatic C-H), 1620 (amide I), 1601, 1581 and 1496 (C=C), 1525 
(amide II) and 827 (para-disubstituted benzene) cm·1; OH (D6-DMSO) 9.53 (1 
H, br s, O-H), 7.20 (2 H, AA'BB', 3J= 8.6, 3-H), 6.70 (2 H, AA'BB', 3J= 8.6, 2-
H), 6.58 (1 H, br s, N-H), 3.29 (2 H, s, 5-H), 1.28 (6 H, s, 7-H) and 1.06 (9 H, 
s, 10-H); Oc (D6-DMSO) 177.3 (C-8), 156.5 (C-1), 132.4 (C-3), 125.3 (C-4), 
116.1 (C-2), 53.5 (C-6), 45.0 (C-5), 38.6 (C-9), 27.5 (C-10) and 26.6 (C-7); 
m/z 281 (M+, 2.2),180 (49.6),142 (11.4) and 125 (27.3%) (Found: M+, 
281.1445; C, 64.14; H, 8.26; N, 4.87; S, 11.55%. C1sH23N02S requires M, 
281.1449; C, 64.02; H, 8.24; N, 4.98; S, 11.37%). 
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N-{[(2-( 4-Hyd roxyphenyl)thio)-1. 1-dimethyl]ethyl}benzamide 
(155). 
OH 
4-Hydroxythiophenol (0.454 g, 3.6 mmol) was heated at reflux with 
oxazoline 149 (0.700g, 4 mmol) in DMF (5 ml) for 24 h at 120°C. Upon 
cooling, the reaction mixture was dissolved in EtOAc (25 ml) and washed 
with brine (2 x 25 ml) and water (2 x 25 ml). After drying, the organic layer 
was concentrated and the residual solid was dissolved in EtOH (10 ml). 
Upon addition of water (20 ml) an oily solid precipitated which crystallised 
upon vigorous scratching. This solid was recovered and recrystallised to 
yield benzamide 155 (0.225 g, 21 %) as white crystals, m.p. 117-119 °c 
(from EtOAc); Rt 0.79 (EtOAc); V max (KBr) 3380 (N-H), 3109 br (Ar-H), 1633 
(amide 1),1602, 1575, 1533 (amide II), 1493, 817 (para-disubstituted 
benzene) and 715 (monosub. benzene) cm-1; BH (CDCI3) 8.22 (1 H, br s, 0-
H), 7.54 (2 H, dd, 10-H), 7.48-7.35 (3 H, m, 11-H &12-H), 7.26 (2 H, AA'BB', 
3-H), 6.77 (2 H, AA'BB', 2-H), 6.30 (1 H, br s, N-H), 3.39 (2 H, s, 5-H) and 
1.54 (6 H, s, 7-H); Be (CDCI3) 168.2 (C-8), 156.3 (C-1), 134.8 (C-9), 133.5 (C-
3),131.5 (C-12), 128.5 (C-10), 126.7 (C-11), 125.2 (C-4), 116.4 (C-2), 55.2 
(C-6), 46.7 (C-5), 26.7 (C-7); m/z 301 (M+, 1.6), 180 (35.0),162 (8.9),125 
(11.1) and 105 (100%) (Found: M+, 301.1125; C, 67.49; H, 6.18; N, 4.59%. 
C17H19N02S requires M, 301.1135; C, 67.75; H, 6.36; N, 4.65%). 
(RJ-2.4-Dimethyl-2-oxazoline (157a). 
5 
~ ~ ~ 3 4/\ 
N~O 
1 
This compound has previously been synthesised161 but has not been fully 
characterised. Acetonitrile (0.652 g, 16 mmol), (R)-2-amino-1-propanol 
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(1.196 g, 16 mmol) and cadmium acetate (0.106 g, 0.4 mmol) were reacted 
according to method A. Distillation of the reaction mixture at atmospheric 
pressure yielded oxazoline 157a (0.538 g, 34%) as a colourless liquid, b.p. 
65-70 °C; [a]D22 +80.7 ° (c = 3.28 in MeOH); Rf 0.39 (EtOAc); Vmax (KBr) 2972 
(aliphatic C-H), 1674 (C=N) and 1236 (imidic ester C-O) cm-1; OH (CDCI3) 
4.28-3.62 (2 H, m, ABX, 3-H), 4.02 (1 H, m, 4-H), 1.87 (3 H, s, 1-H) and 1.15 
(3 H, d, 3J= 6.5, 5-H); Oc (CDCI3) 164.2 (C-2), 73.7 (C-3), 61.2 (C-4), 21.2 (C-
5) and 13.6 (C-1); m/z 99 (M+, 33.7), 84 (57.2), 69 (68.9) and 56 (42.7%) 
(Found: M+, 99.0680; CsHgNO requires M, 99.0682). 
(S)-2,4-Dimethyl-2-oxazoline (157b). 
~ 
N~O 
1 
This compound has previously been synthesised161 ,162 but has not been 
fully characterised. Acetonitrile (1.165 g, 27 mmol), (S)-2-amino-1-propanol 
(2.136 g, 28 mmol) and cadmium acetate (1.866 g, 7 mmol) were reacted 
together according to method A. Distillation of the reaction mixture at 
atmospheric pressure yielded 157b (0.327 g, 12%) as a colourless liquid, 
b.p. 65-70 °C; [a]D20 = -80.2 ° (e= 2.43, MeOH); Rf 0.39 (EtOAc); Vmax (KBr) 
2972, 2930 (aliphatic C-H), 1672 (C=N) and 1234 (imidic ester C-O) cm-1; OH 
(CDCI3) 4.30-3.64 (2 H, m, ABX, 3-H), 4.05 (1 H, m, 4-H), 1.89 (3 H, s, 1-H) 
and 1.17 (3 H, d, 3J= 6.5, 5-H); Oc (CDCI3) 164.5 (C-2), 73.9 (C-3), 61.3 (C-
4), 21.3 (C-5) and 13.8 (C-1); m/z 99 (M+, 30.2), 84 (50.8), 69 (65.3) and 56 
(38.6%) (Found: M+, 99.0687; CsHgNO requires M, 99.0682). 
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(R )':'N-{[(2-( 4-Hyd roxyphenyl)th io)-l-methyl]ethyl}acetamide 
(159a). 
OH 
This compound has previously been prepared161 but has not been fully 
characterised. 4-Hydroxythiophenol (0.567 g, 4.5 mmol) and oxazoline 
157a (0.445 g, 4.5 mmol) were heated at reflux under N2 at 120°C for 24 h. 
The reaction mixture was dissolved in acetone (50 ml), pre-adsorbed onto 
silica and subjected to flash column chromatography on silica with EtOAc as 
eluent. The oily product was triturated in hexane for 72 h yielding white 
crystal~ of amide 159a (0.583 g, 58%), m.p. 60-62 °C; [a]D22= -30.0 0 (c = 
0.97 in MeOH); Rt 0.2 (EtOAc); Vmax (KBr) 3401 and 3349 (N-H), 1636 (amide 
I), 1578, 1494 (C=C), 1545 (amide II) and 825 (para-disubstituted benzene) 
cm-1; OH (CDCI3) 8.71 (1 H, br s, O-H), 7.27 (2 H, AA'BB', 3J= 8.6, 3-H), 6.75 
(2 H, AA'BB', 3J= 8.6, 2-H), 5.62(1 H, br d, N-H), 4.05 (1 H, m, 6-H), 2.82 (2 H, 
d, 3J= 6.0, 5-H), 1.82 (3 H, s, 9-H) and 1.16 (3 H, d, 3J= 6.6, 7-H); Oc 170.9 
(C=O), 156.9 (C-1), 133.8 (C-3), 123.8 (C-4), 116.3 (C-2), 45.2 (C-6), 41.5 
(C-5), 23.0 (C-9) and 19.4 (C-7); m/z 225 (M+, 12.5), 166 (77.1),151 (8.2), 
140 (9.2), 125 (13.3) and 100 (16.8%) (Found: M+, 225.0829; C, 58.76; H, 
6.46; N, 6.12%. C11 H15N02S requires M, 225.0823; C, 58.64; H, 6.72; N, 
6.22%). 
(5 )-N-{[(2-( 4-Hyd roxyphenyl)th i 0 )-l-methyl]ethyl}acetam ide 
(159b). 
OH 
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This compound has previously been prepared161 but has not been fully 
characterised. 4-Hydroxythiophenol (0.176 g, 1.4 mmol) and oxazoline 
157b (0.140 g, 1.4 mmol) were heated at reflux under N2 for 2 h at 120 cC. 
The reaction mixture was dissolved in acetone (50 ml) and pre-adsorbed 
onto silica. Column chromatography on silica with EtOAc-petroleum ether 
(1:1) as the eluent afforded 15gb as a yellow oil. Trituration in hexane for 48 
h gave white crystals of amide 15gb (0.18 g, 57%), m.p. 60-62 °C; [a]o22 
+30.9 0 (c = 0.53 in MeOH); Rf 0.2 (EtOAc); vmax (KBr) 3401 and 3348 (N-H), 
1636 (amide I), 1595, 1578 and 1494 (C=C), 1545 (amide II) and 825 (para-
disubstituted benzene) cm-1; BH (COCI3) 8.80 (1 H, br s, O-H), 7.26 (2 H, 
AA'88', 3J= 8.6, 3-H), 6.73 (2 H, AA'BB', 3J= 8.6, 2-H), 5.66 (1 H, br d, N-H), 
4.04 (1 H, m, 6-H), 2.82 (2 H, d, 3J= 6.0, 5-H), 1.82 (3 H, s, 9-H) and 1.16 (3 
H, d, 3J= 6.6, 7-H); Be 170.8 (C=O), 156.9 (C-1), 133.7 (C-3), 123.8 (C-4), 
116.3 (C-2), 45.2 (C-6), 41.5 (C-5), 23.0 (C-9) and 19.4 (C-7); m/z 225 (M+, 
29.3), 166 (100),151 (16.3),140 (21.7),125 (32.0) and 100 (30.9%) (Found: 
M+, 225.0818; C11 H15N02S requires M, 225.0823). 
N-{2-[(2-Benzimidazolyl)thio]ethyl}acetamide (161 ). 
~--N 
~ 4 H 1 N 5 S~NIY H 3 10 
o 
2-Mercaptobenzimidazole (1.00 g, 6.6 mmol) was heated at reflux with 
oxazoline 145 (4 ml) under N2 for 4 h between 90-100 °C. Upon cooling, 
needle like crystals of amide 161 formed (0.150 g, 10%). The reaction 
mixture was concentrated and the residual solid was recrystallised to yield a 
second crop of 161 (0.295 g, 19%), m.p. 247-249 °C (EtOAc); Rf 0.77 
(EtOAc); v max (KBr) 3155 (N-H, H-bonded), 1666 (amide I), 1514, 1468 
(C=C), 1238 (C-S) and 742 (ortho-disubstituted benzene) cm- 1; BH (04-
methanol) 7.23-7.12 (4 H, m, phenyl), 5.02 (2 H, br s, 2 x N-H), 4.28 (2 H, t, 
3J= 9.6, 3-H), 3.76 (2 H, t, 3J= 9.5, 4-H) and 1.94 (3 H, s, 1-H); Be (06-0MSO) 
168.2 (C-2), 163.9 (C-5), 132.4 (C-6 & C-11), 122.4 (C-8 & C-9), 109.6 (C-7 
& C-10), 66.9 (C-3), 54.1 (C-4) and 13.5 (C-1); m/z 235 (M+, 0.3),150 (100), 
118 (22.4) and 106 (28.7%) (Found: M+, 235.0789; C, 55.98; H, 5.31; N, 
17.88%. C11H13N30S requires M, 235.0779; C, 56.15; H, 5.57; N, 17.87%). 
N-{2-[(2-benzoxazolyl)thio]ethyl}acetamide (162). 
~--N 
~ 4 H 1 
o 5 S~N'(' 
10 
o 
2-Mercaptobenzoxazole (1.00 g, 6.6 mmol) was heated at reflux with 
oxazoline 145 (4 ml) under N2 for 4 h between 90-100 °c. The reaction 
mixture was concentrated and the solid product was recrystallised to yield 
crude 162 (1.469 g, 94%) as cream coloured crystals, m.p. 91-92 °c (from 
EtOAc); Rf 0.16 (EtOAc); Vmax (KBr) 3308 (N-H), 3024 (aromatic C-H), 2963 
(aliphatic C-H), 1649 (amide 1),1556 (amide 11),1506 (C=C), 1236 (C-S) and 
744 (ortho-disubstituted benzene) cm-1; OH (CDCI3) 7.59 (1 H, m, dd, 7-H or 
10-H), 7.45 (1 H, m, dd, 10-H or 7-H), 7.27 (2 H, m, 8-H & 9-H), 6.74 (1 H, br 
s, N-H), 3.71 (2 H, m, 3-H), 3.45 (2 H, t, 4-H) and 1.97 (3 H, s, 3-H); Oc 
(CDCI3) 170.6 (C=O), 164.8 (C-5), 151.9 (C-11), 141.5 (C-6), 124.5 (C-8), 
124.2 (C-9), 118.3 (C-7), 110.0 (C-10), 39.7 (C-3), 31.7 (C-4) and 23.1 (C-1); 
m/z 236 ( M+, 1.4), 177 (17.0), 151 (13.0) and 122 (27.4%) (Found: M+, 
236.0616; C, 55.82; H, 4.98; N, 11.84%. C11H12N202S requires M, 
236.0619; C, 55.91; H, 5.12; N, 11.86%). 
N-{2-[(2-benzothiazolyl)thio]ethyl}acetamide (163). 
~--N 
~ 4 H 1 S 5 S~N'(' 
10 
o 
2-Mercaptobenzothiazole (1.00 g, 5.98 mmol) was heated at reflux with 
oxazoline 145 (4 ml) under N2 for 4 h between 90-100 °C. The reaction 
mixture was concentrated and the solid product was recrystallised to yield 
amide 163 (O.593g, 40%) as white needles, m.p. 88-89 °C (EtOAc); RIO.19 
(EtOAc); vmax (KBr) 3298 (N-H), 2984 (aliphatic C-H), 1642 (amide I), 1544 
(amide II), 1236 (C-S) and 756 (ortho-disubstituted benzene) cm-1; OH 
(CDCI3) 7.80 (1 H, dd, 3J= 8.1, 7-H), 7.72 (1 H, dd, 3J= 8.0, 10-H), 7.39 (1 H, 
ddd, 8-H), 7.20 (1 H, ddd, 9-H), 7.03 (1 H, br s, N-H), 3.64 (2 H, m, 3-H), 3.45, 
(2 H, t, 4-H), 1.94 (3 H, s, 1-H); Oc (CDCI3) 170.6 (C=O), 166.8 (C-5), 152.7 
(C-11), 135.3 (C-6), 126.2 (C-8), 124.5 (C-9), 121.2 (C-10 or C-7), 121.1 (C-
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7 or C-l0), 40.0 (C-3), 32.9 (C-4) and 23.1 (C-l); m/z 252 (M+, 1.0), 192 
(11.1), 180 (8.4), 167 (14.7), 136 (16.0) and 108 (29.2%) (Found: M+, 
252.0392; C, 52.24; H, 4.77; N, 11.07%. C11 H12N20S2 requires M, 
252.0391; C, 52.37; H, 4.79; N, 11.11 %). 
3-[(4-Hydroxyphenyl}thio]propanonitrile (165). 
OH 
7 
4-Hydroxythiophenol (0.609 g, 4.8 mmol) was dissolved in acetonitrile (5 ml) 
and stirred with NaOH (2M, 2.5 ml) for 10 min. Bromopropionitrile (0.709 g, 
5.3 mmol) was introduced and the reaction mixture was heated at reflux for 3 
h. After cooling, the reaction mixture was acidified with HCI (1 M) to pH 3 and 
extracted with CHCI3 (3 x 20 ml). After drying, the organic extracts were 
concentrated under reduced pressure and the crude product pre-adsorbed 
onto silica. Chromatography (silica) with petroleum ether-EtOAc (1:1) as 
eluent, followed by recrystallisation, afforded nitrile 165 (0.496 g, 58%), m.p. 
69-70 °C (from benzene, lit.,163 72-73 °C); Rf 0.84 (EtOAc); Vmax (KBr) 3325br 
(O-H), 3007w (aromatic C-H), 2928w (aliphatic C-H), 2266m (CN), 1599, 
1579, 1493 (C=C) and 829 (para-disubstituted benzene) cm-1; BH (CDCI3) 
7.27 (2 H, AA'BB', 3J= 8.7, 3-H), 6.76 (2 H, AA'BB', 3J= 8.7, 2-H), 6.04 (1 H, 
br s, O-H), 2.91 (2 H, t, 3J= 7.2, 5-H) and 2.45 (2 H, t, 3J= 7.1, 6-H) ; Be 
(CDCI3) 156.5 (C-1), 135.4 (C-3), 122.8 (C-4), 118.2 (C-7), 116.5 (C-2), 31.8 
(C-5), 16.2 (C-6); m/z 179 (M+, 56.7),139 (86.6),125 (59.5) and 97 (61.0%) 
(Found: M+, 179.0381; C, 60.47; H, 5.24; N, 7.98%. CgHgNOS requires M, 
179.0404; C, 60.32; H, 5.03; N, 7.82%). 
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2-[(4-Hydroxyphenyl)thio]acetamide (166). 
OH 
S~CONH2 
6 
Amide 166 was prepared by partial hydrolysis of nitrile 165 according to 
established methodology.164 The nitrile (0.490 g, 3.0 mmol) was added with 
vigorous stirring to HCI (35%, 5 ml) maintained at a temperature of 40°C. 
After 40 min, the flask was cooled to 15-20 °c and cold distilled water (5 ml) 
was added . The reaction mixture was extracted with EtOAc (2 x 20 ml) and 
washed with water (2 x 50 ml). After drying, the organic extracts were 
concentrated yielding a white solid which was recrystallised to give 166 
(0.417 g, 76%) as white needles, m.p. 156-157 °C; Rt 0.21 (EtOAc); Vmax 
(KBr) 3429 and 3179 (NH2), 1670br (amide I & II), 1498 (C=C) and 825 
(para-disubstituted benzene) cm-1; DH (Ds-DMSO) 9.73 (1 H, br s, O-H), 7.50 
and 7.14 (2 H, 2 br s, NH2), 7.30 (2 H, AA'BB', 3J= 8.6, 3-H), 6.77 (2 H, 
AA'BB', 3J= 8.6, 2-H) and 3.47 (2 H, s, 5-H); Oc (D6-DMSO) 170.7 (C-6), 
157.3 (C-1), 132.8 (C-3), 124.0 (C-4), 116.4 (C-2) and 39.2 (C-5); m/z 183 
(M+, 47.8), 139 (47.7), 125 (25.9) and 95 (21.9%) (Found: M+, 183.0362; C, 
52.69; H, 4.81; N, 7.57%. CaHgN02S requires M, 183.0354; C, 52.44; H, 
4.95; N, 7.65%). 
3-[(4-Hydroxyphenyl)thio]propanamide (167). 
OH 
4 
S 6 ~CONH2 
7 
Compound 167 was prepared using the same method as described for 
compound 166, affording a white solid which was recrystallised to give 
amide 167 (0.275 g, 56%) as white needles, m.p. 110-111 °C; Rt 0.16 
(EtOAc); Vmax (KBr) 3379 and 3188 (NH2), 1657br (amide I & 11).1495 (C=C) 
and 821 (para-disubstituted benzene) cm-1; OH (D6-acetone) 8.64 (1 H, br s, 
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O-H), 7.28 (2 H, AA'BB', 3J= 8.7, 3-H), 6.96 and 6.45 (2 H, 2 br s, NH2), 6.80 
(2 H, AA'BB', 3J= 8.7, 2-H), 3.01 (2 H, t, 3J= 7.3, 5-H) and 2.43 (2 H, t, 3J= 7.4, 
6-H); be (D6-acetone) 173.6 (C-7), 157.9 (C-1), 134.5 (C-3), 125.1 (C-4), 
116.9 (C-2), 36.0 (C-5) and 31.9 (C-6); m/z 197 (M+, 50.1),152 (11.2),139 
(12.9), 125 (54.4) and 97 (51.3%) (Found: M+, 197.0509; C, 54.64; H, 5.58; 
N, 7.07%. C9Hl1 N02S requires M, 197.0510; C, 54.81; H, 5.62; N, 7.10%). 
2-[( 4-Hydroxyphenyl)thio]acetic acid (168). 
OH 
4 
S~COOH 
6 
The title compound was prepared by hydrolysis of nitrile 164 according to 
established methodology.165 The nitrile (0.500 g, 3.0 mmol) was heated at 
reflux with NaOH (30%, 5 ml) for 3 h. Upon cooling, the reaction mixture was 
diluted with water (5 ml) and H2S04 (50%, 7 ml) and extracted with EtOAc (2 
x 20 ml). After drying, the organic solvents were removed in vacuo and the 
white powder obtained was recrystallised to yield acid 164 (0.279 g, 50%) 
as rhombic crystals, m.p. 145-146 °C (from EtOAc/hexane); Rf 0.1 (EtOAc); 
V max (KBr) 3160br (COOH), 1693 (C=O), 1586 and 1494 (e=e), 835 (para-
disubstituted benzene) cm-1; bH (D6-DMSO) 12.56 (1 H, br s, eOOH), 9.69 (1 
H, br s, O-H), 7.29 (2 H, AA'BB', 3J= 8.6, 3-H), 6.77 (2 H, AA'BB', 3J= 8.6, 2-
H) and 3.60 (2 H, s, 5-H); be (D6-DMSO) 171.0 (e-6), 157.2 (C-1), 133.0 (e-
3), 123.2 (C-4), 116.2 (C-2) and 37.8 (C-5); m/z 184 (M+, 75.6),139 (70.6), 
125 (48.7) and 95 (28.9%) (Found: M+, 184.0196; C, 52.06; H, 4.57%. 
CaHa03S requires M, 184.0194; C, 52.17; H, 4.38%). 
Methoxypolyethyleneglycol (2000) succinate (MPEG-2000 
succinate) (169). 
o 2 
o 
°ro[l 
The title compound was prepared using established methodology.105 MPEG-
2000 (10 g, 5 mmol) was dissolved in toluene (50 ml) and dried by distilling 
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off most of the toluene. Succinic anhydride (20 g, 20 mmol) was added and 
the mixture was stirred for 5 h on an oil bath at 150°C. The mixture was 
cooled, concentrated and purified from excess succinic anhydride by 
repeated recrystallisation from toluene. The crude product was subjected to 
filtration through Sephadex LH-20 (10 g) with water as eluent, affording 
succinate 169 as a white solid (10.01 g, 95%). The 1H NMR spectrum of 
169 indicated the presence of unreacted MPEG-2000 (16%) in the crude 
product, as did titration with standard NaOH solution (See Chapter 6, 
Section 6.7). Overall yield of MPEG succinate was therefore 80%. The crude 
material was used in successive experiments without further purification. At 
0.23 (acetic acid-MeOH (1: 1»; Vmax (KBr) 2889s (aliphatic C-H), 1736 (ester 
C=O) and 1114 (ester C-O) cm-1; ()H (CDCI3) 3.57 (180 H, s, 2-H), 3.31 (3 H, 
s, 1-H) and 2.56 (3.4 H, s, 4-H & 5-H); ()c (CDCI3) 173.7 (C-6), 172.5 (C-3), 
70.29 (C-2), 63.5 (C-1), 29.1 and 28.7 (C-4 & C-5); ESMS showed a broad 
molecular weight distribution centred at approximately 2100. 
Methoxypolyethyleneglycol (2000) succinate derivative with 142 
(170). 
o 
o 
~9 
10 0 
S 12 ~ ~N 13 CH3 11 H 14 
The title compound was prepared using established methodology.l05 Crude 
MPEG-2000 succinate (2.100 g, 0.84 mmol), N-{2-[(4-
Hydroxyphenyl)thio ]ethyl} acetamide (0.232 g, 1.1 mmol) and OMAP (30 mg, 
0.25 mmol) were dissolved in dry OCM (25 ml) in a flame dried apparatus 
under N2. A solution of DCC (300 mg, 1.2 mmol) in OCM (5 ml) was added 
and the mixture was stirred for 16 h. The white precipitate of OCU was 
filtered off and the organic filtrate was concentrated, taken up in acetone and 
the product precipitated by pouring into ice-cold diethyl ether. Filtration and 
drying under suction yielded crude 170 (0.914 g, 49%). The 1 H NMA 
spectra indicated that 75% of this crude product was the title compound. The 
remainder was unreacted MPEG-2000 or MPEG-2000 succinate The 
- 205-
integrals for the polymer protons in the 1 H NMR spectrum include these 
impurities, giving fractional integrals; Rf 0.31 (acetic acid-MeOH (1:1)); Vmax 
(KBr) 2921 (aliphatic C-H), 1730 (ester C=O), 1660 (amide C=O), 1463, 
1376 and 1120 cm-1; OH (CDCI3); 7.52 (2 H, AA'BB', 3J=8.7, 9-H), 7.16 (2 H, 
AA'BB', 3J= 8.6, 8-H), 6.89 (1 H, br s, N-H), 4.34 (2.6 H, m, terminal PEG unit, 
CH2 adjacent to ester, 2a-H), 4.03 (2.6 H, m, terminal PEG unit, penultimate 
CH2, 2b-H), 3.56 (241 H, br m, 2-H, 1-H & 12-H), 2.95 (2 H, m, 11-H) and 
1.97 (3 H, s, 14-H); oe (CDCI3) 173.2 (C-6), 172.0 (C-3), 171.5 (C-13), 131.3 
(C-9), 122.5 (C-8), 70.4 (C-2), 63.7 (C-1), 39.0 (C-12), 34.0 (C-11), 29.5 (C-4 
& C-5) and 23.3 (C-14); ESMS showed a broad molecular weight 
distribution centred at approximately 2300. 
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